{"parse":{"title":"BIA 10-2474","pageid":49110893,"revid":846897491,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em;border-spacing:2px;\"><caption><span title=\"International nonproprietary name (INN): BIA 10-2474\">BIA 10-2474</span></caption><tbody><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/File:Bia102474_corrected.svg\" class=\"image\"><img alt=\"Bia102474 corrected.svg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Bia102474_corrected.svg/220px-Bia102474_corrected.svg.png\" width=\"220\" height=\"98\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Bia102474_corrected.svg/330px-Bia102474_corrected.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Bia102474_corrected.svg/440px-Bia102474_corrected.svg.png 2x\" data-file-width=\"512\" data-file-height=\"228\" /></a></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Clinical data</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Route_of_administration\" title=\"Route of administration\">Routes of<br />administration</a></th><td>\nOral</td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Legal status</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Regulation_of_therapeutic_goods\" title=\"Regulation of therapeutic goods\">Legal status</a></th><td>\n<div class=\"plainlist\">\n<ul><li><small><abbr class=\"country-name\" title=\"United States\">US</abbr>:</small>&#x20;<a href=\"/wiki/Investigational_New_Drug\" title=\"Investigational New Drug\">Investigational New Drug</a>&#x20;</li></ul></div>\n</td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Identifiers</th></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<div class=\"NavFrame collapsed\" style=\"border: none; padding: 0;\">\n<div class=\"NavHead\" style=\"font-size: 105%; background: transparent; text-align: left;\"><a href=\"/wiki/IUPAC_nomenclature_of_chemistry\" title=\"IUPAC nomenclature of chemistry\">IUPAC name</a></div>\n<ul class=\"NavContent\" style=\"list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;\"><li style=\"line-height: inherit; margin: 0\"><span style=\"font-size: 11px;\">3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide</span></li></ul>\n</div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/CAS_Registry_Number\" title=\"CAS Registry Number\">CAS Number</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.commonchemistry.org\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.commonchemistry.org/ChemicalDetail.aspx?ref=1233855-46-3\">1233855-46-3</a></span></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/PubChem#CID\" title=\"PubChem\">PubChem</a> <span style=\"font-weight:normal\"><abbr title=\"Compound ID\">CID</abbr></span></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"pubchem.ncbi.nlm.nih.gov\"><a rel=\"nofollow\" class=\"external text\" href=\"https://pubchem.ncbi.nlm.nih.gov/compound/46831476\">46831476</a></span></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Guide_to_Pharmacology\" title=\"Guide to Pharmacology\">IUPHAR/BPS</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.guidetopharmacology.org\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9001\">9001</a></span></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/ChemSpider\" title=\"ChemSpider\">ChemSpider</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.chemspider.com\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chemspider.com/Chemical-Structure.41628677.html\">41628677</a></span></li></ul></div></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Chemical and physical data</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Chemical_formula\" title=\"Chemical formula\">Formula</a></th><td>\n<span title=\"Carbon\">C</span><sub>16</sub><span title=\"Hydrogen\">H</span><sub>20</sub><span title=\"Nitrogen\">N</span><sub>4</sub><span title=\"Oxygen\">O</span><sub>2</sub></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Molar_mass\" title=\"Molar mass\">Molar mass</a></th><td>\n300.36 g/mol</td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\">3D model (<a href=\"/wiki/JSmol\" class=\"mw-redirect\" title=\"JSmol\">JSmol</a>)</th><td>\n<div class=\"plainlist\"><ul><li><span title=\"chemapps.stolaf.edu (3D interactive model)\"><a rel=\"nofollow\" class=\"external text\" href=\"https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N1C%3DC%28C2%3DC%5BN%2B%5D%28%5BO-%5D%29%3DCC%3DC2%29N%3DC1%29N%28C3CCCCC3%29C\">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<div class=\"NavFrame collapsed\" style=\"border: none; padding: 0;\">\n<div class=\"NavHead\" style=\"font-size: 105%; background: transparent; text-align: left;\"><a href=\"/wiki/Simplified_molecular-input_line-entry_system\" title=\"Simplified molecular-input line-entry system\">SMILES</a></div>\n<ul class=\"NavContent\" style=\"list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;\"><li style=\"line-height: inherit; margin: 0\"><div style=\"word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;\">O=C(N1C=C(C2=C[N+]([O-])=CC=C2)N=C1)N(C3CCCCC3)C</div></li></ul>\n</div></td></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<div class=\"NavFrame collapsed\" style=\"border: none; padding: 0;\">\n<div class=\"NavHead\" style=\"font-size: 105%; background: transparent; text-align: left;\"><a href=\"/wiki/International_Chemical_Identifier\" title=\"International Chemical Identifier\">InChI</a></div>\n<ul class=\"NavContent\" style=\"list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;\"><li style=\"line-height: inherit; margin: 0\"><div style=\"word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;\">InChI=1S/C16H20N4O2/c1-18(14-7-3-2-4-8-14)16(21)19-11-15(17-12-19)13-6-5-9-20(22)10-13/h5-6,9-12,14H,2-4,7-8H2,1H3</div></li><li style=\"line-height: inherit; margin: 0\"><div style=\"word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;\">Key:DOWVMJFBDGWVML-UHFFFAOYSA-N</div></li></ul>\n</div></td></tr></tbody></table>\n<p><b>BIA 10-2474</b> is an experimental <a href=\"/wiki/Fatty_acid_amide_hydrolase\" title=\"Fatty acid amide hydrolase\">fatty acid amide hydrolase</a> inhibitor developed by the Portuguese pharmaceutical company <a href=\"/wiki/Bial\" title=\"Bial\">Bial-Portela &amp; Ca. SA</a>. It interacts with the human <a href=\"/wiki/Endocannabinoid_system\" title=\"Endocannabinoid system\">endocannabinoid system</a>.<sup id=\"cite_ref-Bialstatement_1-0\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup> The drug was in development for the treatment of a range of different <a href=\"/wiki/Medical_conditions\" class=\"mw-redirect\" title=\"Medical conditions\">medical conditions</a> from <a href=\"/wiki/Anxiety_disorder\" title=\"Anxiety disorder\">anxiety disorder</a> to <a href=\"/wiki/Parkinson%27s_disease\" title=\"Parkinson&#39;s disease\">Parkinson's disease</a>, also for the treatment of <a href=\"/wiki/Chronic_pain\" title=\"Chronic pain\">chronic pain</a> of <a href=\"/wiki/Multiple_sclerosis\" title=\"Multiple sclerosis\">multiple sclerosis</a>, <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a>, <a href=\"/wiki/Hypertension\" title=\"Hypertension\">hypertension</a> or the treatment of <a href=\"/wiki/Obesity\" title=\"Obesity\">obesity</a>.<sup id=\"cite_ref-Breizh_2-0\" class=\"reference\"><a href=\"#cite_note-Breizh-2\">&#91;2&#93;</a></sup> A clinical trial with this drug was underway in Rennes, France, in January 2016, in which <a href=\"/wiki/Serious_adverse_event\" title=\"Serious adverse event\">serious adverse events</a> occurred affecting five participants, including the death of one man.<sup id=\"cite_ref-Bialstatement_1-1\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-ANSM_Statement_3-0\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-Ministry_Statement_4-0\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-Rennes2_5-0\" class=\"reference\"><a href=\"#cite_note-Rennes2-5\">&#91;5&#93;</a></sup> The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.<sup id=\"cite_ref-ANSMfinal_6-0\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-Hinnerk_7-0\" class=\"reference\"><a href=\"#cite_note-Hinnerk-7\">&#91;7&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Structure_and_action\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Structure and action</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Preclinical_studies\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Preclinical studies</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Pharmacodynamics_and_pharmacokinetics\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Pharmacodynamics and pharmacokinetics</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Safety_pharmacology_and_toxicology\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Safety pharmacology and toxicology</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Phase_I_clinical_trial\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Phase I clinical trial</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Overview\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Overview</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Trial_details\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Trial details</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Starting_dose_and_subsequent_doses\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">Starting dose and subsequent doses</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Trial_status_at_the_time_of_serious_adverse_events\"><span class=\"tocnumber\">3.4</span> <span class=\"toctext\">Trial status at the time of serious adverse events</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Death_and_serious_adverse_events\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Death and serious adverse events</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Reaction_and_investigations\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Reaction and investigations</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#French_authorities\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">French authorities</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-13\"><a href=\"#Inspection_g\u00e9n\u00e9rale_des_affaires_sociales_reports\"><span class=\"tocnumber\">5.1.1</span> <span class=\"toctext\">Inspection g\u00e9n\u00e9rale des affaires sociales reports</span></a></li>\n<li class=\"toclevel-3 tocsection-14\"><a href=\"#ANSM_Comit\u00e9_Scientifique_Sp\u00e9cialis\u00e9_Temporaire\"><span class=\"tocnumber\">5.1.2</span> <span class=\"toctext\">ANSM Comit\u00e9 Scientifique Sp\u00e9cialis\u00e9 Temporaire</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Agencies_outside_France\"><span class=\"tocnumber\">5.2</span> <span class=\"toctext\">Agencies outside France</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-16\"><a href=\"#Outcome_for_trial_participants\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Outcome for trial participants</span></a></li>\n<li class=\"toclevel-1 tocsection-17\"><a href=\"#Implications_for_other_FAAH_inhibitors\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Implications for other FAAH inhibitors</span></a></li>\n<li class=\"toclevel-1 tocsection-18\"><a href=\"#See_also\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-19\"><a href=\"#Further_reading\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">Further reading</span></a></li>\n<li class=\"toclevel-1 tocsection-20\"><a href=\"#References\"><span class=\"tocnumber\">10</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-21\"><a href=\"#External_links\"><span class=\"tocnumber\">11</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Structure_and_action\">Structure and action</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=1\" title=\"Edit section: Structure and action\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The chemical name of BIA-10-2474 is 3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide.<sup id=\"cite_ref-protocolansm_8-0\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup> BIA-10-2474 is a long-acting <a href=\"/wiki/Enzyme_inhibitor\" title=\"Enzyme inhibitor\">inhibitor</a> of <a href=\"/wiki/Fatty_acid_amide_hydrolase\" title=\"Fatty acid amide hydrolase\">fatty acid amide hydrolase</a> (FAAH) that increases levels of the <a href=\"/wiki/Neurotransmitter\" title=\"Neurotransmitter\">neurotransmitter</a> <a href=\"/wiki/Anandamide\" title=\"Anandamide\">anandamide</a> in the <a href=\"/wiki/Central_nervous_system\" title=\"Central nervous system\">central nervous system</a> and in peripheral tissues (that is, the rest of the body other than the <a href=\"/wiki/Brain\" title=\"Brain\">brain</a> and <a href=\"/wiki/Spinal_cord\" title=\"Spinal cord\">spinal cord</a>).<sup id=\"cite_ref-Bialstatement_1-2\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-protocolansm_8-1\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</p><p>In normal tissues, the <a href=\"/wiki/Enzyme\" title=\"Enzyme\">enzyme</a> FAAH degrades <a href=\"/wiki/Anandamide\" title=\"Anandamide\">anandamide</a> and other <a href=\"/wiki/Endocannabinoid_system\" title=\"Endocannabinoid system\">endocannabinoid</a> <a href=\"/wiki/Neurotransmitter\" title=\"Neurotransmitter\">neurotransmitters</a>, which relieve <a href=\"/wiki/Pain\" title=\"Pain\">pain</a> and can affect <a href=\"/wiki/Eating\" title=\"Eating\">eating</a> and <a href=\"/wiki/Sleep\" title=\"Sleep\">sleep</a> patterns. FAAH inhibitors have been proposed for a range of <a href=\"/wiki/Nervous_system\" title=\"Nervous system\">nervous system</a> <a href=\"/wiki/Disorder_(medicine)\" class=\"mw-redirect\" title=\"Disorder (medicine)\">disorders</a> including <a href=\"/wiki/Anxiety_disorder\" title=\"Anxiety disorder\">anxiety disorders</a>, <a href=\"/wiki/Alcoholism\" title=\"Alcoholism\">alcoholism</a>, pain and <a href=\"/wiki/Nausea\" title=\"Nausea\">nausea</a>.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-Bisogno_10-0\" class=\"reference\"><a href=\"#cite_note-Bisogno-10\">&#91;10&#93;</a></sup>\n</p><p>The Portuguese pharmaceutical company <a href=\"/wiki/Bial\" title=\"Bial\">Bial</a> holds several <a href=\"/wiki/Patent\" title=\"Patent\">patents</a> on <a href=\"/wiki/Fatty_acid_amide_hydrolase\" title=\"Fatty acid amide hydrolase\">FAAH</a> <a href=\"/wiki/Enzyme_inhibitor\" title=\"Enzyme inhibitor\">enzyme inhibitors</a>.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\nThe structure and synthesis of BIA 10-2474 is disclosed in a Bial patent as 'compound 362', part of a Bial <a href=\"/wiki/Patent_family\" title=\"Patent family\">patent family</a> <a href=\"/wiki/Priority_right\" title=\"Priority right\">dating from</a> December 2008.<sup id=\"cite_ref-synthpatent_13-0\" class=\"reference\"><a href=\"#cite_note-synthpatent-13\">&#91;13&#93;</a></sup>\n</p><p>The patent discloses limited details about BIA 10-2474, mainly the screening assay results for each of the several hundred <a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">candidate compounds</a> to evaluate the effect on FAAH activity. For compound 362 (that is, BIA 10-2474), an <i>in vitro</i> assay in rat brain showed only modest FAAH inhibition, however, mice given compound 362 at 3&#160;mg/kg orally had less than 2% the normal level of FAAH activity in both brain and <a href=\"/wiki/Liver\" title=\"Liver\">liver</a> tissues after 8 hours. Inhibition of other enzymes affected by cannabinoids (<a href=\"/wiki/Monoacylglycerol_lipase\" title=\"Monoacylglycerol lipase\">monoacylglycerol lipase</a> and liver <a href=\"/wiki/Carboxylesterase\" title=\"Carboxylesterase\">carboxylesterase</a>) was performed as a screen for biological selectivity for a small number of compounds, but compound 362 was not included.<sup id=\"cite_ref-synthpatent_13-1\" class=\"reference\"><a href=\"#cite_note-synthpatent-13\">&#91;13&#93;</a></sup> These results appear to be <a href=\"/wiki/High-throughput_screening\" title=\"High-throughput screening\">high-throughput screening</a> data only, and no more definitive data are included (such as inhibitory concentration (<a href=\"/wiki/IC50\" title=\"IC50\">IC50</a>) or <a href=\"/wiki/Inhibition_constant\" class=\"mw-redirect\" title=\"Inhibition constant\">inhibition constant</a> (Ki) values that characterise the potency of the molecule's inhibition of, or binding with, the target).<sup id=\"cite_ref-southanblog_14-0\" class=\"reference\"><a href=\"#cite_note-southanblog-14\">&#91;14&#93;</a></sup>\n</p><p>The <a href=\"/wiki/Agence_Nationale_de_S%C3%A9curit%C3%A9_du_M%C3%A9dicament_et_des_Produits_de_Sant%C3%A9\" title=\"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\">Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9</a> (ANSM) reported that the compound has a rat IC50 of 1.1-1.7 micromolar, and that this is 200 times the concentration required for inhibition with a different FAAH inhibitor developed by Pfizer (that is, much weaker). As such, the ANSM described the molecule as \"a compound with a relatively poor specificity for the endocannabinoid FAAH\".<sup id=\"cite_ref-ANSM_Comite_Minutes_15-0\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> In the same report, the ANSM also noted that the inhibitor is irreversible, not <a href=\"/wiki/Enzyme_inhibitor#Reversible_inhibitors\" title=\"Enzyme inhibitor\">reversible</a> as claimed by the manufacturer Bial.\n</p><p>Publication of the chemical structure created considerable interest among chemists, with some sharing online their assessment of likely binding interactions between BIA 10-2474 and <i>in vivo</i> targets.<sup id=\"cite_ref-southanblog_14-1\" class=\"reference\"><a href=\"#cite_note-southanblog-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> At least one analysis using standard software modelling packages found that although FAAH emerged as the primary target for BIA 10-2474, a number of other proteins rated highly as well. These other targets included <a href=\"/wiki/Histone_deacetylase\" title=\"Histone deacetylase\">histone deacetylases</a>, <a href=\"/wiki/MST1R\" title=\"MST1R\">macrophage-stimulating protein receptor</a> and <a href=\"/wiki/Hormone-sensitive_lipase\" title=\"Hormone-sensitive lipase\">hormone-sensitive lipase</a>.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</p><p>Although the exact mechanism of action leading to BIA 10-2474 toxicity remains unknown, the final report by the ANSM Committee concluded it was likely one of two possible mechanisms \"inhibition of other serine hydrolases, or harmful effect from the imidazole\u2010pyridine \"leaving\" group\". The report also theorised that this leaving group \"may produce an isocyanate to which many brain proteins are likely to bind\".<sup id=\"cite_ref-ANSMfinal_6-1\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup> A 2017 research article suggested the off-target activity of BIA 10-2474 may affect lipid metabolism in neurones.<sup id=\"cite_ref-Hinnerk_7-1\" class=\"reference\"><a href=\"#cite_note-Hinnerk-7\">&#91;7&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Preclinical_studies\">Preclinical studies</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=2\" title=\"Edit section: Preclinical studies\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to a company statement, a project to develop FAAH inhibitors was initiated by Bial in 2005, and studies with this compound began in 2009 with pre-clinical <i>in vitro</i> and <i>in vivo</i> pharmacological and toxicological evaluation.<sup id=\"cite_ref-Bialstatement_1-3\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup> The French medicines regulator (ANSM) released a version of the <a href=\"/wiki/Protocol_(science)\" title=\"Protocol (science)\">clinical trial protocol</a>,<sup id=\"cite_ref-protocolansm_8-2\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-ansm22jan_18-0\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup> after the newspaper <i><a href=\"/wiki/Le_Figaro\" title=\"Le Figaro\">Le Figaro</a></i> leaked a (more recent) version.<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-lefigaro_20-0\" class=\"reference\"><a href=\"#cite_note-lefigaro-20\">&#91;20&#93;</a></sup> The protocol presents a summary of what appears to be a full package of <a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">pharmacodynamic</a>, <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetic</a> and <a href=\"/wiki/Toxicology_testing\" title=\"Toxicology testing\">toxicological</a> studies that might be expected to support a <a href=\"/wiki/First-in-man_study\" class=\"mw-redirect\" title=\"First-in-man study\">first-in-man study</a>. The manufacturer Bial refused the regulator's request to release the <a href=\"/wiki/Investigator%27s_brochure\" title=\"Investigator&#39;s brochure\">Investigator's brochure</a> and the product dossier (the Investigational Medicinal Product Dossier; IMPD), citing French law on trade secrets.<sup id=\"cite_ref-ansm22jan_18-1\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup>\n</p><p>An expert committee, established by the French medicines regulator after the trial, requested clarification from Bial of a range of preclinical issues.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-1\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmacodynamics_and_pharmacokinetics\">Pharmacodynamics and pharmacokinetics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=3\" title=\"Edit section: Pharmacodynamics and pharmacokinetics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In terms of animal <a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">pharmacodynamics</a>, the trial protocol reports that the biological activity of BIA 10-2474 was tested in models of predictive efficacy in treating pain. \u201cBIA 10-2474 produced <a href=\"/wiki/Analgesic\" title=\"Analgesic\">analgesic</a>/<a href=\"/wiki/Anti-inflammatory\" title=\"Anti-inflammatory\">anti-inflammatory</a> activity in the mouse Formalin-Paw and Tail-Flick tests in a time-and dose-dependent manner. BIA 10-2474 also markedly potentiated the antinociceptive effects of exogenous anandamide in the mouse Formalin-Paw and Tail-Flick tests\u201d. In other words, BIA 10-2474 worked as a pain-killer in mice using two different tests (the \u201canalgesic/anti-inflammatory\u201d effect); and, in mice that had been given a dose of the neurotransmitter anandamide, BIA 10-2474 also improved its effects in numbing pain (\u201cantinociceptive\u201d effect).<sup id=\"cite_ref-protocolansm_8-3\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup> The expert committee of the ANSM took the view that this was insufficient basis for commencing human trials, and that further evidence of BIA 10-2474 as an analgesic was warranted.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-2\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> The Committee's final report noted that in fact the original formalin paw study report presented additional data for the gabapentin comparator which was omitted in the Investigators Brochure.<sup id=\"cite_ref-ANSMfinal_6-2\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup> The final ANSM report stated that \"doses used in these tests differ greatly (from 0.3 to 10 mg/Kg), without it being possible to trace a dose\u2010effect curve or to estimate an effective dose 50 (which is a surprising shortcoming)\".<sup id=\"cite_ref-ANSMfinal_6-3\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup>\n</p><p>In terms of animal <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a>, in rats and dogs given a <a href=\"/wiki/Radio_labelling\" class=\"mw-redirect\" title=\"Radio labelling\">radio-labelled</a> dose of BIA 10-2474, the drug was detectable in the <a href=\"/wiki/Blood\" title=\"Blood\">blood</a> for up to a day afterwards (oral or i.v.). Oral <a href=\"/wiki/Bioavailability\" title=\"Bioavailability\">bioavailability</a> was not reported.  Terminal <a href=\"/wiki/Biological_half-life\" title=\"Biological half-life\">half-life</a> (persistence in the blood) of the BIA 10-2474 in rats was 45 hours (oral) or 4 hours (i.v.) and in dogs it was 104 hours (oral) or 52 hours (i.v.). The authors made no prediction of a likely half-life in humans. Around two-thirds of the total dose was <a href=\"/wiki/Clearance_(medicine)\" class=\"mw-redirect\" title=\"Clearance (medicine)\">eliminated</a> in the <a href=\"/wiki/Urine\" title=\"Urine\">urine</a>, about one-fifth in the <a href=\"/wiki/Faeces\" class=\"mw-redirect\" title=\"Faeces\">faeces</a> and the remainder was heavily metabolized in all species studied (rat, mouse, dog, monkey). <a href=\"/wiki/Metabolism\" title=\"Metabolism\">Metabolism</a> of BIA 10-2474 was essentially complete by 72 hours. Main <a href=\"/wiki/Metabolites\" class=\"mw-redirect\" title=\"Metabolites\">metabolites</a> were not described. The studies used total detectable <a href=\"/wiki/Radioactivity\" class=\"mw-redirect\" title=\"Radioactivity\">radioactivity</a> to calculate half-life and did not assess what proportion of this was due to metabolites.<sup id=\"cite_ref-protocolansm_8-4\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</p><p>The preliminary report by the French Inspector General for Social Affairs (IGAS), for the French Ministry of Health, remarked on the difference between the rat oral vs. I.V. half life, and, that in light of the adverse events seen in humans on repeated dosing, this may indicate \"a mechanism of accumulation\".<sup id=\"cite_ref-IGAS_21-0\" class=\"reference\"><a href=\"#cite_note-IGAS-21\">&#91;21&#93;</a></sup> Separately, accumulation of BIA 10-2474 given orally in humans was supported by pharmacokinetic data from the trial itself, reviewed by the ANSM expert committee. The molecule showed non-linear pharmacokinetics at doses between 40\u2013100&#160;mg, suggesting elimination pathways had become saturated, leading to accumulation.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-3\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup>\n</p><p>The final report by the ANSM Committee noted the drug had a very steep dose-effect curve in humans \"going from absence of to almost complete inhibition\" over a narrow concentration range.<sup id=\"cite_ref-ANSMfinal_6-4\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup> The report also found, based on clinical data from the Rennes trial, that complete inhibition by BIA 10-2474 was very long-acting, and persisted well beyond the point where it was no longer detectable in blood of the trial subjects.\n</p>\n<h3><span class=\"mw-headline\" id=\"Safety_pharmacology_and_toxicology\">Safety pharmacology and toxicology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=4\" title=\"Edit section: Safety pharmacology and toxicology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The protocol presents a summary of <a href=\"/wiki/Safety_pharmacology\" title=\"Safety pharmacology\">safety pharmacology</a> studies in two species (rat, dog) and repeated dose toxicity studies in four species (13-week sub-chronic studies in mouse, dog and monkey; a 26-week chronic study in the rat). Of note, few adverse events were observed in any of the studies, with the oral <a href=\"/wiki/No-observed-adverse-effect_level\" title=\"No-observed-adverse-effect level\">No Observed Adverse Effect Level</a> (NOAEL) varying between 10&#160;mg/kg/day in rats to 75&#160;mg/kg/day in monkeys. The authors suggest that these were the maximum doses tested in these studies, though it is not clear. The authors also report no effects of significance in the animal models used for the <a href=\"/wiki/Central_nervous_system\" title=\"Central nervous system\">CNS</a> safety pharmacology studies, which studied a dose of up to 300&#160;mg/kg/day. The protocol nominates a human NOAEL of 100&#160;mg as a <a href=\"/wiki/Human_equivalent\" title=\"Human equivalent\">human equivalent dose</a> to the 26-week rat NOAEL, though with no description how this was calculated. The summary presented however includes no assessment of the relevance of the animal species selected for study (that is, in terms of physiological and genetic similarities with humans and the <a href=\"/wiki/Mechanism_of_action\" title=\"Mechanism of action\">mechanism of action</a> of the study drug).<sup id=\"cite_ref-protocolansm_8-5\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup> Early reports that the molecule had been studied in chimpanzees turned out to be incorrect.<sup id=\"cite_ref-Ministry_Statement_4-1\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-lancet_22-0\" class=\"reference\"><a href=\"#cite_note-lancet-22\">&#91;22&#93;</a></sup><sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p><p>At a hearing convened by the ANSM in March 2016, Bial clarified that the apparently extensive animal toxicology studies (and number of species) was due to a delay in commencement of clinical development, thus some studies had already been completed that would not have been required for a Phase I study. The ANSM Committee found no evidence that the studies had been performed because the company had doubts as to the tolerance of the molecule.<sup id=\"cite_ref-ANSMfinal_6-5\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup>\n</p><p>Notably absent from the protocol were calculations of receptor occupancy; predictions of <i>in vivo</i> ligand binding saturation levels; measures of <a href=\"/wiki/Target_affinity\" class=\"mw-redirect\" title=\"Target affinity\">target affinity</a> or assessment of non-target binding interactions as suggested by the European guidance for Phase I studies (depending on whether BIA 10-2474 could be considered to require 'special consideration' as outlined in the guideline).<sup id=\"cite_ref-protocolansm_8-6\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> On these issues, the French regulator's expert committee pointed out, based on the company's IC50 data, that complete FAAH inhibition should have been achieved with a dose of 1.25&#160;mg in humans. In fact, the trial tested doses up to 80 times more (100&#160;mg BIA 10-2474) than should have been required.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-4\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> The ANSM committee also requested data on non-target enzyme affinity from the manufacturer Bial.\n</p><p>Although the protocol summary reports no animal deaths during the studies, the ANSM expert committee reported that in fact several monkeys died or had to be euthanised during the dose escalation studies and that an explanation from Bial was pending. Also, two animals had to be euthanised in the 13-week dog study due to lung lesions - both from the top dose group.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-5\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> None of these animal deaths were described in the trial protocol.<sup id=\"cite_ref-protocolansm_8-7\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</p><p>It is not clear whether Bial disclosed these adverse animal findings either to Biotrial or to the ANSM in their application for clinical trial authorisation.<sup id=\"cite_ref-schubhan_26-0\" class=\"reference\"><a href=\"#cite_note-schubhan-26\">&#91;26&#93;</a></sup>\n</p><p>The findings presented in the trial protocol provide no explanation for the type and severity of events that would be later observed in Rennes.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-6\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> The preliminary report from the IGAS investigation, released by the French Minister for Health in February 2016, found there was no legal requirement in France for the trial sponsor to disclose all pre-clinical data to the ANSM. The Minister described this as an opportunity for improvement.<sup id=\"cite_ref-ministry2_27-0\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup> Nevertheless, the IGAS report commented that the investigation thus far had not found any reason to fault the ANSM's authorisation of the trial based on the preclinical data.<sup id=\"cite_ref-IGAS_21-1\" class=\"reference\"><a href=\"#cite_note-IGAS-21\">&#91;21&#93;</a></sup>\n</p><p>The final report by the ANSM Committee concluded regarding the preclinical studies that \"no aspects of the data that the TSSC has studied constituted a signal likely to contraindicate administration in humans.\" The report went on however to criticise Bial's Investigator's Brochure: \"the brochure contains many mistakes, inaccuracies, figure inversions or incorrect translation of source documents, making understanding difficult in several aspects. This is highly surprising given the regulatory importance of this document.\"<sup id=\"cite_ref-ANSMfinal_6-6\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Phase_I_clinical_trial\">Phase I clinical trial</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=5\" title=\"Edit section: Phase I clinical trial\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Overview\">Overview</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=6\" title=\"Edit section: Overview\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2015 Biotrial, a <a href=\"/wiki/Contract_research_organization\" title=\"Contract research organization\">contract research organization</a>, initiated a <a href=\"/wiki/First-in-man_study\" class=\"mw-redirect\" title=\"First-in-man study\">first-in-human</a> <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">trial</a> of BIA 10-2474 in healthy volunteers, with secondary endpoints to investigate neuropathic pain.<sup id=\"cite_ref-ANSMfinal_6-7\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup> The study was approved by the French regulatory authority, the <a href=\"/wiki/Agence_Nationale_de_S%C3%A9curit%C3%A9_du_M%C3%A9dicament_et_des_Produits_de_Sant%C3%A9\" title=\"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\">ANSM</a>, on 26 June 2015, and by the Brest regional ethics committee on 3 July 2015.<sup id=\"cite_ref-ANSM_Statement_3-1\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup> The trial protocol was leaked by <i><a href=\"/wiki/Le_Figaro\" title=\"Le Figaro\">Le Figaro</a></i><sup id=\"cite_ref-lefigaro_20-1\" class=\"reference\"><a href=\"#cite_note-lefigaro-20\">&#91;20&#93;</a></sup> before a different version was released by ANSM.<sup id=\"cite_ref-protocolansm_8-8\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-ansm22jan_18-2\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup> The manufacturer Bial refused the regulator's request to release the <a href=\"/wiki/Investigator%27s_brochure\" title=\"Investigator&#39;s brochure\">Investigator's brochure</a> and the product dossier (Investigational Medicinal Product Dossier), citing French law on trade secrets.<sup id=\"cite_ref-ansm22jan_18-3\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Trial_details\">Trial details</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=7\" title=\"Edit section: Trial details\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The study was entitled \"A double-blind, randomised, placebo-controlled, combined single and multiple ascending dose study including food interaction, to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of BIA 10-2474, in healthy volunteers\". The trial commenced on 9 July 2015 at a single centre in the city of <a href=\"/wiki/Rennes\" title=\"Rennes\">Rennes</a>, and commenced recruitment of 128 healthy volunteers, both men and women aged 18 to 55. Participants of the study were to receive \u20ac1,900 and, in turn, asked to stay at Biotrial's facility for two weeks during which time they would take the drug for ten days and undergo tests.<sup id=\"cite_ref-Breizh_2-1\" class=\"reference\"><a href=\"#cite_note-Breizh-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-science_28-0\" class=\"reference\"><a href=\"#cite_note-science-28\">&#91;28&#93;</a></sup> The study drug was presented as capsules in three different strengths (0.25, 2.5 and 10&#160;mg). The protocol describes four distinct parts to the study:\n</p>\n<ul><li>a single dose ascending part</li>\n<li>a <a href=\"/wiki/Crossover_study\" title=\"Crossover study\">cross-over</a> part to evaluate fed vs. fasting conditions (could be either single or multiple dose)</li>\n<li>a multiple dose ascending part</li>\n<li>a pharmacodynamics part to evaluate the effect of BIA 10-2474 vs placebo with different challenge agents<sup id=\"cite_ref-protocolansm_8-9\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup></li></ul>\n<p>The protocol specifies the first three parts would be <a href=\"/wiki/Blind_experiment\" class=\"mw-redirect\" title=\"Blind experiment\">double-blind</a> but the pharmacodynamics part would be <a href=\"/wiki/Open-label_trial\" title=\"Open-label trial\">open label</a>. According to the protocol, dose levels and numbers of groups could be increased, or were not yet defined, and would depend on what was observed with initial dosing, (an approach known as <a href=\"/wiki/Adaptive_clinical_trial\" title=\"Adaptive clinical trial\">adaptive trial design</a>). Thus many details of the key multi-dose part are not included in the trial protocol.<sup id=\"cite_ref-protocolansm_8-10\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup> The absence of these details was criticised by scientists and in the media,<sup id=\"cite_ref-nature_29-0\" class=\"reference\"><a href=\"#cite_note-nature-29\">&#91;29&#93;</a></sup><sup id=\"cite_ref-RSS_30-0\" class=\"reference\"><a href=\"#cite_note-RSS-30\">&#91;30&#93;</a></sup> before the ANSM published further details of the dosing.<sup id=\"cite_ref-ansm27Jan_31-0\" class=\"reference\"><a href=\"#cite_note-ansm27Jan-31\">&#91;31&#93;</a></sup> The <a href=\"/wiki/Royal_Statistical_Society\" title=\"Royal Statistical Society\">Royal Statistical Society</a> was particularly critical, stating that it had \"clear statistical reservations about the trial's study design\", and that the protocol lacked features such as a <a href=\"/wiki/Risk_assessment\" title=\"Risk assessment\">risk assessment</a>, recommended in the wake of the <a href=\"/wiki/TGN1412\" class=\"mw-redirect\" title=\"TGN1412\">TGN1412</a> incident to prevent severe adverse events occurring in these circumstances.<sup id=\"cite_ref-RSS_30-1\" class=\"reference\"><a href=\"#cite_note-RSS-30\">&#91;30&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Starting_dose_and_subsequent_doses\">Starting dose and subsequent doses</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=8\" title=\"Edit section: Starting dose and subsequent doses\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>For the single dose part of the study, the protocol describes eight groups of eight volunteers (3:1 <a href=\"/wiki/Random_assignment\" title=\"Random assignment\">randomised</a>) who were to receive single doses of BIA 10-2474 at 0.25, 1.25, 2.5, 5.0, 10, 20, 40 and 100&#160;mg, with the possibility of additional groups to be added if no <a href=\"/wiki/Maximum_tolerated_dose\" class=\"mw-redirect\" title=\"Maximum tolerated dose\">maximum tolerated dose</a> was reached.<sup id=\"cite_ref-protocolansm_8-11\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup> In describing the rationale for the starting dose, the authors of the protocol conclude that:\n</p>\n<pre><i>No target organ was identified during toxicology studies and few adverse clinical findings were observed at the highest dose tested. For the single ascending dose part [of the clinical trial], a starting dose of 0.25 mg was judged to be safe for a first-in-human administration.</i><sup id=\"cite_ref-protocolansm_8-12\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</pre>\n<p>The protocol provides for the first two subjects of the first single dose cohort to receive the first dose as a sentinel dose, that is, either 0.25&#160;mg BIA 10-2474 or a placebo on the first day, then wait for 24h before treating the other 5:1 subjects. In the event no safety concerns had emerged in the foregoing, all other single- and multi-dose groups were to be dosed with a 10-minute interval between recipients.<sup id=\"cite_ref-protocolansm_8-13\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</p><p>For the multiple ascending dose part of the study, the protocol planned four groups of eight volunteers (3:1 <a href=\"/wiki/Random_assignment\" title=\"Random assignment\">randomised</a>) who were to receive a single dose orally, once daily for 10 days at different dose levels. However, the protocol defines no doses for these groups, stating that this will be based on the outcome of the single dose portion of the trial. Further dose groups up to a maximum of eight groups could be added depending on whether adverse events were observed. The authors note that nonetheless, the starting dose will not exceed 33% of the <a href=\"/wiki/Maximum_tolerated_dose\" class=\"mw-redirect\" title=\"Maximum tolerated dose\">maximum tolerated dose</a> (MTD) identified in the single dose groups (or 33% of the maximum administered dose if the MTD is not reached).<sup id=\"cite_ref-protocolansm_8-14\" class=\"reference\"><a href=\"#cite_note-protocolansm-8\">&#91;8&#93;</a></sup>\n</p><p>Further details of the study as it was actually conducted have been published by the French agency (ANSM). The dose groups for the single dose part were as described in the protocol, with no additional groups undertaken. In the crossover part, a single 40&#160;mg dose was given to a group of 12 subjects. In the multiple dose ascending part, the doses were 2.5, 5.0, 10, 20 and 50&#160;mg BIA 10-2474, each to be given once per day for 10 days to groups of 8 volunteers (3:1 randomised). The severe adverse events were observed in the 50&#160;mg dose group.<sup id=\"cite_ref-Ministry_Statement_4-2\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-ansm27Jan_31-1\" class=\"reference\"><a href=\"#cite_note-ansm27Jan-31\">&#91;31&#93;</a></sup>\n</p><p>The ANSM expert committee reported<sup id=\"cite_ref-ANSM_Comite_Minutes_15-7\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> that complete FAAH inhibition should have been achieved by a dose of 1.25&#160;mg remarking that:\n</p>\n<pre><i>It appears unjustified to plan to test a dose (100 mg) 80 times higher than that presumed to induce complete and prolonged FAAH inhibition.</i><sup id=\"cite_ref-ANSM_Comite_Minutes_15-8\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup> \n</pre>\n<p>Further, the ANSM committee remarked that the gap between the 20&#160;mg and 50&#160;mg dose cohorts, in effect, skipped a dose based on extrapolation from the single dose part of the study, and that the progression to 50&#160;mg was too large a jump. On reviewing the subject data from the trial itself, the committee noted that BIA 10-2474 showed non-linear pharmacokinetics at doses between 40\u2013100&#160;mg (that is, the molecule appeared to be accumulating at higher doses) and that most likely the elimination mechanism had become saturated. Thus dosing at 50&#160;mg daily was - each day - 40 times more than required to achieve complete inhibition, and in practice this dose level resulted in accumulation.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-9\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Trial_status_at_the_time_of_serious_adverse_events\">Trial status at the time of serious adverse events</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=9\" title=\"Edit section: Trial status at the time of serious adverse events\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>According to Bial and the Rennes University Hospital, by the time the serious adverse reactions emerged, 116 subjects had been recruited and 84 other volunteers had received the drug during the trial, with no <a href=\"/wiki/Serious_adverse_event\" title=\"Serious adverse event\">serious adverse events</a> being reported.<sup id=\"cite_ref-Bialstatement_1-4\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Ministry_Statement_4-3\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-Rennes2_5-1\" class=\"reference\"><a href=\"#cite_note-Rennes2-5\">&#91;5&#93;</a></sup> The single dose part (up to 100&#160;mg BIA 10-2474), the fed vs. fasting part, and the first four dose groups of the multi-dose part of the study had each been completed in 2015. Notably, the administration of 20&#160;mg BIA 10-2474 once daily for 10 consecutive days elicited no serious adverse events in the six volunteers who received it.<sup id=\"cite_ref-ansm22jan_18-4\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-ansm27Jan_31-2\" class=\"reference\"><a href=\"#cite_note-ansm27Jan-31\">&#91;31&#93;</a></sup>\n</p><p>Dosing of eight volunteers in the highest multi-dose dose group in the BIA 10-2474 trial commenced on 6 January 2016. Six of the participants received 50&#160;mg per day of the drug while two received placebo.<sup id=\"cite_ref-Bialstatement_1-5\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Ministry_Statement_4-4\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup> The first subject became ill on the evening of the 5th day of dosing (10 January). On the following day, the other subjects received a 6th dose at 8:00am before the trial was suspended later that day (11 January).<sup id=\"cite_ref-ansm27Jan_31-3\" class=\"reference\"><a href=\"#cite_note-ansm27Jan-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-Biotrial_32-0\" class=\"reference\"><a href=\"#cite_note-Biotrial-32\">&#91;32&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Death_and_serious_adverse_events\">Death and serious adverse events</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=10\" title=\"Edit section: Death and serious adverse events\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The fifth dose level (50&#160;mg per day for 10 days) of the multi-dose part of study had been underway for five days when the first volunteer became ill and was hospitalized at the <a href=\"/wiki/Rennes_University_Hospital\" title=\"Rennes University Hospital\">Rennes University Hospital</a> on the evening of 10 January 2016 with <a href=\"/wiki/Symptom\" title=\"Symptom\">symptoms</a> similar to a <a href=\"/wiki/Stroke\" title=\"Stroke\">stroke</a>.<sup id=\"cite_ref-ladepeche_33-0\" class=\"reference\"><a href=\"#cite_note-ladepeche-33\">&#91;33&#93;</a></sup> The following day, the man lapsed into a coma and was shortly thereafter declared <a href=\"/wiki/Brain_dead\" class=\"mw-redirect\" title=\"Brain dead\">brain dead</a>.<sup id=\"cite_ref-Ministry_Statement_4-5\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-Rennes2_5-2\" class=\"reference\"><a href=\"#cite_note-Rennes2-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-ansm27Jan_31-4\" class=\"reference\"><a href=\"#cite_note-ansm27Jan-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-bbc_34-0\" class=\"reference\"><a href=\"#cite_note-bbc-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-reuters_35-0\" class=\"reference\"><a href=\"#cite_note-reuters-35\">&#91;35&#93;</a></sup> According to the hospital, the man died at midday on 17 January 2016.<sup id=\"cite_ref-Rennes2_5-3\" class=\"reference\"><a href=\"#cite_note-Rennes2-5\">&#91;5&#93;</a></sup> Four of the other five men in the same dosage group were also hospitalized between 10\u201313 January<sup id=\"cite_ref-ladepeche_33-1\" class=\"reference\"><a href=\"#cite_note-ladepeche-33\">&#91;33&#93;</a></sup> suffering injuries similar to the man who died, including deep <a href=\"/wiki/Haemorrhagic\" class=\"mw-redirect\" title=\"Haemorrhagic\">haemorrhagic</a> and <a href=\"/wiki/Necrosis\" title=\"Necrosis\">necrotic</a> <a href=\"/wiki/Lesions\" class=\"mw-redirect\" title=\"Lesions\">lesions</a> seen on <a href=\"/wiki/Brain_MRI\" class=\"mw-redirect\" title=\"Brain MRI\">brain MRI</a>. All the MRI findings, though widely varying in severity, were of the same form and seen in the <a href=\"/wiki/Hippocampus\" title=\"Hippocampus\">hippocampus</a> and <a href=\"/wiki/Pons\" title=\"Pons\">pons</a> of the affected individuals.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-10\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup>  Biotrial stopped the study on 11 January and both the ANSM and regional ethics committee were notified on 14 January.<sup id=\"cite_ref-Bialstatement_1-6\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-ANSM_Statement_3-2\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup>\n</p><p>The men who were hospitalised were all from the group which received the highest dose of the multiple ascending part of the trial. A neurologist at the University of Rennes Hospital Center, Professor Pierre-Gilles Edan, stated in a press conference with the French Minister for Health, that 3 of the 4 men who were displaying neurological symptoms \"already have a severe enough clinical picture to fear that even in the best situation there will be an irreversible handicap\" and were being given <a href=\"/wiki/Corticosteroid\" title=\"Corticosteroid\">corticosteroids</a> to control the <a href=\"/wiki/Inflammation\" title=\"Inflammation\">inflammation</a>.<sup id=\"cite_ref-ladepeche_33-2\" class=\"reference\"><a href=\"#cite_note-ladepeche-33\">&#91;33&#93;</a></sup> The sixth man from the group was not showing adverse effects but was hospitalized on 15 January 2016 for observation.<sup id=\"cite_ref-reuters_35-1\" class=\"reference\"><a href=\"#cite_note-reuters-35\">&#91;35&#93;</a></sup><sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup><sup id=\"cite_ref-science_28-1\" class=\"reference\"><a href=\"#cite_note-science-28\">&#91;28&#93;</a></sup> Other study volunteers who had received doses with no ill effects were asked to return for further testing.<sup id=\"cite_ref-ANSM_Statement_3-3\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup>\n</p><p>The man who died was later named by local news media as Guillaume Molinet, 49, an artist and father of four from Guilliers, a town in the <a href=\"/wiki/Brittany_(administrative_region)\" title=\"Brittany (administrative region)\">Breton</a> <a href=\"/wiki/Departments_of_France\" title=\"Departments of France\">department</a> of <a href=\"/wiki/Morbihan\" title=\"Morbihan\">Morbihan</a>.<sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup> According to the man's brother Laurent Molinet, Mr Molinet was recruited as a stand-by and went to Rennes not expecting to be dosed, only being given BIA 10-2474 because another volunteer dropped out. Molinet's family said they were originally told he had suffered a stroke that was unrelated to the clinical trial, though this quickly turned out not to be the case.<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup> Molinet's family objected that key information was hidden by Bial/Biotrial and is reported to have launched a manslaughter lawsuit.<sup id=\"cite_ref-lemonde2_39-0\" class=\"reference\"><a href=\"#cite_note-lemonde2-39\">&#91;39&#93;</a></sup><sup id=\"cite_ref-ledauphine_40-0\" class=\"reference\"><a href=\"#cite_note-ledauphine-40\">&#91;40&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Reaction_and_investigations\">Reaction and investigations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=11\" title=\"Edit section: Reaction and investigations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The events in Rennes were made public on 15 January 2016<sup id=\"cite_ref-Bialstatement_1-7\" class=\"reference\"><a href=\"#cite_note-Bialstatement-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-ANSM_Statement_3-4\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-Ministry_Statement_4-6\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup> and were reported widely in the media in France,<sup id=\"cite_ref-lemonde_41-0\" class=\"reference\"><a href=\"#cite_note-lemonde-41\">&#91;41&#93;</a></sup>\n<sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup><sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup> internationally in mainstream news<sup id=\"cite_ref-44\" class=\"reference\"><a href=\"#cite_note-44\">&#91;44&#93;</a></sup><sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup><sup id=\"cite_ref-abc_46-0\" class=\"reference\"><a href=\"#cite_note-abc-46\">&#91;46&#93;</a></sup><sup id=\"cite_ref-47\" class=\"reference\"><a href=\"#cite_note-47\">&#91;47&#93;</a></sup> and scientific media.<sup id=\"cite_ref-48\" class=\"reference\"><a href=\"#cite_note-48\">&#91;48&#93;</a></sup><sup id=\"cite_ref-49\" class=\"reference\"><a href=\"#cite_note-49\">&#91;49&#93;</a></sup><sup id=\"cite_ref-bioworld_50-0\" class=\"reference\"><a href=\"#cite_note-bioworld-50\">&#91;50&#93;</a></sup> All these reports drew comparisons between this incident and the <a href=\"/wiki/TGN1412\" class=\"mw-redirect\" title=\"TGN1412\">TGN1412</a> trial at Northwick Park, London in which six volunteers suffered life-threatening drug reactions during a Phase I study in 2006.<sup id=\"cite_ref-51\" class=\"reference\"><a href=\"#cite_note-51\">&#91;51&#93;</a></sup> \n</p><p>The journal <a href=\"/wiki/Nature_(journal)\" title=\"Nature (journal)\">Nature</a> quoted Bial spokeswoman Susana Vasconcelos as saying \"the trial had been conducted in accordance with all the good international practices guidelines, with the completion of tests and preclinical trials and that the company is committed to determine thoroughly and exhaustively the causes which are at the origin of this situation\u201d. Bial also denounced the unauthorised release of the trial protocol and was critical of the wide-ranging speculation by scientists and the media about the possible cause of the incident.<sup id=\"cite_ref-nature_29-1\" class=\"reference\"><a href=\"#cite_note-nature-29\">&#91;29&#93;</a></sup> In July 2016, Bial's Executive Director Ant\u00f3nio Portela confirmed his company's decision to permanently abandon development of the molecule.<sup id=\"cite_ref-52\" class=\"reference\"><a href=\"#cite_note-52\">&#91;52&#93;</a></sup>   \n</p><p>The journal also sought comment from Jean-Marc Gandon, the president and chief executive of the CRO Biotrial, who said \"he cannot immediately respond to queries from Nature, that he is focused on trying to save the patients and that the company will respond later\".<sup id=\"cite_ref-53\" class=\"reference\"><a href=\"#cite_note-53\">&#91;53&#93;</a></sup> Biotrial stated its position that \"The trial was conducted in full compliance with the international regulations and Biotrial\u2019s procedures, in particular the emergency procedures\".<sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup><sup id=\"cite_ref-55\" class=\"reference\"><a href=\"#cite_note-55\">&#91;55&#93;</a></sup>\n</p><p>As of March 2016 it remained unclear whether Bial disclosed the adverse animal findings to Biotrial, including the deaths of monkeys and dogs in several studies. Fran\u00e7ois Peaucelle, the director general of Biotrial, is reported to have told Le Figaro. \u201cWe received a 15-page summary of the tests that was based on data that would have filled a lorry. From that data, there was nothing worrying in view of the dosage we were administering to humans.\u201d<sup id=\"cite_ref-schubhan_26-1\" class=\"reference\"><a href=\"#cite_note-schubhan-26\">&#91;26&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"French_authorities\">French authorities</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=12\" title=\"Edit section: French authorities\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM) announced an investigation, and that an inspection of the trial site was already underway.<sup id=\"cite_ref-ANSM_Statement_3-5\" class=\"reference\"><a href=\"#cite_note-ANSM_Statement-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-bioworld_50-1\" class=\"reference\"><a href=\"#cite_note-bioworld-50\">&#91;50&#93;</a></sup> and formation of a specialist committee of <a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">pharmacologists</a>, <a href=\"/wiki/Toxicology\" title=\"Toxicology\">toxicologists</a> and <a href=\"/wiki/Neurology\" title=\"Neurology\">neurologists</a> to review all existing data on FAAH inhibitor drugs.<sup id=\"cite_ref-ansm22jan_18-5\" class=\"reference\"><a href=\"#cite_note-ansm22jan-18\">&#91;18&#93;</a></sup> The French health minister <a href=\"/wiki/Marisol_Touraine\" title=\"Marisol Touraine\">Marisol Touraine</a> who visited the trial site in Rennes and spoke with the victims' families, called the events \u201can accident of exceptional gravity, promised to investigate the matter via the <a href=\"https://fr.wikipedia.org/wiki/Inspection_g%C3%A9n%C3%A9rale_des_affaires_sociales\" class=\"extiw\" title=\"fr:Inspection g\u00e9n\u00e9rale des affaires sociales\">Inspector General for Social Affairs</a> (IGAS) with a final report due end of March.<sup id=\"cite_ref-Ministry_Statement_4-7\" class=\"reference\"><a href=\"#cite_note-Ministry_Statement-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-ministry2_27-1\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-bioworld_50-2\" class=\"reference\"><a href=\"#cite_note-bioworld-50\">&#91;50&#93;</a></sup> A <a href=\"/wiki/Judiciary\" title=\"Judiciary\">judicial</a> investigation was also initiated after the <a href=\"https://fr.wikipedia.org/wiki/Procureur_g%C3%A9n%C3%A9ral_(France)\" class=\"extiw\" title=\"fr:Procureur g\u00e9n\u00e9ral (France)\">Office of the Chief Prosecutor</a> for Paris announced it would look into potential charges of involuntary injury through its public health enforcement section, seeking assistance from the <a href=\"/wiki/Gendarmerie\" title=\"Gendarmerie\">Gendarmerie</a> in Rennes and the <a href=\"/wiki/Ministry_of_Justice_(France)\" title=\"Ministry of Justice (France)\">Ministry of Justice's</a> Office for the Environment and Public Health.<sup id=\"cite_ref-bioworld_50-3\" class=\"reference\"><a href=\"#cite_note-bioworld-50\">&#91;50&#93;</a></sup>\n</p><p>The ONIAM (Office National d\u2019Indemnisation des Accidents M\u00e9dicaux), responsible for medical injury compensation, stated only 10 accidents had occurred during clinical trials over the past 15 years per its records, and that those cases had \u201cconsequences infinitely less serious\u201d than the incident in Rennes.<sup id=\"cite_ref-56\" class=\"reference\"><a href=\"#cite_note-56\">&#91;56&#93;</a></sup>\n</p><p>Initial reports from the authorities suggested that the causes of the brain injuries was likely to be due to the mechanism of BIA 10-2474 and the doses employed in the trial.<sup id=\"cite_ref-ANSM_Comite_Minutes_15-11\" class=\"reference\"><a href=\"#cite_note-ANSM_Comite_Minutes-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-IGAS_21-2\" class=\"reference\"><a href=\"#cite_note-IGAS-21\">&#91;21&#93;</a></sup> ANSM Director General Dominique Martin said \"It is clearly the molecule that is the cause\u201d, following the publication of the ANSM expert committee's initial findings on 7 March 2016.<sup id=\"cite_ref-57\" class=\"reference\"><a href=\"#cite_note-57\">&#91;57&#93;</a></sup>\n</p><p>In May 2016, the French Health Minister announced several new measures for clinical trials in France, including the establishment of an expert group within the ANSM for review of first in human and early phase studies.<sup id=\"cite_ref-58\" class=\"reference\"><a href=\"#cite_note-58\">&#91;58&#93;</a></sup> \n</p>\n<h4><span id=\"Inspection_g.C3.A9n.C3.A9rale_des_affaires_sociales_reports\"></span><span class=\"mw-headline\" id=\"Inspection_g\u00e9n\u00e9rale_des_affaires_sociales_reports\">Inspection g\u00e9n\u00e9rale des affaires sociales reports</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=13\" title=\"Edit section: Inspection g\u00e9n\u00e9rale des affaires sociales reports\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>The Inspection g\u00e9n\u00e9rale des affaires sociales (IGAS) released a preliminary report on 5 February 2016.<sup id=\"cite_ref-IGAS_21-3\" class=\"reference\"><a href=\"#cite_note-IGAS-21\">&#91;21&#93;</a></sup> The French Minister of Health indicated that the cause of the death of one of the subjects had not been identified; it claimed Biotrial failed three major issues: The study should have been stopped when the first subject was hospitalized so  the drug would not have been given to five others; the incident should have been reported immediately, namely January 10, not four days later; all other subjects should have been notified right away asking them if they would like to continue in the study.<sup id=\"cite_ref-ministry2_27-2\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-59\" class=\"reference\"><a href=\"#cite_note-59\">&#91;59&#93;</a></sup> The Health Minister noted further that a number of the trial protocol provisions had been too vague and not precise enough; that the eligibility criteria should have been more explicit regarding substance use habits of the volunteers and that there was no legal requirement for the sponsor to disclose all pre-clinical data to the ANSM. The Minister announced that all clinical trials in France in the event of a serious, unexpected adverse event such as this would be explicitly required to re-consent the remaining trial participants.<sup id=\"cite_ref-ministry2_27-3\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup> The Comit\u00e9 de Protection des Personnes (CPP) in Brest, a research ethics committee, has asked Bial for the exclusion criteria on the consuming cannabis and other psychoactive substances.<sup id=\"cite_ref-60\" class=\"reference\"><a href=\"#cite_note-60\">&#91;60&#93;</a></sup>\n</p><p>Biotrial published a detailed response on its website, expressing its disappointment to learn of the report via the media and not prior to its publication from the Health Ministry.<sup id=\"cite_ref-Biotrial_32-1\" class=\"reference\"><a href=\"#cite_note-Biotrial-32\">&#91;32&#93;</a></sup> It stated the trial was halted as soon as it became apparent that the first volunteer had a serious adverse event, and that the man's initial symptoms on 10 January had been mild enough that he was expected to return to the trial facility on 11 January which is why it did not re-consent all volunteers. CHU informed Biotrial at 10:00 am on 11 January that the man had likely had a <a href=\"/wiki/Stroke\" title=\"Stroke\">stroke</a>, at which point the trial was halted, though it was not known whether the stroke had anything to do with the study drug. This was after further doses had been given to the other volunteers (at 8:00 am that morning). Biotrial's statement offered no comment on the time taken between the trial halt at 10:00 am on the 11th and the notification of the authorities three days later on the 14th.<sup id=\"cite_ref-Biotrial_32-2\" class=\"reference\"><a href=\"#cite_note-Biotrial-32\">&#91;32&#93;</a></sup>\n</p>\n<h4><span id=\"ANSM_Comit.C3.A9_Scientifique_Sp.C3.A9cialis.C3.A9_Temporaire\"></span><span class=\"mw-headline\" id=\"ANSM_Comit\u00e9_Scientifique_Sp\u00e9cialis\u00e9_Temporaire\">ANSM Comit\u00e9 Scientifique Sp\u00e9cialis\u00e9 Temporaire</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=14\" title=\"Edit section: ANSM Comit\u00e9 Scientifique Sp\u00e9cialis\u00e9 Temporaire\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>The final report from the ANSM Committee appointed to investigate the matter concluded in April 2016 that:\n<i>[T]he most likely hypothesis to date is that of toxicity specific to the molecule via its binding to other brain cell structures, facilitated by (1) its low specificity for its target enzyme; (2) use of multiple doses a lot higher than those leading (at least in humans) to complete and lasting FAAH inhibition, and; (3) its probable gradual accumulation in the brain, undoubtedly related to the specific pharmacokinetic features of BIA 10\u20102474.</i><sup id=\"cite_ref-ANSMfinal_6-8\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup>\n</p><p>The Committee also criticised the clinical study design which \"probably significantly contributed to the accident\", noting that administration of the top multi-dose groups did not and could not take into account emerging pharmacokinetic data from latest dose groups and offered no chance to adjust the dose as adverse events emerged. The choice of dose escalation levels (20 to 50 to 100&#160;mg) was based on pharmacokinetic data from the 10&#160;mg group and data from the 50&#160;mg dose group (that would have clearly shown non-proportional dose kinetics) were not yet available when administration to the 100&#160;mg multi-dose group commenced.<sup id=\"cite_ref-ANSMfinal_6-9\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup>\n</p><p>The Committee made six recommendations, which it invited European and International regulators to consider (reproduced here in brief):\n</p>\n<ul><li>Justification and demonstration of pharmacological activity predictive of efficacy in humans cannot be considered to be secondary. [P]harmacology studies [should be sufficient] to establish a dose\u2010effect curve (where appropriate) [and] to be reasonably predictive of real\u2010life, future therapeutic efficacy.</li>\n<li>A neuropsychological assessment with clinical interview and cognitive tests should be a compulsory part of assessment during volunteer screening, inclusion and clinical monitoring in a Phase 1 trial for drugs with \"central nervous system\" tropism.</li>\n<li>All first\u2010in\u2010human and Phase 1 protocols should, unless unnecessary, provide for the doses to be tested in volunteers to be adjusted according to the data collected in volunteers already having been exposed during the trial.</li>\n<li>During first\u2010in\u2010human and Phase 1 trials, volunteer safety should take precedence over any practical, economic or regulatory considerations.</li>\n<li>Dose escalation strategies in first\u2010in\u2010human and Phase 1 trials should take account of considerations based on common clinical and pharmacological sense.</li>\n<li>The Committee would like to see a debate opened at European and international level, on access to data from ongoing or previous first\u2010in\u2010human and Phase 1 trials.<sup id=\"cite_ref-ANSMfinal_6-10\" class=\"reference\"><a href=\"#cite_note-ANSMfinal-6\">&#91;6&#93;</a></sup></li></ul>\n<h3><span class=\"mw-headline\" id=\"Agencies_outside_France\">Agencies outside France</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=15\" title=\"Edit section: Agencies outside France\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>A <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> (EMA) spokesperson said in January 2016 that \"EU authorities will look carefully at the findings to determine if further measures are needed to protect health of clinical trial participants. Until EU authorities have the full picture, it is not possible to say whether any revisions to EU guidelines are required\".<sup id=\"cite_ref-61\" class=\"reference\"><a href=\"#cite_note-61\">&#91;61&#93;</a></sup> Later, in July 2016, the agency proposed to revise its key first-in-human clinical trial guideline, the last significant revision having been published in response to the 2006 <a href=\"/wiki/TGN1412\" class=\"mw-redirect\" title=\"TGN1412\">TGN1412</a> clinical trial that had had similarly dire effects in its trial volunteers.<sup id=\"cite_ref-62\" class=\"reference\"><a href=\"#cite_note-62\">&#91;62&#93;</a></sup> The EMA stated the proposal aimed to address risks posed by complex trials, such as the one undertaken in Rennes, having 'several steps of clinical development within a single clinical trial protocol'.<sup id=\"cite_ref-63\" class=\"reference\"><a href=\"#cite_note-63\">&#91;63&#93;</a></sup>\n</p><p>The <a href=\"/wiki/European_Investment_Bank\" title=\"European Investment Bank\">European Investment Bank</a>, which provided 110 million euros in funding for Bial's FAAH inhibitor programme stated it had been in contact with the company about the incident, but that \"it would be premature to consider recall of the EIB loan at this stage\".<sup id=\"cite_ref-64\" class=\"reference\"><a href=\"#cite_note-64\">&#91;64&#93;</a></sup>\n</p><p>The US <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a> issued a statement that it was in contact with its counterparts the ANSM as well as the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">EMA</a> and announced investigations into FAAH inhibitors as a <a href=\"/wiki/Drug_class\" title=\"Drug class\">drug class</a>.\"FDA is in the process of collecting and reviewing safety information pertinent to FAAH inhibitors under investigation in the US. FDA will work with sponsors to ensure the safety of participants in clinical studies and take regulatory action as appropriate.\" Later, in August 2016, the Agency issued a further statement: \"The Agency has found, based on the available information, that BIA 10-2474 exhibits a unique toxicity that does not extend to other drugs in the class, called fatty acid amide hydrolase (FAAH) inhibitors.\"<sup id=\"cite_ref-FDA_65-0\" class=\"reference\"><a href=\"#cite_note-FDA-65\">&#91;65&#93;</a></sup>\n</p><p>The German drug regulator, the <a href=\"/wiki/Federal_Institute_for_Drugs_and_Medical_Devices\" title=\"Federal Institute for Drugs and Medical Devices\">Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)</a> issued a statement 19 January that no clinical trials with FAAH inhibitors were underway in Germany, but that it had authorised seven such trials previously, which were completed without serious incidents.<sup id=\"cite_ref-66\" class=\"reference\"><a href=\"#cite_note-66\">&#91;66&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Outcome_for_trial_participants\">Outcome for trial participants</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=16\" title=\"Edit section: Outcome for trial participants\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The Rennes University Hospital provided updates on the remaining volunteers in the study and the treating specialists later published a medical report describing the sickened volunteers in November 2016 in <a href=\"/wiki/The_New_England_Journal_of_Medicine\" title=\"The New England Journal of Medicine\">The New England Journal of Medicine</a>.<sup id=\"cite_ref-NEJM_67-0\" class=\"reference\"><a href=\"#cite_note-NEJM-67\">&#91;67&#93;</a></sup> The published medical report described the adverse events as \"An acute and rapidly progressive neurologic syndrome [of which] the main clinical features were headache, a cerebellar syndrome, memory impairment, and altered consciousness\". The authors were of the view that \"the toxic effects we observed were related to drug accumulation. This hypothesis is supported by the nonlinear pharmacokinetics of BIA 10-2474 for doses higher than 40 to 100 mg\" and as reported by the ANSM's expert committee. The authors were not however granted access to information from the post-mortem of the man who died.<sup id=\"cite_ref-NEJM_67-1\" class=\"reference\"><a href=\"#cite_note-NEJM-67\">&#91;67&#93;</a></sup> \n</p><p>Of the five survivors from the top dose group and the other trial participants:\n</p>\n<ul><li>Two of the top dose group survivors with serious neurological injuries were discharged to care facilities closer to their homes on 18 January 2016, and a third on the 20th.<sup id=\"cite_ref-Rennes4_68-0\" class=\"reference\"><a href=\"#cite_note-Rennes4-68\">&#91;68&#93;</a></sup><sup id=\"cite_ref-Rennes5_69-0\" class=\"reference\"><a href=\"#cite_note-Rennes5-69\">&#91;69&#93;</a></sup> As of 26 January, one of these men was being treated as an outpatient; one was suffering an intercurrent illness and had not yet been discharged, and a third had improved enough to go home.<sup id=\"cite_ref-Rennes7_70-0\" class=\"reference\"><a href=\"#cite_note-Rennes7-70\">&#91;70&#93;</a></sup> The last of the patients had improved enough to be discharged to home 21 January 2016.<sup id=\"cite_ref-Rennes6_71-0\" class=\"reference\"><a href=\"#cite_note-Rennes6-71\">&#91;71&#93;</a></sup> All five survivors were due to have a follow-up evaluation at the hospital in Rennes at the end of February 2016.<sup id=\"cite_ref-ministry2_27-4\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup></li>\n<li>The hospital contacted the other 84 volunteers who received BIA 10-2474 and found no clinical or radiological abnormalities on re-examination of 75 of the volunteers in January 2016.<sup id=\"cite_ref-ministry2_27-5\" class=\"reference\"><a href=\"#cite_note-ministry2-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-Rennes7_70-1\" class=\"reference\"><a href=\"#cite_note-Rennes7-70\">&#91;70&#93;</a></sup> An ANSM investigation into these 84 volunteers looked for evidence of brain abnormalities on MRI and any report of neurological symptoms experienced during or after the trial.<sup id=\"cite_ref-72\" class=\"reference\"><a href=\"#cite_note-72\">&#91;72&#93;</a></sup> The ANSM report, published in November 2016, concluded that the findings reported in these individuals were consistent with the typical incidence in the wider population and were not similar in characteristics to those seen in the top dose group.</li>\n<li>The participant from the top dose group who was hospitalised for observation did not develop any symptoms, nor any findings by MRI, and returned home on 18 January 2016.<sup id=\"cite_ref-Rennes3_73-0\" class=\"reference\"><a href=\"#cite_note-Rennes3-73\">&#91;73&#93;</a></sup> The individual had remained asymptomatic as of November 2016.<sup id=\"cite_ref-NEJM_67-2\" class=\"reference\"><a href=\"#cite_note-NEJM-67\">&#91;67&#93;</a></sup></li>\n<li>According to the published medical report, at least two of the top dose group survivors continued to suffer effects as of November 2016 - \"residual memory impairment\" in one case, and \"a residual cerebellar syndrome\" in another.<sup id=\"cite_ref-NEJM_67-3\" class=\"reference\"><a href=\"#cite_note-NEJM-67\">&#91;67&#93;</a></sup> In December 2016, a Bial representative at a British Pharmacological Society conference in London confirmed that the four symptomatic survivors who received the top dose were continuing to suffer neurological side-effects.<sup id=\"cite_ref-74\" class=\"reference\"><a href=\"#cite_note-74\">&#91;74&#93;</a></sup></li></ul>\n<p>News reports from March 2016 described the condition of St\u00e9phane Schubhan (42), a professional photographer from <a href=\"/wiki/La_Fl%C3%A8che\" title=\"La Fl\u00e8che\">La Fl\u00e8che</a>, <a href=\"/wiki/Sarthe\" title=\"Sarthe\">Sarthe</a> and participant of the top dose cohort. Mr. Schubhan \"sleeps badly, has nightmares, sees double at all times, walks with difficulty, and succumbs to dizziness and nausea if he stands more than 10 minutes at a time\" and does not know if he will be able to work again. Mr. Schubhan said he had participated in a previous clinical trial, but in this case he was never informed about the animal deaths that were later revealed and would never have consented to take part had he known. Doctors have told Schubhan that they hope he will improve over the coming 6\u201312 months but that they do not know what the outcome will be.<sup id=\"cite_ref-schubhan_26-2\" class=\"reference\"><a href=\"#cite_note-schubhan-26\">&#91;26&#93;</a></sup>\n</p><p>Under French Law, all clinical trial participants are protected by the 1988 <a href=\"/wiki/Loi_Huriet_S%C3%A9rusclat\" title=\"Loi Huriet S\u00e9rusclat\">Huriet Law</a> on the protection of persons in clinical research. The BIA 10-2474 trial participants are therefore entitled to financial compensation as well as recourse to civil and criminal proceedings.<sup id=\"cite_ref-75\" class=\"reference\"><a href=\"#cite_note-75\">&#91;75&#93;</a></sup> The family of Guillaume Molinet commenced manslaughter proceedings in late January 2016.<sup id=\"cite_ref-lemonde2_39-1\" class=\"reference\"><a href=\"#cite_note-lemonde2-39\">&#91;39&#93;</a></sup><sup id=\"cite_ref-ledauphine_40-1\" class=\"reference\"><a href=\"#cite_note-ledauphine-40\">&#91;40&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Implications_for_other_FAAH_inhibitors\">Implications for other FAAH inhibitors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=17\" title=\"Edit section: Implications for other FAAH inhibitors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table class=\"plainlinks metadata ambox ambox-content ambox-Primary_sources\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Question_book-new.svg\" class=\"image\"><img alt=\"Question book-new.svg\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png\" width=\"50\" height=\"39\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x\" data-file-width=\"512\" data-file-height=\"399\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This section <b>needs additional <a href=\"/wiki/Wikipedia:Scientific_citation_guidelines\" title=\"Wikipedia:Scientific citation guidelines\">citations</a> to <a href=\"/wiki/Wikipedia:Reliable_sources#Scholarship\" class=\"mw-redirect\" title=\"Wikipedia:Reliable sources\">secondary or tertiary sources</a></b><span class=\"hide-when-compact\"> such as review articles, monographs, or textbooks.  Please add such references to provide context and establish the relevance of any <a href=\"/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources\" title=\"Wikipedia:No original research\">primary research articles</a> cited. Unsourced material may be challenged and removed.</span>  <small><i>(January 2016)</i></small></div></td></tr></tbody></table>\n<p>Other pharmaceutical companies, including <a href=\"/wiki/Merck_%26_Co.\" title=\"Merck &amp; Co.\">Merck</a>, <a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a>, <a href=\"/wiki/Johnson_%26_Johnson\" title=\"Johnson &amp; Johnson\">Johnson &amp; Johnson</a>, <a href=\"/wiki/Sanofi\" title=\"Sanofi\">Sanofi</a>, and <a href=\"/wiki/Vernalis_plc\" title=\"Vernalis plc\">Vernalis</a>, have previously taken other FAAH inhibitors into clinical trials without experiencing such adverse events (e.g., respectively, <a href=\"/wiki/MK-4409\" title=\"MK-4409\">MK-4409</a>,<sup id=\"cite_ref-76\" class=\"reference\"><a href=\"#cite_note-76\">&#91;76&#93;</a></sup><sup id=\"cite_ref-77\" class=\"reference\"><a href=\"#cite_note-77\">&#91;77&#93;</a></sup> <a href=\"/wiki/PF-04457845\" title=\"PF-04457845\">PF-04457845</a>, <a href=\"/wiki/JNJ-42165279\" title=\"JNJ-42165279\">JNJ-42165279</a>,<sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup> SSR411298, and V158866.<sup id=\"cite_ref-Bisogno_10-1\" class=\"reference\"><a href=\"#cite_note-Bisogno-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-79\" class=\"reference\"><a href=\"#cite_note-79\">&#91;79&#93;</a></sup><sup id=\"cite_ref-80\" class=\"reference\"><a href=\"#cite_note-80\">&#91;80&#93;</a></sup> Related enzyme inhibitor compounds such as <a href=\"/wiki/URB-597\" class=\"mw-redirect\" title=\"URB-597\">URB-597</a> and <a href=\"/wiki/LY-2183240\" title=\"LY-2183240\">LY-2183240</a> have been sold illicitly as <a href=\"/wiki/Designer_drug\" title=\"Designer drug\">designer drugs</a>.<sup id=\"cite_ref-81\" class=\"reference\"><a href=\"#cite_note-81\">&#91;81&#93;</a></sup><sup id=\"cite_ref-82\" class=\"reference\"><a href=\"#cite_note-82\">&#91;82&#93;</a></sup><sup class=\"noprint Inline-Template noprint Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources\" title=\"Wikipedia:No original research\"><span title=\"This claim needs references to reliable secondary sources. (January 2016)\">non-primary source needed</span></a></i>&#93;</sup><sup class=\"noprint Inline-Template noprint noexcerpt Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:NOTRS\" class=\"mw-redirect\" title=\"Wikipedia:NOTRS\"><span title=\"This claim needs references to better sources. (January 2016)\">better&#160;source&#160;needed</span></a></i>&#93;</sup>\n</p><p>Following the events in Rennes, <a href=\"/wiki/Janssen-Cilag\" title=\"Janssen-Cilag\">Janssen</a> announced that it was temporarily suspending dosing in two Phase II clinical trials with its own FAAH inhibitor, <a href=\"/wiki/JNJ-42165279\" title=\"JNJ-42165279\">JNJ-42165279</a>, headlining the decision as \"precautionary measure follows safety issue with different drug in class\". Janssen was emphatic that no serious adverse events had been reported in any of the clinical trials with JNJ-42165279 to date. Janssen did not state whether the suspension, though voluntary, was at the request of the FDA.<sup id=\"cite_ref-83\" class=\"reference\"><a href=\"#cite_note-83\">&#91;83&#93;</a></sup> The suspension was to remain in effect until more information is available about the BIA 10-2474 study.<sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items\" title=\"Wikipedia:Manual of Style/Dates and numbers\"><span title=\"The date of the event predicted near this tag has passed. (April 2016)\">needs update</span></a></i>&#93;</sup>\n</p><p>Pfizer had previously been developing an FAAH inhibitor PF-04457845 for indications including osteoarthritis pain and trauma. A spokesperson commented after the events in Rennes that \"we [Pfizer] did explore the potential of a FAAH-inhibitor for osteoarthritic pain in Phase 2 trials, however, no significant efficacy was observed. The FAAH-inhibitor was recently being evaluated in Post-Traumatic Stress Disorder but this trial was discontinued in 2015 for business reasons. We do not have any active trials in this area\".<sup id=\"cite_ref-in-pharma_84-0\" class=\"reference\"><a href=\"#cite_note-in-pharma-84\">&#91;84&#93;</a></sup>\n</p><p>Sanofi also had been developing an FAAH inhibitor candidate SSR411298 for the treatment of depression. However, a spokesperson stated in January 2016 that \"we have no projects in development that target this enzyme\".<sup id=\"cite_ref-in-pharma_84-1\" class=\"reference\"><a href=\"#cite_note-in-pharma-84\">&#91;84&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=18\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"div-col columns column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em;\">\n<ul><li><a href=\"/wiki/4-Nonylphenylboronic_acid\" title=\"4-Nonylphenylboronic acid\">4-Nonylphenylboronic acid</a> - FAAH inhibitor, preclinical stage</li>\n<li><a href=\"/wiki/Arachidonoyl_serotonin\" title=\"Arachidonoyl serotonin\">Arachidonoyl serotonin</a> - FAAH inhibitor, preclinical stage</li>\n<li><a href=\"/wiki/URB-597\" class=\"mw-redirect\" title=\"URB-597\">URB-597</a> - FAAH inhibitor, preclinical stage</li>\n<li><a href=\"/wiki/TGN1412\" class=\"mw-redirect\" title=\"TGN1412\">TGN1412</a> - A <a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">monoclonal antibody</a> trialed in 2006 in London, with serious adverse events prompting change of EMA recommendations</li>\n<li><a href=\"/wiki/Fialuridine\" title=\"Fialuridine\">Fialuridine</a> - A nucleoside analogue to treat Hepatitis B, fatality rate 5 out of 15 patients,</li></ul></div>\n<div style=\"clear:both;\"></div>\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=19\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><cite class=\"citation journal\">Michael Eddleston; Adam F. Cohen; David J. Webb (April 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1111/bcp.12920/epdf\">\"Editorial - Implications of the BIA-102474-101 study for review of first-into-human clinical trials\"</a>. <i>Br J Clin Pharmacol</i>. The British Pharmacological Society. <b>81</b>: 582\u2013586. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/bcp.12920\">10.1111/bcp.12920</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4799914\">4799914</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Br+J+Clin+Pharmacol&amp;rft.atitle=Editorial+-+Implications+of+the+BIA-102474-101+study+for+review+of+first-into-human+clinical+trials&amp;rft.volume=81&amp;rft.pages=582-586&amp;rft.date=2016-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4799914&amp;rft_id=info%3Adoi%2F10.1111%2Fbcp.12920&amp;rft.au=Michael+Eddleston&amp;rft.au=Adam+F.+Cohen&amp;rft.au=David+J.+Webb&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fbcp.12920%2Fepdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation journal\">Hawkes, Nigel (2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.bmj.com/content/352/bmj.i466\">\"News: French Drug Trial Protocol Fails to Answer Key Questions\"</a>. <i><a href=\"/wiki/The_British_Medical_Journal\" class=\"mw-redirect\" title=\"The British Medical Journal\">The British Medical Journal</a></i>. <b>352</b> (25 January): 466. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1136/bmj.i466\">10.1136/bmj.i466</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">25 January</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Medical+Journal&amp;rft.atitle=News%3A+French+Drug+Trial+Protocol+Fails+to+Answer+Key+Questions&amp;rft.volume=352&amp;rft.issue=25+January&amp;rft.pages=466&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.i466&amp;rft.au=Hawkes%2C+Nigel&amp;rft_id=http%3A%2F%2Fwww.bmj.com%2Fcontent%2F352%2Fbmj.i466&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation web\">Expert Group on Phase One Clinical Trials (Chairman: Professor Gordon W. Duff) (30 November 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/%40dh/%40en/documents/digitalasset/dh_073165.pdf\">\"Expert Scientific Group on Phase One Clinical Trials - FINAL REPORT\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Department of Health, United Kingdom. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117\">the original</a> on 7 January 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Expert+Scientific+Group+on+Phase+One+Clinical+Trials+-+FINAL+REPORT&amp;rft.pub=Department+of+Health%2C+United+Kingdom&amp;rft.date=2006-11-30&amp;rft.au=Expert+Group+on+Phase+One+Clinical+Trials+%28Chairman%3A+Professor+Gordon+W.+Duff%29&amp;rft_id=http%3A%2F%2Fwebarchive.nationalarchives.gov.uk%2F%2B%2Fhttp%3A%2F%2Fwww.dh.gov.uk%2Fen%2FPublicationsandstatistics%2FPublications%2FPublicationsPolicyAndGuidance%2FDH_063117&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1467-985X.2007.00481.x/epdf\">\"Statistical issues in first-in-man studies. &#91;The report of the Royal Statistical Society's Working Party on Statistical Issues In First-in-Man Studies chaired by Professor Stephen Senn&#93;\"</a>. <i>J. R. Statist. Soc. A</i>. <b>170</b> (Part 3): 517\u2013579. 2007. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.1467-985x.2007.00481.x\">10.1111/j.1467-985x.2007.00481.x</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+R.+Statist.+Soc.+A&amp;rft.atitle=Statistical+issues+in+first-in-man+studies.+%5BThe+report+of+the+Royal+Statistical+Society%27s+Working+Party+on+Statistical+Issues+In+First-in-Man+Studies+chaired+by+Professor+Stephen+Senn%5D&amp;rft.volume=170&amp;rft.issue=Part+3&amp;rft.pages=517-579&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1467-985x.2007.00481.x&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fj.1467-985X.2007.00481.x%2Fepdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=20\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Bialstatement-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Bialstatement_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Bialstatement_1-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bial.com/en/pressroom.138/news.140/phase_i_clinical_trial_rennes.a558.html\">\"News Release - Phase I Clinical Trial Rennes\"</a>. www.bial.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=News+Release+-+Phase+I+Clinical+Trial+Rennes&amp;rft.pub=www.bial.com&amp;rft_id=https%3A%2F%2Fwww.bial.com%2Fen%2Fpressroom.138%2Fnews.140%2Fphase_i_clinical_trial_rennes.a558.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Breizh-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Breizh_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Breizh_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.breizh-info.com/2016/01/15/rennes-biotrial-bialessai-therapeutique/\">\"Essai th\u00e9rapeutique mortel \u00e0 Biotrial Rennes. Le contenu du test du Bia 10 \u2013 2474 de Bial r\u00e9v\u00e9l\u00e9 &#91;exclusif&#93;\"</a>. Breizh-info.com. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+th%C3%A9rapeutique+mortel+%C3%A0+Biotrial+Rennes.+Le+contenu+du+test+du+Bia+10+%E2%80%93+2474+de+Bial+r%C3%A9v%C3%A9l%C3%A9+%5Bexclusif%5D&amp;rft.pub=Breizh-info.com&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.breizh-info.com%2F2016%2F01%2F15%2Frennes-biotrial-bialessai-therapeutique%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ANSM_Statement-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ANSM_Statement_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ANSM_Statement_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ANSM_Statement_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ANSM_Statement_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ANSM_Statement_3-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ANSM_Statement_3-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ansm.sante.fr/S-informer/Actualite/La-survenue-d-effets-graves-ayant-entraine-l-hospitalisation-de-6-patients-dont-un-en-etat-de-mort-cerebrale-a-conduit-a-l-arret-premature-d-un-essai-clinique-du-laboratoire-BIAL-Point-d-information\">\"La survenue d'effets graves ayant entra\u00een\u00e9 l'hospitalisation de 6 patients, dont un en \u00e9tat de mort c\u00e9r\u00e9brale, a conduit \u00e0 l'arr\u00eat pr\u00e9matur\u00e9 d'un essai clinique du laboratoire BIAL - Point d'information\"</a>. <i>Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament, France (ANSM)</i>. 15 January 2016.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament%2C+France+%28ANSM%29&amp;rft.atitle=La+survenue+d%E2%80%99effets+graves+ayant+entra%C3%AEn%C3%A9+l%E2%80%99hospitalisation+de+6+patients%2C+dont+un+en+%C3%A9tat+de+mort+c%C3%A9r%C3%A9brale%2C+a+conduit+%C3%A0+l%E2%80%99arr%C3%AAt+pr%C3%A9matur%C3%A9+d%E2%80%99un+essai+clinique+du+laboratoire+BIAL+-+Point+d%27information&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.ansm.sante.fr%2FS-informer%2FActualite%2FLa-survenue-d-effets-graves-ayant-entraine-l-hospitalisation-de-6-patients-dont-un-en-etat-de-mort-cerebrale-a-conduit-a-l-arret-premature-d-un-essai-clinique-du-laboratoire-BIAL-Point-d-information&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Ministry_Statement-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Ministry_Statement_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Ministry_Statement_4-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://social-sante.gouv.fr/actualites/presse/discours/article/accident-grave-dans-le-cadre-d-un-essai-clinique-intervention-de-marisol\">\"Accident grave dans le cadre d'un essai clinique - Intervention de Marisol Touraine \u00e0 Rennes\"</a>. <i>Minist\u00e8re des Affaires Sociales, de la Sant\u00e9 et des Droits des Femmes, France</i>. 15 January 2016.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Minist%C3%A8re+des+Affaires+Sociales%2C+de+la+Sant%C3%A9+et+des+Droits+des+Femmes%2C+France&amp;rft.atitle=Accident+grave+dans+le+cadre+d%E2%80%99un+essai+clinique+-+Intervention+de+Marisol+Touraine+%C3%A0+Rennes&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fsocial-sante.gouv.fr%2Factualites%2Fpresse%2Fdiscours%2Farticle%2Faccident-grave-dans-le-cadre-d-un-essai-clinique-intervention-de-marisol&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Rennes2-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Rennes2_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Rennes2_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Rennes2_5-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Rennes2_5-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_13/17_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n2.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b02 concernant les patients hospitalis\u00e9s au CHU et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 17 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B02+concernant+les+patients+hospitalis%C3%A9s+au+CHU+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-17&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_13%2F17_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n2.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ANSMfinal-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ANSMfinal_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-ANSMfinal_6-10\"><sup><i><b>k</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-de-Rennes-Rapport-final-du-CSST-inhibiteurs-de-la-FAAH\">\"Essai clinique de Rennes - Rapport final du CSST \" inhibiteurs de la FAAH <span style=\"padding-right:0.2em;\">\"</span>\"</a>. Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9(ANSM). 19 April 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 May</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+clinique+de+Rennes+-+Rapport+final+du+CSST+%22+inhibiteurs+de+la+FAAH+%22&amp;rft.pub=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament+et+des+Produits+de+Sant%C3%A9%28ANSM%29&amp;rft.date=2016-04-19&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2FS-informer%2FActualite%2FEssai-clinique-de-Rennes-Rapport-final-du-CSST-inhibiteurs-de-la-FAAH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Hinnerk-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Hinnerk_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Hinnerk_7-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Hinnerk Feldwisch-Drentrup (8 June 2017). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemag.org/news/2017/06/new-clues-why-french-drug-trial-went-horribly-wrong\">\"New clues to why a French drug trial went horribly wrong\"</a>. <a href=\"/wiki/Science_(magazine)\" class=\"mw-redirect\" title=\"Science (magazine)\">Science</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=New+clues+to+why+a+French+drug+trial+went+horribly+wrong&amp;rft.pub=Science&amp;rft.date=2017-06-08&amp;rft.au=Hinnerk+Feldwisch-Drentrup&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2017%2F06%2Fnew-clues-why-french-drug-trial-went-horribly-wrong&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-protocolansm-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-protocolansm_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-protocolansm_8-14\"><sup><i><b>o</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/content/download/84681/1069223/version/1/file/protocole_BIAL_102474+101-22012016131259.pdf\">\"Clinical Study Protocol N\u00b0 BIA-102474-101 (Version 1.2, 1 July 2015)\"</a> <span style=\"font-size:85%;\">(PDF)</span>. 1 July 2015<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 Jan</span> 2016</span>  &#8211; via ANSM.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Clinical+Study+Protocol+N%C2%B0+BIA-102474-101+%28Version+1.2%2C+1+July+2015%29&amp;rft.date=2015-07-01&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2Fcontent%2Fdownload%2F84681%2F1069223%2Fversion%2F1%2Ffile%2Fprotocole_BIAL_102474%2B101-22012016131259.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Katerina Otrubova; Cyrine Ezzili; Dale L. Boger (15 August 2011). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581\">\"The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH)(pre-print published online 28 June 2011)\"</a>. <i>Bioorg Med Chem Lett</i>. <b>21</b> (16): 4674\u20134685. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.bmcl.2011.06.096\">10.1016/j.bmcl.2011.06.096</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581\">3146581</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21764305\">21764305</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bioorg+Med+Chem+Lett&amp;rft.atitle=The+Discovery+and+Development+of+Inhibitors+of+Fatty+Acid+Amide+Hydrolase+%28FAAH%29%28pre-print+published+online+28+June+2011%29&amp;rft.volume=21&amp;rft.issue=16&amp;rft.pages=4674-4685.&amp;rft.date=2011-08-15&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3146581&amp;rft_id=info%3Apmid%2F21764305&amp;rft_id=info%3Adoi%2F10.1016%2Fj.bmcl.2011.06.096&amp;rft.au=Katerina+Otrubova&amp;rft.au=Cyrine+Ezzili&amp;rft.au=Dale+L.+Boger&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3146581&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Bisogno-10\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Bisogno_10-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Bisogno_10-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Bisogno T.; Maccarrone M. (2013). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.tandfonline.com/doi/abs/10.1517/17460441.2013.780021?journalCode=iedc20\">\"Latest Advances in the Discovery of Fatty Acid Amide Hydrolase Inhibitors\"</a>. <i>Expert Opin. Drug Discov</i>. <b>8</b> (5, May): 509\u2013522. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1517/17460441.2013.780021\">10.1517/17460441.2013.780021</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23488865\">23488865</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opin.+Drug+Discov.&amp;rft.atitle=Latest+Advances+in+the+Discovery+of+Fatty+Acid+Amide+Hydrolase+Inhibitors&amp;rft.volume=8&amp;rft.issue=5%2C+May&amp;rft.pages=509-522&amp;rft.date=2013&amp;rft_id=info%3Adoi%2F10.1517%2F17460441.2013.780021&amp;rft_id=info%3Apmid%2F23488865&amp;rft.au=Bisogno+T.&amp;rft.au=Maccarrone+M.&amp;rft_id=http%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1517%2F17460441.2013.780021%3FjournalCode%3Diedc20&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><span class=\"citation patent\" id=\"CITEREFCarla_Patr\u00edcia_DA_COSTA_PEREIRA_ROSA,_Rita_GUSM\u00c3O_DE_NORONHA,_Laszlo_Erno_KISS2018\"><a rel=\"nofollow\" class=\"external text\" href=\"https://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=WO2015012708A1\">WO 2015012708A1</a>,&#32;Carla Patr\u00edcia DA COSTA PEREIRA ROSA, Rita GUSM\u00c3O DE NORONHA, Laszlo Erno KISS,&#32;\"Imidazolecarboxamides and their use as FAAH inhibitors\",&#32;published 29 January 2015,&#32; assigned to BIAL PORTELA &amp; CA SA.</span><span class=\"Z3988\" title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=2015012708A1&amp;rft.cc=WO&amp;rft.title=Imidazolecarboxamides+and+their+use+as+FAAH+inhibitors&amp;rft.inventor=Carla+Patr%C3%ADcia+DA+COSTA+PEREIRA+ROSA%2C+Rita+GUSM%C3%83O+DE+NORONHA%2C+Laszlo+Erno+KISS&amp;rft.assignee=BIAL+PORTELA+%26+CA+SA.&amp;rft.appldate=24 July 2014&amp;rft.pubdate=29 January 2015&amp;rft.prioritydate=24 July 2013\"><span style=\"display: none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><span class=\"citation patent\" id=\"CITEREFLaszlo_Erno_KISS,_Rita_GUSM\u00c3O_DE_NORONHA,_Carla_Patr\u00edcia_DA_COSTA_PEREIRA_ROSA,_Rui_PINTO2018\"><a rel=\"nofollow\" class=\"external text\" href=\"https://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=WO2015016729\">WO 2015016729</a>,&#32;Laszlo Erno KISS, Rita GUSM\u00c3O DE NORONHA, Carla Patr\u00edcia DA COSTA PEREIRA ROSA, Rui PINTO,&#32;\"Urea compounds and their use as FAAH enzyme inhibitors\",&#32;published Feb 5, 2015,&#32; assigned to BIAL PORTELA &amp; CA SA.</span><span class=\"Z3988\" title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=2015016729&amp;rft.cc=WO&amp;rft.title=Urea+compounds+and+their+use+as+FAAH+enzyme+inhibitors&amp;rft.inventor=Laszlo+Erno+KISS%2C+Rita+GUSM%C3%83O+DE+NORONHA%2C+Carla+Patr%C3%ADcia+DA+COSTA+PEREIRA+ROSA%2C+Rui+PINTO&amp;rft.assignee=BIAL+PORTELA+%26+CA+SA.&amp;rft.appldate=Aug 1, 2014&amp;rft.pubdate=Feb 5, 2015&amp;rft.prioritydate=Aug 2, 2013\"><span style=\"display: none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-synthpatent-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-synthpatent_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-synthpatent_13-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><span class=\"citation patent\" id=\"CITEREFLaszlo_Erno_KISS,_David_Alexander_LEARMONTH,_Carla_Patr\u00edcia_DA_COSTA_PEREIRA_ROSA,_Rita_GUSM\u00c3O_DE_NORONHA,_Pedro_Nuno_Leal_PALMA,_Patricio_Manuel_Vieira_Ara\u00fajo_SOARES_DA_SILVA,_Alexander_BELIAEV2018\"><a rel=\"nofollow\" class=\"external text\" href=\"https://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=WO2010074588\">WO 2010074588</a>,&#32;Laszlo Erno KISS, David Alexander LEARMONTH, Carla Patr\u00edcia DA COSTA PEREIRA ROSA, Rita GUSM\u00c3O DE NORONHA, Pedro Nuno Leal PALMA, Patricio Manuel Vieira Ara\u00fajo SOARES DA SILVA, Alexander BELIAEV,&#32;\"PHARMACEUTICAL COMPOUNDS\",&#32;published 1 July 2010,&#32; assigned to BIAL PORTELA &amp; CA SA.</span><span class=\"Z3988\" title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=2010074588&amp;rft.cc=WO&amp;rft.title=PHARMACEUTICAL+COMPOUNDS&amp;rft.inventor=Laszlo+Erno+KISS%2C+David+Alexander+LEARMONTH%2C+Carla+Patr%C3%ADcia+DA+COSTA+PEREIRA+ROSA%2C+Rita+GUSM%C3%83O+DE+NORONHA%2C+Pedro+Nuno+Leal+PALMA%2C+Patricio+Manuel+Vieira+Ara%C3%BAjo+SOARES+DA+SILVA%2C+Alexander+BELIAEV&amp;rft.assignee=BIAL+PORTELA+%26+CA+SA.&amp;rft.appldate=23 December 2009&amp;rft.pubdate=1 July 2010&amp;rft.prioritydate=24 December 2008\"><span style=\"display: none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-southanblog-14\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-southanblog_14-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-southanblog_14-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Christopher Southan, University of Edinburgh (23 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://cdsouthan.blogspot.se/2016/01/molecular-details-related-to-bia-10-2474.html\">\"Molecular details related to BIA 10-2474\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Molecular+details+related+to+BIA+10-2474&amp;rft.date=2016-01-23&amp;rft.au=Christopher+Southan%2C+University+of+Edinburgh&amp;rft_id=http%3A%2F%2Fcdsouthan.blogspot.se%2F2016%2F01%2Fmolecular-details-related-to-bia-10-2474.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ANSM_Comite_Minutes-15\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ANSM_Comite_Minutes_15-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-ANSM_Comite_Minutes_15-11\"><sup><i><b>l</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-de-Rennes-Compte-rendu-de-la-premiere-reunion-du-CSST-inhibiteurs-de-la-FAAH\">\"Version anglaise&#160;: Minutes of the Temporary Specialist Scientific Committee (TSSC) meeting on \"FAAH (Fatty Acid Amide Hydrolase) Inhibitors\" of 15/02/2016 (08/03/2016)\"</a>. Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM). 7 March 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Version+anglaise+%3A+Minutes+of+the+Temporary+Specialist+Scientific+Committee+%28TSSC%29+meeting+on+%22FAAH+%28Fatty+Acid+Amide+Hydrolase%29+Inhibitors%22+of+15%2F02%2F2016+%2808%2F03%2F2016%29&amp;rft.pub=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament+et+des+Produits+de+Sant%C3%A9+%28ANSM%29&amp;rft.date=2016-03-07&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2FS-informer%2FActualite%2FEssai-clinique-de-Rennes-Compte-rendu-de-la-premiere-reunion-du-CSST-inhibiteurs-de-la-FAAH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Sean Ekins (21 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.collabchem.com/2016/01/21/lets-do-it-all-again-updating-predictions-for-the-real-bia-10-2474/\">\"Lets do it all again updating predictions for the 'real' BIA 10-2474\"</a>. Collaborative Chemistry Forum<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Lets+do+it+all+again+updating+predictions+for+the+%E2%80%98real%E2%80%99+BIA+10-2474&amp;rft.pub=Collaborative+Chemistry+Forum&amp;rft.date=2016-01-21&amp;rft.au=Sean+Ekins&amp;rft_id=http%3A%2F%2Fwww.collabchem.com%2F2016%2F01%2F21%2Flets-do-it-all-again-updating-predictions-for-the-real-bia-10-2474%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Madolyn Bowman Rogers (29 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.alzforum.org/news/community-news/will-death-french-drug-trial-lead-tighter-phase-1-rules\">\"Will Death in French Drug Trial Lead to Tighter Phase 1 Rules?\"</a>. www.alzforum.org; Biomedical Research Forum<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Will+Death+in+French+Drug+Trial+Lead+to+Tighter+Phase+1+Rules%3F&amp;rft.pub=www.alzforum.org%3B+Biomedical+Research+Forum&amp;rft.date=2016-01-29&amp;rft.au=Madolyn+Bowman+Rogers&amp;rft_id=http%3A%2F%2Fwww.alzforum.org%2Fnews%2Fcommunity-news%2Fwill-death-french-drug-trial-lead-tighter-phase-1-rules&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ansm22jan-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ansm22jan_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ansm22jan_18-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ansm22jan_18-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ansm22jan_18-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ansm22jan_18-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ansm22jan_18-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-BIA-102474-101-du-laboratoire-BIAL-Publication-du-protocole-clinique-Point-d-Information\">\"Essai clinique BIA-102474-101 du laboratoire BIAL&#160;: Publication du protocole clinique\"</a> (in French). Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. 22 Jan 2016.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+clinique+BIA-102474-101+du+laboratoire+BIAL+%3A+Publication+du+protocole+clinique&amp;rft.pub=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament+et+des+Produits+de+Sant%C3%A9&amp;rft.date=2016-01-22&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2FS-informer%2FActualite%2FEssai-clinique-BIA-102474-101-du-laboratoire-BIAL-Publication-du-protocole-clinique-Point-d-Information&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://sante.lefigaro.fr/actualite/2016/01/21/24518-drame-rennes-protocole-lessai-clinique-accusation\">\"Drame de Rennes&#160;: le protocole de l'essai clinique en accusation\"</a>. <i>sante.lefigaro.fr</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-21</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=sante.lefigaro.fr&amp;rft.atitle=Drame+de+Rennes+%3A+le+protocole+de+l%27essai+clinique+en+accusation&amp;rft_id=http%3A%2F%2Fsante.lefigaro.fr%2Factualite%2F2016%2F01%2F21%2F24518-drame-rennes-protocole-lessai-clinique-accusation&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-lefigaro-20\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-lefigaro_20-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-lefigaro_20-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://en.youscribe.com/catalogue/tous/current-affairs-and-social-debate/current-affairs-events/document-le-protocole-de-l-essai-clinique-de-rennes-2691486\">\"Clinical Study Protocol N\u00b0 BIA-102474-101 (Version 2.0, 16 October 2015)\"</a>. Le Figaro. 21 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">23 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Clinical+Study+Protocol+N%C2%B0+BIA-102474-101+%28Version+2.0%2C+16+October+2015%29&amp;rft.pub=Le+Figaro&amp;rft.date=2016-01-21&amp;rft_id=http%3A%2F%2Fen.youscribe.com%2Fcatalogue%2Ftous%2Fcurrent-affairs-and-social-debate%2Fcurrent-affairs-events%2Fdocument-le-protocole-de-l-essai-clinique-de-rennes-2691486&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-IGAS-21\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-IGAS_21-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-IGAS_21-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-IGAS_21-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-IGAS_21-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://social-sante.gouv.fr/IMG/pdf/fevrier_2016_-_note_etape_-_accident_essai_clinique.pdf\">\"NOTE D'ETAPE&#160;: ENQUETE SUR DES INCIDENTS GRAVES SURVENUS DANS LE CADRE DE LA REALISATION D'UN ESSAI CLINIQUE\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Inspection g\u00e9n\u00e9rale des affaires sociales. February 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NOTE+D%E2%80%99ETAPE+%3A+ENQUETE+SUR+DES+INCIDENTS+GRAVES+SURVENUS+DANS+LE+CADRE+DE+LA+REALISATION+D%E2%80%99UN+ESSAI+CLINIQUE&amp;rft.pub=Inspection+g%C3%A9n%C3%A9rale+des+affaires+sociales&amp;rft.date=2016-02&amp;rft_id=http%3A%2F%2Fsocial-sante.gouv.fr%2FIMG%2Fpdf%2Ffevrier_2016_-_note_etape_-_accident_essai_clinique.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-lancet-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-lancet_22-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Barbara Casassus (23 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736%2816%2900154-9.pdf\">\"France investigates drug trial disaster\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>The Lancet</i>. <b>387</b> (10016): 326. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2816%2900154-9\">10.1016/S0140-6736(16)00154-9</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26842439\">26842439</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=France+investigates+drug+trial+disaster&amp;rft.volume=387&amp;rft.issue=10016&amp;rft.pages=326&amp;rft.date=2016-01-23&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2900154-9&amp;rft_id=info%3Apmid%2F26842439&amp;rft_id=http%3A%2F%2Fwww.thelancet.com%2Fpdfs%2Fjournals%2Flancet%2FPIIS0140-6736%252816%252900154-9.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemediacentre.org/expert-reaction-to-french-drug-trial-reports-of-one-patient-dying-and-five-others-in-hospital-and-of-the-paris-prosecutors-office-having-opened-an-investigation-into-what-happened\">\"Expert reaction to French drug trial - reports of one patient dying and five others in hospital and of the Paris prosecutor's office having opened an investigation into what happened\"</a>. Science Media Centre, London. 16 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Expert+reaction+to+French+drug+trial+-+reports+of+one+patient+dying+and+five+others+in+hospital+and+of+the+Paris+prosecutor%27s+office+having+opened+an+investigation+into+what+happened&amp;rft.pub=Science+Media+Centre%2C+London&amp;rft.date=2016-01-16&amp;rft_id=http%3A%2F%2Fwww.sciencemediacentre.org%2Fexpert-reaction-to-french-drug-trial-reports-of-one-patient-dying-and-five-others-in-hospital-and-of-the-paris-prosecutors-office-having-opened-an-investigation-into-what-happened&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf\">\"Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products (CHMP/SWP/28367/07)\"</a> <span style=\"font-size:85%;\">(PDF)</span>. European Medicines Agency. 1 September 2007<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">22 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Strategies+to+identify+and+mitigate+risks+for+first-in-human+clinical+trials+with+investigational+medicinal+products+%28CHMP%2FSWP%2F28367%2F07%29&amp;rft.pub=European+Medicines+Agency&amp;rft.date=2007-09-01&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2009%2F09%2FWC500002988.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Gareth MacDonald (26 February 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.in-pharmatechnologist.com/Regulatory-Safety/Bial-cannot-rule-out-link-between-BIA-10-2474-and-lung-lesions-in-study-dogs\">\"Bial cannot rule out link between BIA 10-2474 and lung lesions in study dogs\"</a>. In-Pharma Technologist<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Bial+cannot+rule+out+link+between+BIA+10-2474+and+lung+lesions+in+study+dogs&amp;rft.pub=In-Pharma+Technologist&amp;rft.date=2016-02-26&amp;rft.au=Gareth+MacDonald&amp;rft_id=http%3A%2F%2Fwww.in-pharmatechnologist.com%2FRegulatory-Safety%2FBial-cannot-rule-out-link-between-BIA-10-2474-and-lung-lesions-in-study-dogs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-schubhan-26\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-schubhan_26-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-schubhan_26-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-schubhan_26-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Lara Marlowe (1 March 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.irishtimes.com/news/world/europe/survivor-of-lethal-french-drug-trial-speaks-out-1.2554593\">\"Survivor of lethal French drug trial speaks out\"</a>. The Irish Times<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Survivor+of+lethal+French+drug+trial+speaks+out&amp;rft.pub=The+Irish+Times&amp;rft.date=2016-03-01&amp;rft.au=Lara+Marlowe&amp;rft_id=http%3A%2F%2Fwww.irishtimes.com%2Fnews%2Fworld%2Feurope%2Fsurvivor-of-lethal-french-drug-trial-speaks-out-1.2554593&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ministry2-27\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ministry2_27-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ministry2_27-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ministry2_27-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ministry2_27-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ministry2_27-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ministry2_27-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://social-sante.gouv.fr/actualites/presse/discours/article/intervention-de-marisol-touraine-conference-de-presse-accident-d-essai-clinique\">\"Intervention de Marisol Touraine - Conf\u00e9rence de presse - Accident d'essai clinique \u2013 point d'\u00e9tape\"</a>. Minist\u00e8re des Affaires Sociales, de la Sant\u00e9 et des Droits des Femmes, France. 4 February 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Intervention+de+Marisol+Touraine+-+Conf%C3%A9rence+de+presse+-+Accident+d%E2%80%99essai+clinique+%E2%80%93+point+d%E2%80%99%C3%A9tape&amp;rft.pub=Minist%C3%A8re+des+Affaires+Sociales%2C+de+la+Sant%C3%A9+et+des+Droits+des+Femmes%2C+France&amp;rft.date=2016-02-04&amp;rft_id=http%3A%2F%2Fsocial-sante.gouv.fr%2Factualites%2Fpresse%2Fdiscours%2Farticle%2Fintervention-de-marisol-touraine-conference-de-presse-accident-d-essai-clinique&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-science-28\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-science_28-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-science_28-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Martin Enserink (16 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemag.org/news/2016/01/more-details-emerge-fateful-french-drug-trial\">\"More details emerge on fateful French drug trial\"</a>. <a href=\"/wiki/Science_Magazine\" class=\"mw-redirect\" title=\"Science Magazine\">Science Magazine</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=More+details+emerge+on+fateful+French+drug+trial&amp;rft.date=2016-01-16&amp;rft.au=Martin+Enserink&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2016%2F01%2Fmore-details-emerge-fateful-french-drug-trial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nature-29\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-nature_29-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-nature_29-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Ewen Callaway; Declan Butler (22 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/news/researchers-question-design-of-fatal-french-clinical-trial-1.19221\">\"Researchers question design of fatal French clinical trial\"</a>. Nature. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nature.2016.19221\">10.1038/nature.2016.19221</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Researchers+question+design+of+fatal+French+clinical+trial&amp;rft.pub=Nature&amp;rft.date=2016-01-22&amp;rft_id=info%3Adoi%2F10.1038%2Fnature.2016.19221&amp;rft.au=Ewen+Callaway&amp;rft.au=Declan+Butler&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnews%2Fresearchers-question-design-of-fatal-french-clinical-trial-1.19221&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-RSS-30\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-RSS_30-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-RSS_30-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.statslife.org.uk/news/2660-rss-issues-statement-regarding-tragic-first-in-man-clinical-trial\">\"RSS issues statement regarding tragic 'first-in-man' clinical trial\"</a>. Royal Statistical Society. 26 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">28 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=RSS+issues+statement+regarding+tragic+%27first-in-man%27+clinical+trial&amp;rft.pub=Royal+Statistical+Society&amp;rft.date=2016-01-26&amp;rft_id=http%3A%2F%2Fwww.statslife.org.uk%2Fnews%2F2660-rss-issues-statement-regarding-tragic-first-in-man-clinical-trial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ansm27Jan-31\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ansm27Jan_31-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ansm27Jan_31-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ansm27Jan_31-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ansm27Jan_31-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ansm27Jan_31-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-BIA-102474-101-Bial-Biotrial\">\"Essai clinique BIA-102474-101- Bial/Biotrial&#160;: Chronologie\"</a>. Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM)<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-28</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+clinique+BIA-102474-101-+Bial%2FBiotrial+%3A+Chronologie&amp;rft.pub=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament+et+des+Produits+de+Sant%C3%A9+%28ANSM%29&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2FS-informer%2FActualite%2FEssai-clinique-BIA-102474-101-Bial-Biotrial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Biotrial-32\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Biotrial_32-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Biotrial_32-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Biotrial_32-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.biotrial.com/news/press-release-february-4th-2016.html\">\"PRESS RELEASE - IGAS Status Report: Clarifications from Biotrial\"</a>. www.biotrial.com. 5 February 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">6 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=PRESS+RELEASE+-+IGAS+Status+Report%3A+Clarifications+from+Biotrial&amp;rft.pub=www.biotrial.com&amp;rft.date=2016-02-05&amp;rft_id=http%3A%2F%2Fwww.biotrial.com%2Fnews%2Fpress-release-february-4th-2016.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ladepeche-33\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ladepeche_33-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ladepeche_33-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ladepeche_33-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ladepeche.fr/article/2016/01/15/2256528-accident-grave-lors-d-un-essai-therapeutique-pres-de-rennes.htmlwith\">\"Accident \"in\u00e9dit\" lors d'un essai clinique: un homme en \u00e9tat de mort c\u00e9r\u00e9brale, cinq hospitalis\u00e9s\"</a>. La Depeche. January 15, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">January 18,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Accident+%22in%C3%A9dit%22+lors+d%27un+essai+clinique%3A+un+homme+en+%C3%A9tat+de+mort+c%C3%A9r%C3%A9brale%2C+cinq+hospitalis%C3%A9s&amp;rft.pub=La+Depeche&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.ladepeche.fr%2Farticle%2F2016%2F01%2F15%2F2256528-accident-grave-lors-d-un-essai-therapeutique-pres-de-rennes.htmlwith&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-bbc-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-bbc_34-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bbc.com/news/world-europe-35320895\">\"France clinical trial: 90 given drug, one man brain-dead\"</a>. BBC. January 15, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">January 16,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=France+clinical+trial%3A+90+given+drug%2C+one+man+brain-dead&amp;rft.pub=BBC&amp;rft.date=2016-01-15&amp;rft_id=https%3A%2F%2Fwww.bbc.com%2Fnews%2Fworld-europe-35320895&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-reuters-35\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-reuters_35-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-reuters_35-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Matthias Blamont (January 15, 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.reuters.com/article/us-france-health-test-idUSKCN0UT131\">\"French drug trial disaster leaves one brain dead, five injured\"</a>. Reuters<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">January 16,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=French+drug+trial+disaster+leaves+one+brain+dead%2C+five+injured&amp;rft.date=2016-01-15&amp;rft.au=Matthias+Blamont&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-france-health-test-idUSKCN0UT131&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bbc.com/news/world-europe-35327053\">\"France clinical trial: 'No known antidote' to drug\"</a>. BBC News. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=France+clinical+trial%3A+%27No+known+antidote%27+to+drug&amp;rft.pub=BBC+News&amp;rft.date=2016-01-15&amp;rft_id=https%3A%2F%2Fwww.bbc.com%2Fnews%2Fworld-europe-35327053&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Linda BENOTMANE; Olivier CLERO (19 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ouest-france.fr/bretagne/rennes-35000/essai-clinique-le-patient-decede-etait-un-artiste-morbihannais-3979793\">\"Essai clinique: le patient d\u00e9c\u00e9d\u00e9 \u00e9tait un artiste\"</a>. L'Edition du Soir Ouest France<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">6 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+clinique%3A+le+patient+d%C3%A9c%C3%A9d%C3%A9+%C3%A9tait+un+artiste&amp;rft.pub=L%27Edition+du+Soir+Ouest+France&amp;rft.date=2016-01-19&amp;rft.au=Linda+BENOTMANE&amp;rft.au=Olivier+CLERO&amp;rft_id=http%3A%2F%2Fwww.ouest-france.fr%2Fbretagne%2Frennes-35000%2Fessai-clinique-le-patient-decede-etait-un-artiste-morbihannais-3979793&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Victoria Macdonald (2 February 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://blogs.channel4.com/victoria-macdonald-on-health-and-social-care/french-drug-trial-death-interview-victims-brother/3276\">\"French drug trial death: interview with victim's brother\"</a>. Channel 4 News<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">6 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=French+drug+trial+death%3A+interview+with+victim%E2%80%99s+brother&amp;rft.pub=Channel+4+News&amp;rft.date=2016-02-02&amp;rft.au=Victoria+Macdonald&amp;rft_id=http%3A%2F%2Fblogs.channel4.com%2Fvictoria-macdonald-on-health-and-social-care%2Ffrench-drug-trial-death-interview-victims-brother%2F3276&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-lemonde2-39\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-lemonde2_39-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-lemonde2_39-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.lemonde.fr/sante/article/2016/03/11/essai-clinique-de-rennes-des-choses-ont-ete-cachees-accusent-les-proches-de-la-victime_4881348_1651302.html\">\"Essai clinique de Rennes&#160;: \" Des choses ont \u00e9t\u00e9 cach\u00e9es \", selon les proches de la victime\"</a>. Le Monde. 11 March 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+clinique+de+Rennes+%3A+%22+Des+choses+ont+%C3%A9t%C3%A9+cach%C3%A9es+%22%2C+selon+les+proches+de+la+victime&amp;rft.pub=Le+Monde&amp;rft.date=2016-03-11&amp;rft_id=http%3A%2F%2Fwww.lemonde.fr%2Fsante%2Farticle%2F2016%2F03%2F11%2Fessai-clinique-de-rennes-des-choses-ont-ete-cachees-accusent-les-proches-de-la-victime_4881348_1651302.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ledauphine-40\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ledauphine_40-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ledauphine_40-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ledauphine.com/france-monde/2016/03/11/le-frere-de-la-victime-je-lui-ai-dit-de-ne-pas-le-faire\">\"ESSAI CLINIQUE MORTEL. Le fr\u00e8re de la victime&#160;: \"Je lui ai dit de ne pas le faire<span style=\"padding-right:0.2em;\">\"</span>\"</a>. Le Dauphine. 11 March 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=ESSAI+CLINIQUE+MORTEL.+Le+fr%C3%A8re+de+la+victime+%3A+%22Je+lui+ai+dit+de+ne+pas+le+faire%22&amp;rft.pub=Le+Dauphine&amp;rft.date=2016-03-11&amp;rft_id=http%3A%2F%2Fwww.ledauphine.com%2Ffrance-monde%2F2016%2F03%2F11%2Fle-frere-de-la-victime-je-lui-ai-dit-de-ne-pas-le-faire&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-lemonde-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-lemonde_41-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.lemonde.fr/societe/article/2016/01/15/essai-therapeutique-a-rennes-un-volontaire-en-etat-de-mort-cerebrale_4848001_3224.html\">\"Ce que l'on sait de l'accident survenu lors d'un essai clinique \u00e0 Rennes\"</a>, <i>Le Monde</i>, 15 January 2016</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Le+Monde&amp;rft.atitle=Ce+que+l%E2%80%99on+sait+de+l%E2%80%99accident+survenu+lors+d%E2%80%99un+essai+clinique+%C3%A0+Rennes&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.lemonde.fr%2Fsociete%2Farticle%2F2016%2F01%2F15%2Fessai-therapeutique-a-rennes-un-volontaire-en-etat-de-mort-cerebrale_4848001_3224.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ouest-france.fr/bretagne/rennes-35000/essai-therapeutique-rennes-un-patient-en-etat-de-mort-clinique-3972041\">\"Essai th\u00e9rapeutique \u00e0 Rennes. Une mort c\u00e9r\u00e9brale, cinq hospitalis\u00e9s\"</a>. Ouest-France. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+th%C3%A9rapeutique+%C3%A0+Rennes.+Une+mort+c%C3%A9r%C3%A9brale%2C+cinq+hospitalis%C3%A9s&amp;rft.pub=Ouest-France&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.ouest-france.fr%2Fbretagne%2Frennes-35000%2Fessai-therapeutique-rennes-un-patient-en-etat-de-mort-clinique-3972041&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ledauphine.com/france-monde/2016/01/15/rennes-un-patient-en-etat-de-mort-clinique-apres-un-essai-therapeutique\">\"France/Monde - Essai th\u00e9rapeutique&#160;: 90 personnes ont pris la mol\u00e9cule\"</a>. <i>Ledauphine.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Ledauphine.com&amp;rft.atitle=France%2FMonde+-+Essai+th%C3%A9rapeutique+%3A+90+personnes+ont+pris+la+mol%C3%A9cule&amp;rft_id=http%3A%2F%2Fwww.ledauphine.com%2Ffrance-monde%2F2016%2F01%2F15%2Frennes-un-patient-en-etat-de-mort-clinique-apres-un-essai-therapeutique&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-44\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Matthias Blamont (15 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.reuters.com/article/us-france-health-test-idUSKCN0UT131\">\"French drug trial disaster leaves one brain dead, five injured\"</a>. Reuters<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=French+drug+trial+disaster+leaves+one+brain+dead%2C+five+injured&amp;rft.pub=Reuters&amp;rft.date=2016-01-15&amp;rft.au=Matthias+Blamont&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-france-health-test-idUSKCN0UT131&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.theguardian.com/world/2016/jan/15/french-drug-trial-one-person-in-coma-and-five-critically-ill\">\"French drug trial leaves one brain dead and five critically ill\"</a>. The Guardian. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=French+drug+trial+leaves+one+brain+dead+and+five+critically+ill&amp;rft.pub=The+Guardian&amp;rft.date=2016-01-15&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fworld%2F2016%2Fjan%2F15%2Ffrench-drug-trial-one-person-in-coma-and-five-critically-ill&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-abc-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-abc_46-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Adamson B (January 15, 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://abcnews.go.com/Technology/wireStory/fall-ill-france-participating-clinical-trial-36309158\">\"Botched Drug Trial Leaves 1 Brain Dead, 5 in Hospital\"</a>. ABC, AP<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">January 16,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Botched+Drug+Trial+Leaves+1+Brain+Dead%2C+5+in+Hospital&amp;rft.date=2016-01-15&amp;rft.au=Adamson+B&amp;rft_id=http%3A%2F%2Fabcnews.go.com%2FTechnology%2FwireStory%2Ffall-ill-france-participating-clinical-trial-36309158&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-47\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-47\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Angeline Benoit; Makiko Kitamura (15 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.bloomberg.com/news/articles/2016-01-15/testing-on-bial-s-drug-led-to-brain-dead-patient-france-says\">\"France Ties Brain-Dead Person to Tests of Bial-Portela Drug\"</a>. <i>Bloomberg.com</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Bloomberg.com&amp;rft.atitle=France+Ties+Brain-Dead+Person+to+Tests+of+Bial-Portela+Drug&amp;rft.date=2016-01-15&amp;rft.au=Angeline+Benoit&amp;rft.au=Makiko+Kitamura&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-01-15%2Ftesting-on-bial-s-drug-led-to-brain-dead-patient-france-says&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-48\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-48\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Martin Enserink (16 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemag.org/news/2016/01/more-details-emerge-fateful-french-drug-trial\">\"More Details Emerge on Fateful French Drug Trial\"</a>. <a href=\"/wiki/Science_(magazine)\" class=\"mw-redirect\" title=\"Science (magazine)\">Science</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">16 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=More+Details+Emerge+on+Fateful+French+Drug+Trial&amp;rft.pub=Science&amp;rft.date=2016-01-16&amp;rft.au=Martin+Enserink&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2016%2F01%2Fmore-details-emerge-fateful-french-drug-trial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-49\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Debora Mackenzie. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.newscientist.com/article/dn28782-six-in-hospital-after-french-pain-relief-drug-trial-goes-wrong/\">\"Six in hospital after French pain relief drug trial goes wrong\"</a>. <i>New Scientist</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=New+Scientist&amp;rft.atitle=Six+in+hospital+after+French+pain+relief+drug+trial+goes+wrong&amp;rft.au=Debora+Mackenzie&amp;rft_id=https%3A%2F%2Fwww.newscientist.com%2Farticle%2Fdn28782-six-in-hospital-after-french-pain-relief-drug-trial-goes-wrong%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-bioworld-50\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-bioworld_50-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-bioworld_50-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-bioworld_50-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-bioworld_50-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.bioworld.com/content/six-hospitalized-bial-clinical-trial-france-0\">\"Six hospitalized in Bial clinical trial in France\"</a>. <i>BioWorld.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BioWorld.com&amp;rft.atitle=Six+hospitalized+in+Bial+clinical+trial+in+France&amp;rft_id=http%3A%2F%2Fwww.bioworld.com%2Fcontent%2Fsix-hospitalized-bial-clinical-trial-france-0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-51\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-51\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/2/hi/uk_news/england/london/4807042.stm\">\"Six taken ill after drug trials\"</a>. BBC. 15 March 2006<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Six+taken+ill+after+drug+trials&amp;rft.pub=BBC&amp;rft.date=2006-03-15&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F2%2Fhi%2Fuk_news%2Fengland%2Flondon%2F4807042.stm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-52\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Andrea Cunha Freitas (5 July 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.publico.pt/2016/07/05/sociedade/noticia/bial-vai-lancar-medicamento-para-parkinson-no-final-do-verao-1737330\">\"Bial vai lan\u00e7ar medicamento para Parkinson no final do Ver\u00e3o\"</a>. <a href=\"/wiki/P%C3%BAblico_(Portugal)\" title=\"P\u00fablico (Portugal)\">P\u00fablico (Portugal)</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Bial+vai+lan%C3%A7ar+medicamento+para+Parkinson+no+final+do+Ver%C3%A3o&amp;rft.pub=P%C3%BAblico+%28Portugal%29&amp;rft.date=2016-07-05&amp;rft.au=Andrea+Cunha+Freitas&amp;rft_id=https%3A%2F%2Fwww.publico.pt%2F2016%2F07%2F05%2Fsociedade%2Fnoticia%2Fbial-vai-lancar-medicamento-para-parkinson-no-final-do-verao-1737330&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-53\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-53\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Declan Butler; Ewen Callaway (18 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/news/scientists-in-the-dark-after-french-clinical-trial-proves-fatal-1.19189\">\"Scientists in the dark after French clinical trial proves fatal\"</a>. <i>Nature</i>. <b>529</b> (21 January 2016): 263\u2013264. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nature.2016.19189\">10.1038/nature.2016.19189</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26791697\">26791697</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature&amp;rft.atitle=Scientists+in+the+dark+after+French+clinical+trial+proves+fatal&amp;rft.volume=529&amp;rft.issue=21+January+2016&amp;rft.pages=263-264&amp;rft.date=2016-01-18&amp;rft_id=info%3Adoi%2F10.1038%2Fnature.2016.19189&amp;rft_id=info%3Apmid%2F26791697&amp;rft.au=Declan+Butler&amp;rft.au=Ewen+Callaway&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnews%2Fscientists-in-the-dark-after-french-clinical-trial-proves-fatal-1.19189&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.biotrial.com/news/message-from-biotrial.html\">\"Message from Biotrial\"</a>. www.biotrial.com. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Message+from+Biotrial&amp;rft.pub=www.biotrial.com&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.biotrial.com%2Fnews%2Fmessage-from-biotrial.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-55\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-55\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.biotrial.com/news/communication-from-biotrial.html\">\"Communication from Biotrial February 5th, 2016\"</a>. www.biotrial.com. 5 February 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">6 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Communication+from+Biotrial+February+5th%2C+2016&amp;rft.pub=www.biotrial.com&amp;rft.date=2016-02-05&amp;rft_id=http%3A%2F%2Fwww.biotrial.com%2Fnews%2Fcommunication-from-biotrial.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-56\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-56\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Agence France-Presse (18 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.theguardian.com/science/2016/jan/17/man-dies-rennes-hospital-drug-trial-left-him-brain-dead\">\"Man dies in Rennes hospital after drug trial left him brain dead\"</a>. The Guardian<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Man+dies+in+Rennes+hospital+after+drug+trial+left+him+brain+dead&amp;rft.pub=The+Guardian&amp;rft.date=2016-01-18&amp;rft.au=Agence+France-Presse&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fscience%2F2016%2Fjan%2F17%2Fman-dies-rennes-hospital-drug-trial-left-him-brain-dead&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-57\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-57\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">AFP Paris (8 March 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.theguardian.com/science/2016/mar/07/french-drug-trial-man-dead-expert-report-unprecidented-reaction\">\"Man who died in French drug trial had 'unprecedented' reaction, say experts\"</a>. The Guardian Online<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 March</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Man+who+died+in+French+drug+trial+had+%E2%80%98unprecedented%E2%80%99+reaction%2C+say+experts&amp;rft.pub=The+Guardian+Online&amp;rft.date=2016-03-08&amp;rft.au=AFP+Paris&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fscience%2F2016%2Fmar%2F07%2Ffrench-drug-trial-man-dead-expert-report-unprecidented-reaction&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-58\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-58\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Martin Enserink (23 May 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemag.org/news/2016/05/france-tightens-rules-wake-fatal-clinical-trial\">\"France tightens rules in wake of fatal clinical trial\"</a>. Science<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=France+tightens+rules+in+wake+of+fatal+clinical+trial&amp;rft.pub=Science&amp;rft.date=2016-05-23&amp;rft.au=Martin+Enserink&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2016%2F05%2Ffrance-tightens-rules-wake-fatal-clinical-trial&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-59\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-59\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.spiegel.de/gesundheit/diagnose/todesfall-bei-biotrial-studie-welche-fehler-wurden-gemacht-a-1075734.html\">\"Todesfall bei Medikamententest: Ministerin wirft Institut Biotrial Fehler vor\"</a> (in German). <a href=\"/wiki/Der_Spiegel\" title=\"Der Spiegel\">Der Spiegel</a>. February 4, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">February 4,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Todesfall+bei+Medikamententest%3A+Ministerin+wirft+Institut+Biotrial+Fehler+vor&amp;rft.date=2016-02-04&amp;rft_id=http%3A%2F%2Fwww.spiegel.de%2Fgesundheit%2Fdiagnose%2Ftodesfall-bei-biotrial-studie-welche-fehler-wurden-gemacht-a-1075734.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-60\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-60\">^</a></b></span> <span class=\"reference-text\">Barbara Casassus. France releases interim report on drug trial disaster. The Lancet. Volume 387, Issue 10019, 13\u201319 February 2016, Pages 634\u2013635. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS0140-6736%2816%2900318-4\">10.1016/S0140-6736(16)00318-4</a></span>\n</li>\n<li id=\"cite_note-61\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-61\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.raps.org/Regulatory-Focus/News/2016/01/19/23925/EMA-Will-Assess-ANSM-Review-of-Botched-Clinical-Trial-in-France/\">\"EMA Will Assess ANSM Review of Botched Clinical Trial in France\"</a>. RAPS Regulatory Affairs Professional Society. 19 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=EMA+Will+Assess+ANSM+Review+of+Botched+Clinical+Trial+in+France&amp;rft.pub=RAPS+Regulatory+Affairs+Professional+Society&amp;rft.date=2016-01-19&amp;rft_id=http%3A%2F%2Fwww.raps.org%2FRegulatory-Focus%2FNews%2F2016%2F01%2F19%2F23925%2FEMA-Will-Assess-ANSM-Review-of-Botched-Clinical-Trial-in-France%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-62\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-62\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Hinnerk Feldwisch-Drentrup (25 July 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencemag.org/news/2016/07/europe-overhauls-rules-first-human-trials-wake-french-disaster\">\"Europe overhauls rules for 'first-in-human' trials in wake of French disaster\"</a>. Science. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1126/science.aag0686\">10.1126/science.aag0686</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 October</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Europe+overhauls+rules+for+%E2%80%98first-in-human%E2%80%99+trials+in+wake+of+French+disaster&amp;rft.pub=Science&amp;rft.date=2016-07-25&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.aag0686&amp;rft.au=Hinnerk+Feldwisch-Drentrup&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fnews%2F2016%2F07%2Feurope-overhauls-rules-first-human-trials-wake-french-disaster&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-63\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-63\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002572.jsp&amp;mid=WC0b01ac058004d5c1\">\"Proposals to revise guidance on first-in-human clinical trials\"</a>. European Medicines Agency, London. 21 July 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 October</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Proposals+to+revise+guidance+on+first-in-human+clinical+trials&amp;rft.pub=European+Medicines+Agency%2C+London&amp;rft.date=2016-07-21&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fnews_and_events%2Fnews%2F2016%2F07%2Fnews_detail_002572.jsp%26mid%3DWC0b01ac058004d5c1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-64\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-64\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Andrew Ward; Peter Wise (24 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ft.com/cms/s/0/acceb104-c0fe-11e5-9fdb-87b8d15baec2.html\">\"Drugmaker in fatal trial received EU funds\"</a>. The Financial Times<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Drugmaker+in+fatal+trial+received+EU+funds&amp;rft.pub=The+Financial+Times&amp;rft.date=2016-01-24&amp;rft.au=Andrew+Ward&amp;rft.au=Peter+Wise&amp;rft_id=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Facceb104-c0fe-11e5-9fdb-87b8d15baec2.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-FDA-65\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-FDA_65-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm482740.htm\">\"FDA works with regulatory partners to understand French-based Biotrial phase 1 clinical study\"</a>. US Food and Drug Administration. 22 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">23 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+works+with+regulatory+partners+to+understand+French-based+Biotrial+phase+1+clinical+study&amp;rft.pub=US+Food+and+Drug+Administration&amp;rft.date=2016-01-22&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm482740.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-66\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-66\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2016/pm1-2016.html\">\"Zwischenfall bei einer klinischen Pr\u00fcfung in Frankreich: keine vergleichbaren F\u00e4lle in Deutschland. Probandensicherheit hat bei der Genehmigung klinischer Pr\u00fcfungen h\u00f6chste Priorit\u00e4t\"</a>. Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). 19 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Zwischenfall+bei+einer+klinischen+Pr%C3%BCfung+in+Frankreich%3A+keine+vergleichbaren+F%C3%A4lle+in+Deutschland.+Probandensicherheit+hat+bei+der+Genehmigung+klinischer+Pr%C3%BCfungen+h%C3%B6chste+Priorit%C3%A4t&amp;rft.pub=Bundesinstitut+f%C3%BCr+Arzneimittel+und+Medizinprodukte+%28BfArM%29&amp;rft.date=2016-01-19&amp;rft_id=http%3A%2F%2Fwww.bfarm.de%2FSharedDocs%2FPressemitteilungen%2FDE%2F2016%2Fpm1-2016.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NEJM-67\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NEJM_67-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NEJM_67-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NEJM_67-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NEJM_67-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kerbrat et al. (3 November 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1604221\">\"Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase\"</a>. <i>New England Journal of Medicine</i>. <b>375</b> (18): 1717. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMoa1604221\">10.1056/NEJMoa1604221</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Acute+Neurologic+Disorder+from+an+Inhibitor+of+Fatty+Acid+Amide+Hydrolase&amp;rft.volume=375&amp;rft.issue=18&amp;rft.pages=1717&amp;rft.date=2016-11-03&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1604221&amp;rft_id=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1604221&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) CS1 maint: Explicit use of et al. (<a href=\"/wiki/Category:CS1_maint:_Explicit_use_of_et_al.\" title=\"Category:CS1 maint: Explicit use of et al.\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-Rennes4-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Rennes4_68-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_15/19_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n4.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b04 concernant les patients hospitalis\u00e9s au CHU de Rennes et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 19 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">25 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B04+concernant+les+patients+hospitalis%C3%A9s+au+CHU+de+Rennes+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-19&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_15%2F19_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n4.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Rennes5-69\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Rennes5_69-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_16/20_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n5.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b05 concernant les patients hospitalis\u00e9s au CHU de Rennes et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 20 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B05+concernant+les+patients+hospitalis%C3%A9s+au+CHU+de+Rennes+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-20&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_16%2F20_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n5.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Rennes7-70\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Rennes7_70-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Rennes7_70-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_18/26_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n7.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b07 concernant les patients hospitalis\u00e9s dans des structures proches de leur domicile et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 26 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B07+concernant+les+patients+hospitalis%C3%A9s+dans+des+structures+proches+de+leur+domicile+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-26&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_18%2F26_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n7.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Rennes6-71\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Rennes6_71-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_17/21_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n6.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b06 concernant les patients hospitalis\u00e9s au CHU de Rennes et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 21 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">25 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B06+concernant+les+patients+hospitalis%C3%A9s+au+CHU+de+Rennes+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-21&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_17%2F21_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n6.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-72\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-72\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ansm.sante.fr/L-ANSM/Comites-scientifiques-specialises-temporaires/Comites-scientifiques-specialises-temporaires/Comites-scientifiques-specialises-temporaires/CSST-Examens-des-donnees-cliniques-et-d-imagerie-cerebrale-des-volontaires-sains-inclus-dans-l-essai-mene-avec-le-BIA-10-2474-et-conduit-a-Rennes\">\"CSST Examens des donn\u00e9es cliniques et d'imagerie c\u00e9r\u00e9brale des volontaires sains inclus dans l'essai men\u00e9 avec le BIA 10-2474 et conduit \u00e0 Rennes\"</a>. Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM). 25 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=CSST+Examens+des+donn%C3%A9es+cliniques+et+d%27imagerie+c%C3%A9r%C3%A9brale+des+volontaires+sains+inclus+dans+l%27essai+men%C3%A9+avec+le+BIA+10-2474+et+conduit+%C3%A0+Rennes&amp;rft.pub=Agence+Nationale+de+S%C3%A9curit%C3%A9+du+M%C3%A9dicament+et+des+Produits+de+Sant%C3%A9+%28ANSM%29&amp;rft.date=2016-11-25&amp;rft_id=http%3A%2F%2Fansm.sante.fr%2FL-ANSM%2FComites-scientifiques-specialises-temporaires%2FComites-scientifiques-specialises-temporaires%2FComites-scientifiques-specialises-temporaires%2FCSST-Examens-des-donnees-cliniques-et-d-imagerie-cerebrale-des-volontaires-sains-inclus-dans-l-essai-mene-avec-le-BIA-10-2474-et-conduit-a-Rennes&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Rennes3-73\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Rennes3_73-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_14/18_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n3.pdf\">\"COMMUNIQUE DE PRESSE: Point de situation n\u00b03 concernant les patients hospitalis\u00e9s au CHU et les personnes volontaires incluses dans l'essai clinique r\u00e9alis\u00e9 par le centre de recherche priv\u00e9 Biotrial pour le compte de la soci\u00e9t\u00e9 Bial\"</a> <span style=\"font-size:85%;\">(PDF)</span>. University Hospital Rennes. 18 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=COMMUNIQUE+DE+PRESSE%3A+Point+de+situation+n%C2%B03+concernant+les+patients+hospitalis%C3%A9s+au+CHU+et+les+personnes+volontaires+incluses+dans+l%27essai+clinique+r%C3%A9alis%C3%A9+par+le+centre+de+recherche+priv%C3%A9+Biotrial+pour+le+compte+de+la+soci%C3%A9t%C3%A9+Bial&amp;rft.pub=University+Hospital+Rennes&amp;rft.date=2016-01-18&amp;rft_id=http%3A%2F%2Fwww.chu-rennes.fr%2Fsections%2Fautres_professionnel%2Frelations_presse%2Fdossiers_et_communiq%2Fdu_16_au_20_mars_les%2FdownloadFile%2FFichierJoint_14%2F18_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n3.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-74\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-74\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">James Randerson (22 December 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nature.com/news/fatal-french-clinical-trial-failed-to-check-data-before-raising-drug-dose-1.21190\">\"Fatal French clinical trial failed to check data before raising drug dose\"</a>. Nature<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Fatal+French+clinical+trial+failed+to+check+data+before+raising+drug+dose&amp;rft.pub=Nature&amp;rft.date=2016-12-22&amp;rft.au=James+Randerson&amp;rft_id=https%3A%2F%2Fwww.nature.com%2Fnews%2Ffatal-french-clinical-trial-failed-to-check-data-before-raising-drug-dose-1.21190&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-75\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-75\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ouest-france.fr/sante/essais-therapeutiques/essai-therapeutique-que-dit-la-loi-3972224\">\"Essai th\u00e9rapeutique. Que dit la loi?\"</a>. Ouest-France. 15 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Essai+th%C3%A9rapeutique.+Que+dit+la+loi%3F&amp;rft.pub=Ouest-France&amp;rft.date=2016-01-15&amp;rft_id=http%3A%2F%2Fwww.ouest-france.fr%2Fsante%2Fessais-therapeutiques%2Fessai-therapeutique-que-dit-la-loi-3972224&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-76\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-76\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Chobanian;  et al. (10 April 2014). <a rel=\"nofollow\" class=\"external text\" href=\"http://pubs.acs.org/doi/abs/10.1021/ml5001239\">\"Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain\"</a>. <i>ACS Med. Chem. Lett</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=ACS+Med.+Chem.+Lett.&amp;rft.atitle=Discovery+of+MK-4409%2C+a+Novel+Oxazole+FAAH+Inhibitor+for+the+Treatment+of+Inflammatory+and+Neuropathic+Pain&amp;rft.date=2014-04-10&amp;rft.au=Chobanian&amp;rft_id=http%3A%2F%2Fpubs.acs.org%2Fdoi%2Fabs%2F10.1021%2Fml5001239&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-77\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-77\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Merck (15 October 2009). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.merck.com/research/pipeline/MerckPipeline_Oct09_Final_10-15-09_10-Q.pdf\">\"Merck Pipeline, Oct 2009\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Merck</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Merck&amp;rft.atitle=Merck+Pipeline%2C+Oct+2009&amp;rft.date=2009-10-15&amp;rft.au=Merck&amp;rft_id=https%3A%2F%2Fwww.merck.com%2Fresearch%2Fpipeline%2FMerckPipeline_Oct09_Final_10-15-09_10-Q.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/results?term=jnj-42165279\">\"Seven studies found for: jnj-42165279\"</a>. <i>Clinicaltrials.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Clinicaltrials.gov&amp;rft.atitle=Seven+studies+found+for%3A+jnj-42165279&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Djnj-42165279&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-79\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-79\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/results?term=V158866&amp;Search=Search\">\"2 studies found for: V158866\"</a>. <i>Clinicaltrials.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-01-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Clinicaltrials.gov&amp;rft.atitle=2+studies+found+for%3A+V158866&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DV158866%26Search%3DSearch&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-80\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-80\">^</a></b></span> <span class=\"reference-text\">Kay Ahn, Douglas S. Johnson, and Benjamin F. Cravatt. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. <i>Expert Opin Drug Discov</i>. 2009 Jul; 4(7): 763\u2013784. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1517%2F17460440903018857\">10.1517/17460440903018857</a></span>\n</li>\n<li id=\"cite_note-81\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-81\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Shanks KG, Behonick GS, Dahn T, Terrell A (Oct 2013). \"Identification of novel third-generation synthetic cannabinoids in products by ultra-performance liquid chromatography and time-of-flight mass spectrometry\". <i>J Anal Toxicol</i>. <b>37</b> (8): 517\u201325. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/jat/bkt062\">10.1093/jat/bkt062</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23946450\">23946450</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Anal+Toxicol&amp;rft.atitle=Identification+of+novel+third-generation+synthetic+cannabinoids+in+products+by+ultra-performance+liquid+chromatography+and+time-of-flight+mass+spectrometry&amp;rft.volume=37&amp;rft.issue=8&amp;rft.pages=517-25&amp;rft.date=2013-10&amp;rft_id=info%3Adoi%2F10.1093%2Fjat%2Fbkt062&amp;rft_id=info%3Apmid%2F23946450&amp;rft.aulast=Shanks&amp;rft.aufirst=KG&amp;rft.au=Behonick%2C+GS&amp;rft.au=Dahn%2C+T&amp;rft.au=Terrell%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-82\">^</a></b></span> <span class=\"reference-text\">Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y. Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, \u03b1-PHPP and \u03b1-POP, with 11 newly distributed designer drugs in illegal products. <i>Forensic Sci Int</i>. 2014 Oct;243:1-13.<a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.forsciint.2014.03.013\">10.1016/j.forsciint.2014.03.013</a> <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24769262\">24769262</a></span>\n</li>\n<li id=\"cite_note-83\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-83\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.janssen.com/janssen-research-development-llc-voluntarily-suspends-dosing-phase-2-clinical-trials-experimental\">\"Janssen Research &amp; Development, LLC Voluntarily Suspends Dosing in Phase 2 Clinical Trials of Experimental Treatment for Mood Disorders\"</a>. Janssen.com. 17 January 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 January</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Janssen+Research+%26+Development%2C+LLC+Voluntarily+Suspends+Dosing+in+Phase+2+Clinical+Trials+of+Experimental+Treatment+for+Mood+Disorders&amp;rft.pub=Janssen.com&amp;rft.date=2016-01-17&amp;rft_id=http%3A%2F%2Fwww.janssen.com%2Fjanssen-research-development-llc-voluntarily-suspends-dosing-phase-2-clinical-trials-experimental&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-in-pharma-84\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-in-pharma_84-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-in-pharma_84-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Gareth MacDonald (19 January 2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.in-pharmatechnologist.com/Regulatory-Safety/FAAH-inhibitor-safety-under-microscope-after-Bial-drug-trial-death\">\"FAAH inhibitor safety under microscope after Bial drug trial death\"</a>. In-Pharma Technologist<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 February</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FAAH+inhibitor+safety+under+microscope+after+Bial+drug+trial+death&amp;rft.pub=In-Pharma+Technologist&amp;rft.date=2016-01-19&amp;rft.au=Gareth+MacDonald&amp;rft_id=http%3A%2F%2Fwww.in-pharmatechnologist.com%2FRegulatory-Safety%2FFAAH-inhibitor-safety-under-microscope-after-Bial-drug-trial-death&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABIA+10-2474\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=BIA_10-2474&amp;action=edit&amp;section=21\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"https://pubchem.ncbi.nlm.nih.gov/compound/46831476\">Pubchem compound summary</a> Open Chemistry Database</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://cdsouthan.blogspot.com.au/2016/01/molecular-details-related-to-bia-10-2474.html\">Molecular details related to BIA 10-2474</a> Chemistry blogpost considers the structure of BIA 10-2474</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cyclicarx.com/bia-10-2474/\">Computational prediction of BIA 10-2474 mechanism of neurotoxicity</a> Biotechnology company evaluates BIA 10-2474 side effects</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bial.com/en/r_d.2/pipeline.29/pipeline.a27.html\">Bial Research &amp; Development Pipeline</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000489.jsp\">Clinical trials in human medicines</a> European Medicines Agency</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.biotrial.com/\">Biotrial</a> Contract Research Organisation</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chu-rennes.fr/sections\">Rennes University Hospital (Centre Hospitalier Universitaire de Rennes)</a></li></ul>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Cannabinoids\" style=\"padding:3px\"><table class=\"nowraplinks hlist collapsible collapsed navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Cannabinoids\" title=\"Template:Cannabinoids\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Cannabinoids\" title=\"Template talk:Cannabinoids\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Cannabinoids&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Cannabinoids\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Cannabinoid\" title=\"Cannabinoid\">Cannabinoids</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Cannabinoid#Phytocannabinoids\" title=\"Cannabinoid\">Phytocannabinoids</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Echinacea\" title=\"Echinacea\">Alkylamides</a></li>\n<li><a href=\"/wiki/Caryophyllene\" title=\"Caryophyllene\">Caryophyllene</a></li>\n<li><a href=\"/wiki/Cannabichromene\" title=\"Cannabichromene\">CBC</a></li>\n<li><a href=\"/w/index.php?title=Cannabichromevarin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cannabichromevarin (page does not exist)\">CBCV</a></li>\n<li><a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">CBD</a></li>\n<li><a href=\"/wiki/Cannabidivarin\" title=\"Cannabidivarin\">CBDV</a></li>\n<li><a href=\"/wiki/Cannabigerol\" title=\"Cannabigerol\">CBG</a></li>\n<li><a href=\"/w/index.php?title=Cannabigerol_monoethyl_ether&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cannabigerol monoethyl ether (page does not exist)\">CBGM</a></li>\n<li><a href=\"/w/index.php?title=Cannabigerovarin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cannabigerovarin (page does not exist)\">CBGV</a></li>\n<li><a href=\"/wiki/Cannabicyclol\" title=\"Cannabicyclol\">CBL</a></li>\n<li><a href=\"/wiki/Cannabinodiol\" title=\"Cannabinodiol\">CBDL</a></li>\n<li><a href=\"/wiki/Cannabinol\" title=\"Cannabinol\">CBN</a></li>\n<li><a href=\"/wiki/Cannabivarin\" title=\"Cannabivarin\">CBV</a></li>\n<li><a href=\"/wiki/Epigallocatechin_gallate\" title=\"Epigallocatechin gallate\">Epigallocatechin gallate</a></li>\n<li><a href=\"/wiki/Gallocatechol\" title=\"Gallocatechol\">Gallocatechol</a></li>\n<li><a href=\"/wiki/Perrottetinene\" title=\"Perrottetinene\">Perrottetinene</a></li>\n<li><a href=\"/wiki/Serinolamide_A\" title=\"Serinolamide A\">Serinolamide A</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol\" title=\"Tetrahydrocannabinol\">THC</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol-C4\" title=\"Tetrahydrocannabinol-C4\">THC-C4</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinolic_acid\" title=\"Tetrahydrocannabinolic acid\">THCA</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabivarin\" title=\"Tetrahydrocannabivarin\">THCV</a></li>\n<li><a href=\"/wiki/Yangonin\" title=\"Yangonin\">Yangonin</a></li></ul>\n<ul><li><i>Active metabolites:</i> <a href=\"/w/index.php?title=8,11-Dihydroxy-THC&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"8,11-Dihydroxy-THC (page does not exist)\">8,11-DiOH-THC</a></li>\n<li><a href=\"/wiki/11-nor-9-Carboxy-THC\" class=\"mw-redirect\" title=\"11-nor-9-Carboxy-THC\">11-COOH-THC</a></li>\n<li><a href=\"/wiki/11-Hydroxy-THC\" title=\"11-Hydroxy-THC\">11-OH-THC</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Endocannabinoid\" class=\"mw-redirect\" title=\"Endocannabinoid\">Endocannabinoids</a></th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Anandamide\" title=\"Anandamide\">Arachidonoyl ethanolamide (AEA; anandamide)</a></li>\n<li><a href=\"/wiki/2-Arachidonoylglycerol\" title=\"2-Arachidonoylglycerol\">2-Arachidonoylglycerol (2-AG)</a></li>\n<li><a href=\"/wiki/2-Arachidonyl_glyceryl_ether\" title=\"2-Arachidonyl glyceryl ether\">2-Arachidonyl glyceryl ether (2-AGE; noladin ether)</a></li>\n<li><a href=\"/wiki/2-Oleoylglycerol\" title=\"2-Oleoylglycerol\">2-Oleoylglycerol (2-OG)</a></li>\n<li><a href=\"/wiki/N-Arachidonoyl_dopamine\" title=\"N-Arachidonoyl dopamine\">N-Arachidonoyl dopamine (NADA)</a></li>\n<li><a href=\"/wiki/N-Arachidonylglycine\" title=\"N-Arachidonylglycine\">N-Arachidonylglycine (NAGly)</a></li>\n<li><a href=\"/w/index.php?title=2-Arachidonoyl_lysophosphatidylinositol&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"2-Arachidonoyl lysophosphatidylinositol (page does not exist)\">2-Arachidonoyl lysophosphatidylinositol (2-ALPI)</a></li>\n<li><a href=\"/wiki/Arachidonoyl_serotonin\" title=\"Arachidonoyl serotonin\">N-Arachidonoyl serotonin (AA-5-HT)</a></li>\n<li><a href=\"/wiki/Docosatetraenoylethanolamide\" title=\"Docosatetraenoylethanolamide\">Docosatetraenoylethanolamide (DEA)</a></li>\n<li><a href=\"/wiki/Lysophosphatidylinositol\" title=\"Lysophosphatidylinositol\">Lysophosphatidylinositol (LPI)</a></li>\n<li><a href=\"/wiki/Oleamide\" title=\"Oleamide\">Oleamide</a></li>\n<li><a href=\"/wiki/Oleoylethanolamide\" title=\"Oleoylethanolamide\">Oleoylethanolamide (OEA)</a></li>\n<li><a href=\"/wiki/Palmitoylethanolamide\" title=\"Palmitoylethanolamide\">Palmitoylethanolamide (PEA)</a></li>\n<li><a href=\"/wiki/RVD-Hp%CE%B1\" title=\"RVD-Hp\u03b1\">RVD-Hp\u03b1</a></li>\n<li><a href=\"/wiki/Stearoylethanolamide\" title=\"Stearoylethanolamide\">Stearoylethanolamide (SEA)</a></li>\n<li><a href=\"/wiki/Virodhamine\" title=\"Virodhamine\">O-Arachidonoyl ethanolamine (O-AEA; virodhamine)</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Synthetic_cannabis\" class=\"mw-redirect\" title=\"Synthetic cannabis\">Synthetic<br />cannabinoids</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks hlist navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Classical cannabinoids<br />(dibenzopyrans)</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/A-40174\" title=\"A-40174\">A-40174</a></li>\n<li><a href=\"/wiki/A-41988\" title=\"A-41988\">A-41988</a></li>\n<li><a href=\"/w/index.php?title=A-42574&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"A-42574 (page does not exist)\">A-42574</a></li>\n<li><a href=\"/wiki/Ajulemic_acid\" title=\"Ajulemic acid\">Ajulemic acid</a></li>\n<li><a href=\"/wiki/AM-087\" title=\"AM-087\">AM-087</a></li>\n<li><a href=\"/wiki/AM-411\" title=\"AM-411\">AM-411</a></li>\n<li><a href=\"/wiki/AM-855\" title=\"AM-855\">AM-855</a></li>\n<li><a href=\"/wiki/AM-905\" title=\"AM-905\">AM-905</a></li>\n<li><a href=\"/wiki/AM-906\" title=\"AM-906\">AM-906</a></li>\n<li><a href=\"/wiki/AM-919\" title=\"AM-919\">AM-919</a></li>\n<li><a href=\"/w/index.php?title=AM-926&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-926 (page does not exist)\">AM-926</a></li>\n<li><a href=\"/wiki/AM-938\" title=\"AM-938\">AM-938</a></li>\n<li><a href=\"/wiki/AM-2389\" title=\"AM-2389\">AM-2389</a></li>\n<li><a href=\"/wiki/AM-4030\" title=\"AM-4030\">AM-4030</a></li>\n<li><a href=\"/wiki/AMG-1\" title=\"AMG-1\">AMG-1</a></li>\n<li><a href=\"/wiki/AMG-3\" title=\"AMG-3\">AMG-3</a></li>\n<li><a href=\"/wiki/AMG-36\" title=\"AMG-36\">AMG-36</a></li>\n<li><a href=\"/wiki/AMG-41\" title=\"AMG-41\">AMG-41</a></li>\n<li><a href=\"/wiki/Dexanabinol\" title=\"Dexanabinol\">Dexanabinol (HU-211)</a></li>\n<li><a href=\"/wiki/Dimethylheptylpyran\" title=\"Dimethylheptylpyran\">DMHP</a></li>\n<li><a href=\"/wiki/Dronabinol\" title=\"Dronabinol\">Dronabinol</a></li>\n<li><a href=\"/wiki/9-nor-9%CE%B2-Hydroxyhexahydrocannabinol\" class=\"mw-redirect\" title=\"9-nor-9\u03b2-Hydroxyhexahydrocannabinol\">HHC</a></li>\n<li><a href=\"/wiki/HU-210\" title=\"HU-210\">HU-210</a></li>\n<li><a href=\"/wiki/HU-243\" title=\"HU-243\">HU-243</a></li>\n<li><a href=\"/wiki/JWH-051\" title=\"JWH-051\">JWH-051</a></li>\n<li><a href=\"/wiki/JWH-133\" title=\"JWH-133\">JWH-133</a></li>\n<li><a href=\"/w/index.php?title=JWH-139&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-139 (page does not exist)\">JWH-139</a></li>\n<li><a href=\"/wiki/JWH-161\" title=\"JWH-161\">JWH-161</a></li>\n<li><a href=\"/w/index.php?title=JWH-229&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-229 (page does not exist)\">JWH-229</a></li>\n<li><a href=\"/wiki/JWH-359\" title=\"JWH-359\">JWH-359</a></li>\n<li><a href=\"/wiki/KM-233\" title=\"KM-233\">KM-233</a></li>\n<li><a href=\"/wiki/L-759,633\" title=\"L-759,633\">L-759,633</a></li>\n<li><a href=\"/wiki/L-759,656\" title=\"L-759,656\">L-759,656</a></li>\n<li><a href=\"/wiki/Levonantradol\" title=\"Levonantradol\">Levonantradol (CP 50,5561)</a></li>\n<li><a href=\"/wiki/Menabitan\" title=\"Menabitan\">Menabitan</a></li>\n<li><a href=\"/wiki/Nabazenil\" title=\"Nabazenil\">Nabazenil</a></li>\n<li><a href=\"/wiki/Canbisol\" title=\"Canbisol\">Nabidrox (Canbisol)</a></li>\n<li><a href=\"/wiki/Nabilone\" title=\"Nabilone\">Nabilone</a></li>\n<li><a href=\"/wiki/Nabitan\" title=\"Nabitan\">Nabitan</a></li>\n<li><a href=\"/wiki/Naboctate\" title=\"Naboctate\">Naboctate</a></li>\n<li><a href=\"/w/index.php?title=O-224&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-224 (page does not exist)\">O-224</a></li>\n<li><a href=\"/w/index.php?title=O-581&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-581 (page does not exist)\">O-581</a></li>\n<li><a href=\"/wiki/O-774\" title=\"O-774\">O-774</a></li>\n<li><a href=\"/wiki/O-806\" title=\"O-806\">O-806</a></li>\n<li><a href=\"/wiki/O-823\" title=\"O-823\">O-823</a></li>\n<li><a href=\"/wiki/O-1057\" title=\"O-1057\">O-1057</a></li>\n<li><a href=\"/wiki/O-1125\" title=\"O-1125\">O-1125</a></li>\n<li><a href=\"/w/index.php?title=O-1191&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1191 (page does not exist)\">O-1191</a></li>\n<li><a href=\"/wiki/O-1238\" title=\"O-1238\">O-1238</a></li>\n<li><a href=\"/w/index.php?title=O-2048&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2048 (page does not exist)\">O-2048</a></li>\n<li><a href=\"/wiki/O-2113\" title=\"O-2113\">O-2113</a></li>\n<li><a href=\"/w/index.php?title=O-2365&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2365 (page does not exist)\">O-2365</a></li>\n<li><a href=\"/wiki/O-2372\" title=\"O-2372\">O-2372</a></li>\n<li><a href=\"/w/index.php?title=O-2373&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2373 (page does not exist)\">O-2373</a></li>\n<li><a href=\"/w/index.php?title=O-2383&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2383 (page does not exist)\">O-2383</a></li>\n<li><a href=\"/w/index.php?title=O-2426&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2426 (page does not exist)\">O-2426</a></li>\n<li><a href=\"/w/index.php?title=O-2484&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2484 (page does not exist)\">O-2484</a></li>\n<li><a href=\"/wiki/O-2545\" title=\"O-2545\">O-2545</a></li>\n<li><a href=\"/wiki/O-2694\" title=\"O-2694\">O-2694</a></li>\n<li><a href=\"/w/index.php?title=O-2715&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2715 (page does not exist)\">O-2715</a></li>\n<li><a href=\"/w/index.php?title=O-2716&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2716 (page does not exist)\">O-2716</a></li>\n<li><a href=\"/w/index.php?title=O-3223&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-3223 (page does not exist)\">O-3223</a></li>\n<li><a href=\"/w/index.php?title=O-3226&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-3226 (page does not exist)\">O-3226</a></li>\n<li><a href=\"/wiki/Parahexyl\" title=\"Parahexyl\">Parahexyl</a></li>\n<li><a href=\"/wiki/Pirnabine\" title=\"Pirnabine\">Pirnabine</a></li>\n<li><a href=\"/wiki/THC-O-acetate\" title=\"THC-O-acetate\">THC-O-acetate</a></li>\n<li><a href=\"/wiki/THC-O-phosphate\" title=\"THC-O-phosphate\">THC-O-phosphate</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Non-classical<br />cannabinoids</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Cannabicyclohexanol\" title=\"Cannabicyclohexanol\">Cannabicyclohexanol</a></li>\n<li><a href=\"/wiki/CBD-DMH\" title=\"CBD-DMH\">CBD-DMH</a></li>\n<li><a href=\"/wiki/CP_47,497\" title=\"CP 47,497\">CP 47,497</a></li>\n<li><a href=\"/wiki/(C6)-CP_47,497\" title=\"(C6)-CP 47,497\">(C6)-CP 47,497</a></li>\n<li><a href=\"/wiki/(C9)-CP_47,497\" title=\"(C9)-CP 47,497\">(C9)-CP 47,497</a></li>\n<li><a href=\"/wiki/CP_55,244\" title=\"CP 55,244\">CP 55,244</a></li>\n<li><a href=\"/wiki/CP_55,940\" title=\"CP 55,940\">CP 55,940</a></li>\n<li><a href=\"/wiki/HU-308\" title=\"HU-308\">HU-308</a></li>\n<li><a href=\"/wiki/HU-320\" title=\"HU-320\">HU-320</a></li>\n<li><a href=\"/wiki/HU-331\" title=\"HU-331\">HU-331</a></li>\n<li><a href=\"/wiki/HU-336\" title=\"HU-336\">HU-336</a></li>\n<li><a href=\"/wiki/HU-345\" title=\"HU-345\">HU-345</a></li>\n<li><a href=\"/w/index.php?title=HU-446&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"HU-446 (page does not exist)\">HU-446</a></li>\n<li><a href=\"/w/index.php?title=HU-465&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"HU-465 (page does not exist)\">HU-465</a></li>\n<li><a href=\"/w/index.php?title=HU-910&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"HU-910 (page does not exist)\">HU-910</a></li>\n<li><a href=\"/wiki/HUF-101\" class=\"mw-redirect\" title=\"HUF-101\">HUF-101</a></li>\n<li><a href=\"/wiki/Nonabine\" title=\"Nonabine\">Nonabine</a></li>\n<li><a href=\"/w/index.php?title=O-1376&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1376 (page does not exist)\">O-1376</a></li>\n<li><a href=\"/w/index.php?title=O-1422&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1422 (page does not exist)\">O-1422</a></li>\n<li><a href=\"/w/index.php?title=O-1601&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1601 (page does not exist)\">O-1601</a></li>\n<li><a href=\"/w/index.php?title=O-1656&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1656 (page does not exist)\">O-1656</a></li>\n<li><a href=\"/w/index.php?title=O-1657&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1657 (page does not exist)\">O-1657</a></li>\n<li><a href=\"/w/index.php?title=O-1660&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1660 (page does not exist)\">O-1660</a></li>\n<li><a href=\"/w/index.php?title=O-1663&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1663 (page does not exist)\">O-1663</a></li>\n<li><a href=\"/wiki/O-1871\" title=\"O-1871\">O-1871</a></li>\n<li><a href=\"/w/index.php?title=SPA-229&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"SPA-229 (page does not exist)\">SPA-229</a></li>\n<li><a href=\"/wiki/Tinabinol\" title=\"Tinabinol\">Tinabinol</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Benzoylindoles</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/w/index.php?title=1-Butyl-3-(2-methoxybenzoyl)indole&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"1-Butyl-3-(2-methoxybenzoyl)indole (page does not exist)\">1-Butyl-3-(2-methoxybenzoyl)indole</a></li>\n<li><a href=\"/w/index.php?title=1-Butyl-3-(4-methoxybenzoyl)indole&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"1-Butyl-3-(4-methoxybenzoyl)indole (page does not exist)\">1-Butyl-3-(4-methoxybenzoyl)indole</a></li>\n<li><a href=\"/w/index.php?title=1-Pentyl-3-(2-methoxybenzoyl)indole&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"1-Pentyl-3-(2-methoxybenzoyl)indole (page does not exist)\">1-Pentyl-3-(2-methoxybenzoyl)indole</a></li>\n<li><a href=\"/wiki/AM-630\" title=\"AM-630\">AM-630</a></li>\n<li><a href=\"/wiki/AM-679_(cannabinoid)\" title=\"AM-679 (cannabinoid)\">AM-679</a></li>\n<li><a href=\"/wiki/AM-694\" title=\"AM-694\">AM-694</a></li>\n<li><a href=\"/wiki/AM-1241\" title=\"AM-1241\">AM-1241</a></li>\n<li><a href=\"/wiki/AM-2233\" title=\"AM-2233\">AM-2233</a></li>\n<li><a href=\"/wiki/GW-405,833\" title=\"GW-405,833\">GW-405,833 (L-768,242)</a></li>\n<li><a href=\"/wiki/Pravadoline\" title=\"Pravadoline\">Pravadoline</a></li>\n<li><a href=\"/wiki/RCS-4\" title=\"RCS-4\">RCS-4</a></li>\n<li><a href=\"/wiki/WIN_54,461\" title=\"WIN 54,461\">WIN 54,461</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Naphthoylindoles</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/AM-1220\" title=\"AM-1220\">AM-1220</a></li>\n<li><a href=\"/wiki/AM-1221\" title=\"AM-1221\">AM-1221</a></li>\n<li><a href=\"/wiki/AM-1235\" title=\"AM-1235\">AM-1235</a></li>\n<li><a href=\"/wiki/AM-2201\" title=\"AM-2201\">AM-2201</a></li>\n<li><a href=\"/wiki/AM-2232\" title=\"AM-2232\">AM-2232</a></li>\n<li><a href=\"/w/index.php?title=CHM-081&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CHM-081 (page does not exist)\">CHM-081</a></li>\n<li><a href=\"/wiki/EAM-2201\" title=\"EAM-2201\">EAM-2201</a></li>\n<li><a href=\"/wiki/FUB-JWH-018\" title=\"FUB-JWH-018\">FUB-JWH-018</a></li>\n<li><a href=\"/wiki/JWH-007\" title=\"JWH-007\">JWH-007</a></li>\n<li><a href=\"/wiki/JWH-015\" title=\"JWH-015\">JWH-015</a></li>\n<li><a href=\"/wiki/JWH-018\" title=\"JWH-018\">JWH-018</a></li>\n<li><a href=\"/wiki/JWH-019\" title=\"JWH-019\">JWH-019</a></li>\n<li><a href=\"/wiki/JWH-073\" title=\"JWH-073\">JWH-073</a></li>\n<li><a href=\"/wiki/JWH-081\" title=\"JWH-081\">JWH-081</a></li>\n<li><a href=\"/wiki/JWH-098\" title=\"JWH-098\">JWH-098</a></li>\n<li><a href=\"/wiki/JWH-116\" title=\"JWH-116\">JWH-116</a></li>\n<li><a href=\"/wiki/JWH-122\" title=\"JWH-122\">JWH-122</a></li>\n<li><a href=\"/wiki/JWH-149\" title=\"JWH-149\">JWH-149</a></li>\n<li><a href=\"/wiki/JWH-164\" title=\"JWH-164\">JWH-164</a></li>\n<li><a href=\"/wiki/JWH-182\" class=\"mw-redirect\" title=\"JWH-182\">JWH-182</a></li>\n<li><a href=\"/wiki/JWH-193\" title=\"JWH-193\">JWH-193</a></li>\n<li><a href=\"/wiki/JWH-198\" title=\"JWH-198\">JWH-198</a></li>\n<li><a href=\"/wiki/JWH-200\" title=\"JWH-200\">JWH-200</a></li>\n<li><a href=\"/wiki/JWH-210\" title=\"JWH-210\">JWH-210</a></li>\n<li><a href=\"/wiki/JWH-398\" title=\"JWH-398\">JWH-398</a></li>\n<li><a href=\"/wiki/JWH-424\" title=\"JWH-424\">JWH-424</a></li>\n<li><a href=\"/w/index.php?title=MAM-1220&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MAM-1220 (page does not exist)\">MAM-1220</a></li>\n<li><a href=\"/wiki/MAM-2201\" title=\"MAM-2201\">MAM-2201</a></li>\n<li><a href=\"/wiki/NE-CHMIMO\" title=\"NE-CHMIMO\">NE-CHMIMO</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Naphthoylindazoles</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/THJ-018\" title=\"THJ-018\">THJ-018</a></li>\n<li><a href=\"/wiki/THJ-2201\" title=\"THJ-2201\">THJ-2201</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Pyrrolobenzoxazines</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/WIN_55,212-2\" title=\"WIN 55,212-2\">WIN 55,212-2</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Naphthylmethylindoles</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/JWH-175\" title=\"JWH-175\">JWH-175</a></li>\n<li><a href=\"/wiki/JWH-176\" title=\"JWH-176\">JWH-176</a></li>\n<li><a href=\"/wiki/JWH-184\" title=\"JWH-184\">JWH-184</a></li>\n<li><a href=\"/wiki/JWH-185\" title=\"JWH-185\">JWH-185</a></li>\n<li><a href=\"/w/index.php?title=JWH-192&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-192 (page does not exist)\">JWH-192</a></li>\n<li><a href=\"/w/index.php?title=JWH-194&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-194 (page does not exist)\">JWH-194</a></li>\n<li><a href=\"/w/index.php?title=JWH-195&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-195 (page does not exist)\">JWH-195</a></li>\n<li><a href=\"/wiki/JWH-196\" title=\"JWH-196\">JWH-196</a></li>\n<li><a href=\"/w/index.php?title=JWH-197&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-197 (page does not exist)\">JWH-197</a></li>\n<li><a href=\"/w/index.php?title=JWH-199&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-199 (page does not exist)\">JWH-199</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Phenylacetylindoles</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Cannabipiperidiethanone\" title=\"Cannabipiperidiethanone\">Cannabipiperidiethanone</a></li>\n<li><a href=\"/wiki/JWH-167\" title=\"JWH-167\">JWH-167</a></li>\n<li><a href=\"/wiki/JWH-203\" title=\"JWH-203\">JWH-203</a></li>\n<li><a href=\"/wiki/JWH-249\" title=\"JWH-249\">JWH-249</a></li>\n<li><a href=\"/wiki/JWH-250\" title=\"JWH-250\">JWH-250</a></li>\n<li><a href=\"/wiki/JWH-251\" title=\"JWH-251\">JWH-251</a></li>\n<li><a href=\"/wiki/JWH-302\" title=\"JWH-302\">JWH-302</a></li>\n<li><a href=\"/wiki/RCS-8\" title=\"RCS-8\">RCS-8</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Indole-3-carboxamides</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/5F-ADBICA\" title=\"5F-ADBICA\">5F-ADBICA</a></li>\n<li><a href=\"/wiki/5F-NNE1\" title=\"5F-NNE1\">5F-NNE1</a></li>\n<li><a href=\"/wiki/5F-PCN\" title=\"5F-PCN\">5F-PCN</a></li>\n<li><a href=\"/wiki/5F-SDB-006\" title=\"5F-SDB-006\">5F-SDB-006</a></li>\n<li><a href=\"/wiki/AB-FUBICA\" title=\"AB-FUBICA\">AB-FUBICA</a></li>\n<li><a href=\"/wiki/AB-PICA\" title=\"AB-PICA\">AB-PICA</a></li>\n<li><a href=\"/wiki/ADBICA\" title=\"ADBICA\">ADBICA</a></li>\n<li><a href=\"/wiki/ADB-FUBICA\" title=\"ADB-FUBICA\">ADB-FUBICA</a></li>\n<li><a href=\"/wiki/APICA_(synthetic_cannabinoid_drug)\" title=\"APICA (synthetic cannabinoid drug)\">APICA</a></li>\n<li><a href=\"/w/index.php?title=CUMYL-BICA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CUMYL-BICA (page does not exist)\">CUMYL-BICA</a></li>\n<li><a href=\"/wiki/CUMYL-PICA\" title=\"CUMYL-PICA\">CUMYL-PICA</a></li>\n<li><a href=\"/w/index.php?title=CUMYL-5F-PICA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CUMYL-5F-PICA (page does not exist)\">CUMYL-5F-PICA</a></li>\n<li><a href=\"/wiki/FDU-NNE1\" title=\"FDU-NNE1\">FDU-NNE1</a></li>\n<li><a href=\"/wiki/MDMB-CHMICA\" title=\"MDMB-CHMICA\">MDMB-CHMICA</a></li>\n<li><a href=\"/wiki/MMB-2201\" title=\"MMB-2201\">MMB-2201</a></li>\n<li><a href=\"/wiki/MN-25\" title=\"MN-25\">MN-25</a> (UR-12)</li>\n<li><a href=\"/wiki/NNE1\" title=\"NNE1\">NNE1</a></li>\n<li><a href=\"/wiki/PX-1\" title=\"PX-1\">PX-1</a></li>\n<li><a href=\"/wiki/Org_28312\" title=\"Org 28312\">Org 28312</a></li>\n<li><a href=\"/wiki/Org_28611\" title=\"Org 28611\">Org 28611</a></li>\n<li><a href=\"/wiki/SDB-006\" title=\"SDB-006\">SDB-006</a></li>\n<li><a href=\"/wiki/STS-135_(drug)\" title=\"STS-135 (drug)\">STS-135</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Indole-3-carboxylates</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/5F-PB-22\" title=\"5F-PB-22\">5F-PB-22</a></li>\n<li><a href=\"/wiki/FDU-PB-22\" title=\"FDU-PB-22\">FDU-PB-22</a></li>\n<li><a href=\"/wiki/FUB-PB-22\" title=\"FUB-PB-22\">FUB-PB-22</a></li>\n<li><a href=\"/wiki/QUCHIC\" title=\"QUCHIC\">QUCHIC (BB-22)</a></li>\n<li><a href=\"/wiki/QUPIC\" class=\"mw-redirect\" title=\"QUPIC\">QUPIC (PB-22)</a></li>\n<li><a href=\"/wiki/NM-2201\" title=\"NM-2201\">NM-2201</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Tetramethylcyclo-<br />propanoylindoles</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/w/index.php?title=5Br-UR-144&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5Br-UR-144 (page does not exist)\">5Br-UR-144</a></li>\n<li><a href=\"/w/index.php?title=5Cl-UR-144&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5Cl-UR-144 (page does not exist)\">5Cl-UR-144</a></li>\n<li><a href=\"/wiki/A-796,260\" title=\"A-796,260\">A-796,260</a></li>\n<li><a href=\"/wiki/A-834,735\" title=\"A-834,735\">A-834,735</a></li>\n<li><a href=\"/wiki/FUB-144\" title=\"FUB-144\">FUB-144</a></li>\n<li><a href=\"/wiki/UR-144\" title=\"UR-144\">UR-144</a></li>\n<li><a href=\"/wiki/XLR-11\" title=\"XLR-11\">XLR-11</a></li>\n<li><a href=\"/wiki/XLR-12\" title=\"XLR-12\">XLR-12</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Indazole-3-<br />carboxamides</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/w/index.php?title=5Cl-APINACA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5Cl-APINACA (page does not exist)\">5Cl-APINACA</a></li>\n<li><a href=\"/wiki/5F-ADB\" title=\"5F-ADB\">5F-ADB</a></li>\n<li><a href=\"/wiki/5F-ADB-PINACA\" title=\"5F-ADB-PINACA\">5F-ADB-PINACA</a></li>\n<li><a href=\"/wiki/5F-AMB\" title=\"5F-AMB\">5F-AMB</a></li>\n<li><a href=\"/wiki/5F-APINACA\" title=\"5F-APINACA\">5F-APINACA</a></li>\n<li><a href=\"/wiki/5F-CUMYL-PINACA\" title=\"5F-CUMYL-PINACA\">5F-CUMYL-PINACA</a></li>\n<li><a href=\"/wiki/5F-EMB-PINACA\" title=\"5F-EMB-PINACA\">5F-EMB-PINACA</a></li>\n<li><a href=\"/wiki/AB-CHMINACA\" title=\"AB-CHMINACA\">AB-CHMINACA</a></li>\n<li><a href=\"/wiki/AB-FUBINACA\" title=\"AB-FUBINACA\">AB-FUBINACA</a></li>\n<li><a href=\"/w/index.php?title=AB-FUBINACA_2-fluorobenzyl_isomer&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AB-FUBINACA 2-fluorobenzyl isomer (page does not exist)\">AB-FUBINACA 2-fluorobenzyl isomer</a></li>\n<li><a href=\"/wiki/AB-PINACA\" title=\"AB-PINACA\">AB-PINACA</a></li>\n<li><a href=\"/wiki/ADB-CHMINACA\" title=\"ADB-CHMINACA\">ADB-CHMINACA</a></li>\n<li><a href=\"/wiki/ADB-FUBINACA\" title=\"ADB-FUBINACA\">ADB-FUBINACA</a></li>\n<li><a href=\"/wiki/ADB-PINACA\" title=\"ADB-PINACA\">ADB-PINACA</a></li>\n<li><a href=\"/wiki/ADAMANTYL-THPINACA\" class=\"mw-redirect\" title=\"ADAMANTYL-THPINACA\">ADAMANTYL-THPINACA</a></li>\n<li><a href=\"/wiki/ADSB-FUB-187\" title=\"ADSB-FUB-187\">ADSB-FUB-187</a></li>\n<li><a href=\"/wiki/AMB-CHMINACA\" title=\"AMB-CHMINACA\">AMB-CHMINACA</a></li>\n<li><a href=\"/wiki/AMB-FUBINACA\" title=\"AMB-FUBINACA\">AMB-FUBINACA</a></li>\n<li><a href=\"/wiki/APINACA\" title=\"APINACA\">APINACA (AKB48)</a></li>\n<li><a href=\"/wiki/APP-FUBINACA\" title=\"APP-FUBINACA\">APP-FUBINACA</a></li>\n<li><a href=\"/wiki/CUMYL-4CN-BINACA\" title=\"CUMYL-4CN-BINACA\">CUMYL-4CN-BINACA</a></li>\n<li><a href=\"/wiki/CUMYL-PINACA\" title=\"CUMYL-PINACA\">CUMYL-PINACA</a></li>\n<li><a href=\"/wiki/CUMYL-THPINACA\" title=\"CUMYL-THPINACA\">CUMYL-THPINACA</a></li>\n<li><a href=\"/w/index.php?title=EMB-FUBINACA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"EMB-FUBINACA (page does not exist)\">EMB-FUBINACA</a></li>\n<li><a href=\"/wiki/FUB-APINACA\" title=\"FUB-APINACA\">FUB-APINACA</a></li>\n<li><a href=\"/wiki/MDMB-FUBINACA\" title=\"MDMB-FUBINACA\">MDMB-FUBINACA</a></li>\n<li><a href=\"/wiki/MDMB-CHMINACA\" title=\"MDMB-CHMINACA\">MDMB-CHMINACA</a></li>\n<li><a href=\"/wiki/MN-18\" title=\"MN-18\">MN-18</a></li>\n<li><a href=\"/wiki/PX-2\" title=\"PX-2\">PX-2</a></li>\n<li><a href=\"/wiki/PX-3\" title=\"PX-3\">PX-3</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Tetramethylcyclo-<br />propanoylindazoles</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/FAB-144\" title=\"FAB-144\">FAB-144</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Naphthoylpyrroles</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/JWH-030\" title=\"JWH-030\">JWH-030</a></li>\n<li><a href=\"/wiki/JWH-147\" title=\"JWH-147\">JWH-147</a></li>\n<li><a href=\"/wiki/JWH-307\" title=\"JWH-307\">JWH-307</a></li>\n<li><a href=\"/w/index.php?title=JWH-369&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-369 (page does not exist)\">JWH-369</a></li>\n<li><a href=\"/w/index.php?title=JWH-370&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-370 (page does not exist)\">JWH-370</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Eicosanoid\" title=\"Eicosanoid\">Eicosanoids</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/w/index.php?title=AM-883&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-883 (page does not exist)\">AM-883</a></li>\n<li><a href=\"/w/index.php?title=AM-1346&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-1346 (page does not exist)\">AM-1346</a></li>\n<li><a href=\"/wiki/Arachidonyl-2%27-chloroethylamide\" title=\"Arachidonyl-2&#39;-chloroethylamide\">ACEA</a></li>\n<li><a href=\"/wiki/Arachidonylcyclopropylamide\" title=\"Arachidonylcyclopropylamide\">ACPA</a></li>\n<li><a href=\"/wiki/Methanandamide\" title=\"Methanandamide\">Methanandamide (AM-356)</a></li>\n<li><a href=\"/w/index.php?title=O-585&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-585 (page does not exist)\">O-585</a></li>\n<li><a href=\"/w/index.php?title=O-689&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-689 (page does not exist)\">O-689</a></li>\n<li><a href=\"/wiki/O-1812\" title=\"O-1812\">O-1812</a></li>\n<li><a href=\"/w/index.php?title=O-1860&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1860 (page does not exist)\">O-1860</a></li>\n<li><a href=\"/w/index.php?title=O-1861&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1861 (page does not exist)\">O-1861</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Pyrazolecarboxamides</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/5F-AB-FUPPYCA\" title=\"5F-AB-FUPPYCA\">5F-AB-FUPPYCA</a></li>\n<li><a href=\"/wiki/AB-CHFUPYCA\" title=\"AB-CHFUPYCA\">AB-CHFUPYCA</a></li>\n<li><a href=\"/wiki/AB-CHMFUPPYCA\" class=\"mw-redirect\" title=\"AB-CHMFUPPYCA\">AB-CHMFUPPYCA</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Others</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/4-HTMPIPO\" title=\"4-HTMPIPO\">4-HTMPIPO</a></li>\n<li><a href=\"/w/index.php?title=5F-PY-PICA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5F-PY-PICA (page does not exist)\">5F-PY-PICA</a></li>\n<li><a href=\"/w/index.php?title=5F-PY-PINACA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5F-PY-PINACA (page does not exist)\">5F-PY-PINACA</a></li>\n<li><a href=\"/w/index.php?title=5F-3-pyridinoylindole&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5F-3-pyridinoylindole (page does not exist)\">5F-3-pyridinoylindole</a></li>\n<li><a href=\"/wiki/A-836,339\" title=\"A-836,339\">A-836,339</a></li>\n<li><a href=\"/w/index.php?title=A-955,840&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"A-955,840 (page does not exist)\">A-955,840</a></li>\n<li><a href=\"/wiki/Abnormal_cannabidiol\" title=\"Abnormal cannabidiol\">Abnormal cannabidiol</a></li>\n<li><a href=\"/wiki/AB-001\" title=\"AB-001\">AB-001</a></li>\n<li><a href=\"/wiki/BzODZ-EPyr\" title=\"BzODZ-EPyr\">BzODZ-EPyr</a></li>\n<li><a href=\"/wiki/AM-1248\" title=\"AM-1248\">AM-1248</a></li>\n<li><a href=\"/wiki/AM-1714\" title=\"AM-1714\">AM-1714</a></li>\n<li><a href=\"/wiki/AZ-11713908\" title=\"AZ-11713908\">AZ-11713908</a></li>\n<li><a href=\"/wiki/BAY_38-7271\" title=\"BAY 38-7271\">BAY 38-7271</a></li>\n<li><a href=\"/wiki/BAY_59-3074\" title=\"BAY 59-3074\">BAY 59-3074</a></li>\n<li><a href=\"/wiki/BIM-018\" title=\"BIM-018\">BIM-018</a></li>\n<li><a href=\"/wiki/CB-13\" title=\"CB-13\">CB-13</a></li>\n<li><a href=\"/w/index.php?title=CB-86&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CB-86 (page does not exist)\">CB-86</a></li>\n<li><a href=\"/wiki/CBS-0550\" title=\"CBS-0550\">CBS-0550</a></li>\n<li><a href=\"/w/index.php?title=CUMYL-4CN-B7AICA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CUMYL-4CN-B7AICA (page does not exist)\">CUMYL-4CN-B7AICA</a></li>\n<li><a href=\"/wiki/CUMYL-5F-P7AICA\" class=\"mw-redirect\" title=\"CUMYL-5F-P7AICA\">CUMYL-5F-P7AICA</a></li>\n<li><a href=\"/wiki/CUMYL-PEGACLONE\" title=\"CUMYL-PEGACLONE\">CUMYL-PEGACLONE</a></li>\n<li><a href=\"/wiki/FUBIMINA\" title=\"FUBIMINA\">FUBIMINA</a></li>\n<li><a href=\"/w/index.php?title=GSK-554,418A&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"GSK-554,418A (page does not exist)\">GSK-554,418A</a></li>\n<li><a href=\"/wiki/GW-842,166X\" title=\"GW-842,166X\">GW-842,166X</a></li>\n<li><a href=\"/wiki/JTE_7-31\" title=\"JTE 7-31\">JTE 7-31</a></li>\n<li><a href=\"/wiki/LASSBio-881\" title=\"LASSBio-881\">LASSBio-881</a></li>\n<li><a href=\"/wiki/LBP-1_(drug)\" title=\"LBP-1 (drug)\">LBP-1</a></li>\n<li><a href=\"/wiki/Leelamine\" title=\"Leelamine\">Leelamine</a></li>\n<li><a href=\"/w/index.php?title=MDA-7&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MDA-7 (page does not exist)\">MDA-7</a></li>\n<li><a href=\"/wiki/MDA-19\" title=\"MDA-19\">MDA-19</a></li>\n<li><a href=\"/wiki/MEPIRAPIM\" title=\"MEPIRAPIM\">MEPIRAPIM</a></li>\n<li><a href=\"/wiki/NESS-040C5\" title=\"NESS-040C5\">NESS-040C5</a></li>\n<li><a href=\"/wiki/NMP-7\" title=\"NMP-7\">NMP-7</a></li>\n<li><a href=\"/w/index.php?title=O-889&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-889 (page does not exist)\">O-889</a></li>\n<li><a href=\"/wiki/O-1269\" title=\"O-1269\">O-1269</a></li>\n<li><a href=\"/w/index.php?title=O-1270&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1270 (page does not exist)\">O-1270</a></li>\n<li><a href=\"/w/index.php?title=O-1399&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1399 (page does not exist)\">O-1399</a></li>\n<li><a href=\"/wiki/O-1602\" title=\"O-1602\">O-1602</a></li>\n<li><a href=\"/w/index.php?title=O-2220&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2220 (page does not exist)\">O-2220</a></li>\n<li><a href=\"/wiki/Olorinab\" title=\"Olorinab\">Olorinab</a></li>\n<li><a href=\"/wiki/PF-03550096\" title=\"PF-03550096\">PF-03550096</a></li>\n<li><a href=\"/wiki/PSB-SB-1202\" title=\"PSB-SB-1202\">PSB-SB-1202</a></li>\n<li><a href=\"/wiki/PTI-1\" title=\"PTI-1\">PTI-1</a></li>\n<li><a href=\"/wiki/PTI-2\" title=\"PTI-2\">PTI-2</a></li>\n<li><a href=\"/wiki/QMPSB\" title=\"QMPSB\">QMPSB</a></li>\n<li><a href=\"/wiki/S-444,823\" title=\"S-444,823\">S-444,823</a></li>\n<li><a href=\"/wiki/SER-601\" title=\"SER-601\">SER-601</a></li>\n<li><a href=\"/wiki/Tedalinab\" title=\"Tedalinab\">Tedalinab</a></li>\n<li><a href=\"/w/index.php?title=URB-447&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"URB-447 (page does not exist)\">URB-447</a></li>\n<li><a href=\"/w/index.php?title=VSN-16&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"VSN-16 (page does not exist)\">VSN-16</a></li>\n<li><a href=\"/wiki/WIN_56,098\" title=\"WIN 56,098\">WIN 56,098</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Allosteric_regulation\" title=\"Allosteric regulation\">Allosteric</a> <a href=\"/wiki/Cannabinoid_receptor\" title=\"Cannabinoid receptor\"><abbr title=\"Cannabinoid receptor\">CBR</abbr></a> <a href=\"/wiki/Ligand_(biochemistry)\" title=\"Ligand (biochemistry)\">ligands</a></th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Org_27569\" title=\"Org 27569\">Org 27569</a></li>\n<li><a href=\"/w/index.php?title=Org_27759&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Org 27759 (page does not exist)\">Org 27759</a></li>\n<li><a href=\"/w/index.php?title=Org_29647&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Org 29647 (page does not exist)\">Org 29647</a></li>\n<li><a href=\"/wiki/RTI-371\" title=\"RTI-371\">RTI-371</a></li>\n<li><a href=\"/wiki/Pregnenolone\" title=\"Pregnenolone\">Pregnenolone</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Endocannabinoid_enhancer\" title=\"Endocannabinoid enhancer\">Endocannabinoid<br />enhancers</a><br /><small>(inactivation inhibitors)</small></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/4-Nonylphenylboronic_acid\" title=\"4-Nonylphenylboronic acid\">4-Nonylphenylboronic acid</a></li>\n<li><a href=\"/wiki/AM404\" title=\"AM404\">AM-404</a></li>\n<li><a href=\"/wiki/Arachidonoyl_serotonin\" title=\"Arachidonoyl serotonin\">Arachidonoyl serotonin</a></li>\n<li><a href=\"/w/index.php?title=Arvanil&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Arvanil (page does not exist)\">Arvanil</a></li>\n<li><a class=\"mw-selflink selflink\">BIA 10-2474</a></li>\n<li><a href=\"/wiki/Biochanin_A\" title=\"Biochanin A\">Biochanin A</a></li>\n<li><a href=\"/w/index.php?title=CAY-10401&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CAY-10401 (page does not exist)\">CAY-10401</a></li>\n<li><a href=\"/w/index.php?title=CAY-10429&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CAY-10429 (page does not exist)\">CAY-10429</a></li>\n<li><a href=\"/wiki/Genistein\" title=\"Genistein\">Genistein</a></li>\n<li><a href=\"/wiki/Guineesine\" title=\"Guineesine\">Guineesine</a></li>\n<li><a href=\"/wiki/IDFP\" title=\"IDFP\">IDFP</a></li>\n<li><a href=\"/w/index.php?title=JNJ_1661010&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JNJ 1661010 (page does not exist)\">JNJ 1661010</a></li>\n<li><a href=\"/wiki/JNJ-42165279\" title=\"JNJ-42165279\">JNJ-42165279</a></li>\n<li><a href=\"/wiki/JZL184\" title=\"JZL184\">JZL184</a></li>\n<li><a href=\"/wiki/JZL195\" title=\"JZL195\">JZL195</a></li>\n<li><a href=\"/wiki/Kaempferol\" title=\"Kaempferol\">Kaempferol</a></li>\n<li><a href=\"/wiki/LY-2183240\" title=\"LY-2183240\">LY-2183240</a></li>\n<li><a href=\"/wiki/MK-4409\" title=\"MK-4409\">MK-4409</a></li>\n<li><a href=\"/w/index.php?title=O-1624&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1624 (page does not exist)\">O-1624</a></li>\n<li><a href=\"/w/index.php?title=O-2093&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2093 (page does not exist)\">O-2093</a></li>\n<li><a href=\"/wiki/Oleoylethanolamide\" title=\"Oleoylethanolamide\">Oleoylethanolamide (OEA)</a></li>\n<li><a href=\"/w/index.php?title=Olvanil&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Olvanil (page does not exist)\">Olvanil</a></li>\n<li><a href=\"/wiki/Palmitoylethanolamide\" title=\"Palmitoylethanolamide\">Palmitoylethanolamide (PEA)</a></li>\n<li><a href=\"/wiki/PF-04457845\" title=\"PF-04457845\">PF-04457845</a></li>\n<li><a href=\"/w/index.php?title=PF-622&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PF-622 (page does not exist)\">PF-622</a></li>\n<li><a href=\"/w/index.php?title=PF-750&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PF-750 (page does not exist)\">PF-750</a></li>\n<li><a href=\"/wiki/PF-3845\" title=\"PF-3845\">PF-3845</a></li>\n<li><a href=\"/w/index.php?title=PHOP&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PHOP (page does not exist)\">PHOP</a></li>\n<li><a href=\"/w/index.php?title=URB447&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"URB447 (page does not exist)\">URB-447</a></li>\n<li><a href=\"/wiki/URB597\" title=\"URB597\">URB-597</a></li>\n<li><a href=\"/wiki/URB602\" title=\"URB602\">URB-602</a></li>\n<li><a href=\"/wiki/URB754\" title=\"URB754\">URB-754</a></li>\n<li><a href=\"/wiki/VDM-11\" title=\"VDM-11\">VDM-11</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Cannabinoid_receptor_antagonist\" title=\"Cannabinoid receptor antagonist\">Anticannabinoids</a><br /><small>(antagonists/inverse<br />agonists/antibodies)</small></th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/AM251\" class=\"mw-redirect\" title=\"AM251\">AM-251</a></li>\n<li><a href=\"/w/index.php?title=AM281&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM281 (page does not exist)\">AM-281</a></li>\n<li><a href=\"/wiki/AM-630\" title=\"AM-630\">AM-630</a></li>\n<li><a href=\"/w/index.php?title=AM-1387&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-1387 (page does not exist)\">AM-1387</a></li>\n<li><a href=\"/w/index.php?title=AM-4113&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-4113 (page does not exist)\">AM-4113</a></li>\n<li><a href=\"/w/index.php?title=AM-6527&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-6527 (page does not exist)\">AM-6527</a></li>\n<li><a href=\"/wiki/AM-6545\" title=\"AM-6545\">AM-6545</a></li>\n<li><a href=\"/wiki/BML-190\" title=\"BML-190\">BML-190</a></li>\n<li><a href=\"/w/index.php?title=Brizantin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Brizantin (page does not exist)\">Brizantin (\u0411\u0440\u0438\u0437\u0430\u043d\u0442\u0438\u043d)</a></li>\n<li><a href=\"/w/index.php?title=CAY-10508&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CAY-10508 (page does not exist)\">CAY-10508</a></li>\n<li><a href=\"/w/index.php?title=CB-25&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CB-25 (page does not exist)\">CB-25</a></li>\n<li><a href=\"/w/index.php?title=CB-52&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CB-52 (page does not exist)\">CB-52</a></li>\n<li><a href=\"/w/index.php?title=CB-86&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CB-86 (page does not exist)\">CB-86</a></li>\n<li><a href=\"/w/index.php?title=Dietressa&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Dietressa (page does not exist)\">Dietressa (\u0414\u0438\u0435\u0442\u0440\u0435\u0441\u0441\u0430)</a></li>\n<li><a href=\"/wiki/Drinabant\" title=\"Drinabant\">Drinabant (AVE1625)</a></li>\n<li><a href=\"/wiki/Hemopressin\" title=\"Hemopressin\">Hemopressin</a></li>\n<li><a href=\"/wiki/Ibipinabant\" title=\"Ibipinabant\">Ibipinabant (SLV319)</a></li>\n<li><a href=\"/wiki/JTE-907\" title=\"JTE-907\">JTE-907</a></li>\n<li><a href=\"/w/index.php?title=LH-21&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"LH-21 (page does not exist)\">LH-21</a></li>\n<li><a href=\"/wiki/LY-320,135\" title=\"LY-320,135\">LY-320,135</a></li>\n<li><a href=\"/w/index.php?title=MDA-77&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MDA-77 (page does not exist)\">MDA-77</a></li>\n<li><a href=\"/w/index.php?title=MJ-15&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MJ-15 (page does not exist)\">MJ-15</a></li>\n<li><a href=\"/wiki/MK-9470\" title=\"MK-9470\">MK-9470</a></li>\n<li><a href=\"/wiki/NESS-0327\" title=\"NESS-0327\">NESS-0327</a></li>\n<li><a href=\"/w/index.php?title=NIDA-41020&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"NIDA-41020 (page does not exist)\">NIDA-41020</a></li>\n<li><a href=\"/w/index.php?title=O-606&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-606 (page does not exist)\">O-606</a></li>\n<li><a href=\"/w/index.php?title=O-1184&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1184 (page does not exist)\">O-1184</a></li>\n<li><a href=\"/w/index.php?title=O-1248&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-1248 (page does not exist)\">O-1248</a></li>\n<li><a href=\"/wiki/O-1918\" title=\"O-1918\">O-1918</a></li>\n<li><a href=\"/wiki/O-2050\" title=\"O-2050\">O-2050</a></li>\n<li><a href=\"/w/index.php?title=O-2654&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2654 (page does not exist)\">O-2654</a></li>\n<li><a href=\"/wiki/Otenabant\" title=\"Otenabant\">Otenabant (CP-945,598)</a></li>\n<li><a href=\"/wiki/PF-514273\" title=\"PF-514273\">PF-514273</a></li>\n<li><a href=\"/wiki/PipISB\" title=\"PipISB\">PipISB</a></li>\n<li><a href=\"/wiki/PSB-SB-487\" title=\"PSB-SB-487\">PSB-SB-487</a></li>\n<li><a href=\"/wiki/Rimonabant\" title=\"Rimonabant\">Rimonabant (SR141716)</a></li>\n<li><a href=\"/wiki/Rosonabant\" title=\"Rosonabant\">Rosonabant (E-6776)</a></li>\n<li><a href=\"/wiki/SR-144,528\" title=\"SR-144,528\">SR-144,528</a></li>\n<li><a href=\"/wiki/Surinabant\" title=\"Surinabant\">Surinabant (SR147778)</a></li>\n<li><a href=\"/wiki/Taranabant\" title=\"Taranabant\">Taranabant (MK-0364)</a></li>\n<li><a href=\"/wiki/TM-38837\" title=\"TM-38837\">TM-38837</a></li>\n<li><a href=\"/wiki/VCHSR\" title=\"VCHSR\">VCHSR</a></li></ul>\n</div></td></tr><tr><td class=\"navbox-abovebelow\" colspan=\"2\"><div>\n<ul><li><i><b>See also:</b> <a href=\"/wiki/Template:Cannabinoid_receptor_modulators\" title=\"Template:Cannabinoid receptor modulators\">Cannabinoid receptor modulators</a> (cannabinoids by pharmacology)</i></li>\n<li><i>List of: <a href=\"/wiki/List_of_AM_cannabinoids\" title=\"List of AM cannabinoids\">AM cannabinoids</a></i></li>\n<li><i><a href=\"/wiki/List_of_JWH_cannabinoids\" title=\"List of JWH cannabinoids\">JWH cannabinoids</a></i></li>\n<li><i><a href=\"/wiki/List_of_designer_drugs#Synthetic_cannabimimetics\" title=\"List of designer drugs\">Designer drugs \u00a7 Synthetic cannabimimetics</a></i></li></ul>\n</div></td></tr></tbody></table></div>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Cannabinoid_receptor_modulators\" style=\"padding:3px\"><table class=\"nowraplinks hlist collapsible collapsed navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Cannabinoid_receptor_modulators\" title=\"Template:Cannabinoid receptor modulators\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Cannabinoid_receptor_modulators\" title=\"Template talk:Cannabinoid receptor modulators\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Cannabinoid_receptor_modulators&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Cannabinoid_receptor_modulators\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Cannabinoid_receptor\" title=\"Cannabinoid receptor\">Cannabinoid receptor</a> <a href=\"/wiki/Receptor_modulator\" title=\"Receptor modulator\">modulators</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Receptor_(biochemistry)\" title=\"Receptor (biochemistry)\">Receptor</a><br /><small>(<a href=\"/wiki/Ligand_(biochemistry)\" title=\"Ligand (biochemistry)\">ligands</a>)</small></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Cannabinoid_receptor_type_1\" title=\"Cannabinoid receptor type 1\"><abbr title=\"Cannabinoid receptor type 1\">CB<sub>1</sub></abbr></a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists</b> <i>(abridged; see <a href=\"/wiki/Template:Cannabinoids\" title=\"Template:Cannabinoids\">here</a> for more)</i><b>:</b> <a href=\"/wiki/2-Arachidonoylglycerol\" title=\"2-Arachidonoylglycerol\">2-AG</a></li>\n<li><a href=\"/wiki/2-Arachidonyl_glyceryl_ether\" title=\"2-Arachidonyl glyceryl ether\">2-AGE (noladin ether)</a></li>\n<li><a href=\"/wiki/11-Hydroxy-THC\" title=\"11-Hydroxy-THC\">11-Hydroxy-THC</a></li>\n<li><a href=\"/wiki/%CE%91-Amyrin\" class=\"mw-redirect\" title=\"\u0391-Amyrin\">\u03b1-Amyrin</a></li>\n<li><a href=\"/wiki/%CE%92-Amyrin\" class=\"mw-redirect\" title=\"\u0392-Amyrin\">\u03b2-Amyrin</a></li>\n<li><a href=\"/wiki/AB-CHMINACA\" title=\"AB-CHMINACA\">AB-CHMINACA</a></li>\n<li><a href=\"/w/index.php?title=AM-1172&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-1172 (page does not exist)\">AM-1172</a></li>\n<li><a href=\"/wiki/AM-1220\" title=\"AM-1220\">AM-1220</a></li>\n<li><a href=\"/wiki/AM-1221\" title=\"AM-1221\">AM-1221</a></li>\n<li><a href=\"/wiki/AM-1235\" title=\"AM-1235\">AM-1235</a></li>\n<li><a href=\"/wiki/AM-2201\" title=\"AM-2201\">AM-2201</a></li>\n<li><a href=\"/wiki/AM-2232\" title=\"AM-2232\">AM-2232</a></li>\n<li><a href=\"/wiki/Anandamide\" title=\"Anandamide\">Anandamide</a></li>\n<li><a href=\"/w/index.php?title=Arvanil&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Arvanil (page does not exist)\">Arvanil</a></li>\n<li><a href=\"/wiki/AZ-11713908\" title=\"AZ-11713908\">AZ-11713908</a></li>\n<li><a href=\"/wiki/Cannabinol\" title=\"Cannabinol\">Cannabinol</a></li>\n<li><a href=\"/wiki/CB-13\" title=\"CB-13\">CB-13</a></li>\n<li><a href=\"/wiki/CP_47,497\" title=\"CP 47,497\">CP 47,497</a></li>\n<li><a href=\"/wiki/CP_55,940\" title=\"CP 55,940\">CP 55,940</a></li>\n<li><a href=\"/wiki/Dimethylheptylpyran\" title=\"Dimethylheptylpyran\">Dimethylheptylpyran</a></li>\n<li><a href=\"/wiki/Docosatetraenoylethanolamide\" title=\"Docosatetraenoylethanolamide\">DEA</a></li>\n<li><a href=\"/wiki/Epicatechin_gallate\" title=\"Epicatechin gallate\">ECG</a></li>\n<li><a href=\"/wiki/Epigallocatechin_gallate\" title=\"Epigallocatechin gallate\">EGCG</a></li>\n<li><a href=\"/wiki/Epicatechin\" class=\"mw-redirect\" title=\"Epicatechin\">Epicatechin</a></li>\n<li><a href=\"/wiki/Gallocatechol\" title=\"Gallocatechol\">Gallocatechol (gallocatechin)</a></li>\n<li><a href=\"/wiki/Honokiol\" title=\"Honokiol\">Honokiol</a></li>\n<li><a href=\"/wiki/HU-210\" title=\"HU-210\">HU-210</a></li>\n<li><a href=\"/wiki/JWH-007\" title=\"JWH-007\">JWH-007</a></li>\n<li><a href=\"/wiki/JWH-015\" title=\"JWH-015\">JWH-015</a></li>\n<li><a href=\"/wiki/JWH-018\" title=\"JWH-018\">JWH-018</a></li>\n<li><a href=\"/wiki/JWH-073\" title=\"JWH-073\">JWH-073</a></li>\n<li><a href=\"/wiki/Kavain\" title=\"Kavain\">Kavain</a></li>\n<li><a href=\"/wiki/L-759,633\" title=\"L-759,633\">L-759,633</a></li>\n<li><a href=\"/wiki/Levonantradol\" title=\"Levonantradol\">Levonantradol</a></li>\n<li><a href=\"/wiki/Menabitan\" title=\"Menabitan\">Menabitan</a></li>\n<li><a href=\"/wiki/Nabilone\" title=\"Nabilone\">Nabilone</a></li>\n<li><a href=\"/wiki/Nabitan\" title=\"Nabitan\">Nabitan</a></li>\n<li><a href=\"/wiki/N-Arachidonoyl_dopamine\" title=\"N-Arachidonoyl dopamine\">NADA</a></li>\n<li><a href=\"/wiki/O-1812\" title=\"O-1812\">O-1812</a></li>\n<li><a href=\"/wiki/Oleamide\" title=\"Oleamide\">Oleamide</a></li>\n<li><a href=\"/wiki/Pravadoline\" title=\"Pravadoline\">Pravadoline</a></li>\n<li><a href=\"/wiki/Serinolamide_A\" title=\"Serinolamide A\">Serinolamide A</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol\" title=\"Tetrahydrocannabinol\">THC (dronabinol)</a></li>\n<li><a href=\"/wiki/UR-144\" title=\"UR-144\">UR-144</a></li>\n<li><a href=\"/wiki/WIN_55,212-2\" title=\"WIN 55,212-2\">WIN 55,212-2</a></li>\n<li><a href=\"/wiki/Yangonin\" title=\"Yangonin\">Yangonin</a></li></ul>\n<ul><li><b>Antagonists:</b> <a href=\"/wiki/AM251\" class=\"mw-redirect\" title=\"AM251\">AM-251</a></li>\n<li><a href=\"/wiki/AM-6545\" title=\"AM-6545\">AM-6545</a></li>\n<li><a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">Cannabidiol</a></li>\n<li><a href=\"/wiki/Cannabigerol\" title=\"Cannabigerol\">Cannabigerol</a></li>\n<li><a href=\"/wiki/Drinabant\" title=\"Drinabant\">Drinabant</a></li>\n<li><a href=\"/wiki/Falcarinol\" title=\"Falcarinol\">Falcarinol (carotatoxin)</a></li>\n<li><a href=\"/wiki/Hemopressin\" title=\"Hemopressin\">Hemopressin</a></li>\n<li><a href=\"/wiki/Ibipinabant\" title=\"Ibipinabant\">Ibipinabant</a></li>\n<li><a href=\"/wiki/LY-320,135\" title=\"LY-320,135\">LY-320,135</a></li>\n<li><a href=\"/wiki/MK-9470\" title=\"MK-9470\">MK-9470</a></li>\n<li><a href=\"/wiki/NESS-0327\" title=\"NESS-0327\">NESS-0327</a></li>\n<li><a href=\"/wiki/O-2050\" title=\"O-2050\">O-2050</a></li>\n<li><a href=\"/wiki/Otenabant\" title=\"Otenabant\">Otenabant</a></li>\n<li><a href=\"/wiki/PF-514273\" title=\"PF-514273\">PF-514273</a></li>\n<li><a href=\"/wiki/PipISB\" title=\"PipISB\">PipISB</a></li>\n<li><a href=\"/wiki/Rimonabant\" title=\"Rimonabant\">Rimonabant</a></li>\n<li><a href=\"/wiki/Rosonabant\" title=\"Rosonabant\">Rosonabant</a></li>\n<li><a href=\"/wiki/Surinabant\" title=\"Surinabant\">Surinabant</a></li>\n<li><a href=\"/wiki/Taranabant\" title=\"Taranabant\">Taranabant</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabivarin\" title=\"Tetrahydrocannabivarin\">THCV</a></li>\n<li><a href=\"/wiki/TM-38837\" title=\"TM-38837\">TM-38837</a></li>\n<li><a href=\"/wiki/VCHSR\" title=\"VCHSR\">VCHSR</a></li>\n<li><a href=\"/wiki/Virodhamine\" title=\"Virodhamine\">Virodhamine</a></li></ul>\n<ul><li><b>Antibodies:</b> <a href=\"/w/index.php?title=Brizantin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Brizantin (page does not exist)\">Brizantin (\u0411\u0440\u0438\u0437\u0430\u043d\u0442\u0438\u043d)</a></li>\n<li><a href=\"/w/index.php?title=Dietressa&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Dietressa (page does not exist)\">Dietressa (\u0414\u0438\u0435\u0442\u0440\u0435\u0441\u0441\u0430)</a></li></ul>\n<ul><li><b>Unknown/unsorted:</b> <a href=\"/wiki/Methoxy_arachidonyl_fluorophosphonate\" title=\"Methoxy arachidonyl fluorophosphonate\">MAFP</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Cannabinoid_receptor_type_2\" title=\"Cannabinoid receptor type 2\"><abbr title=\"Cannabinoid receptor type 2\">CB<sub>2</sub></abbr></a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists:</b> <a href=\"/wiki/2-Arachidonoylglycerol\" title=\"2-Arachidonoylglycerol\">2-AG</a></li>\n<li><a href=\"/wiki/2-Arachidonyl_glyceryl_ether\" title=\"2-Arachidonyl glyceryl ether\">2-AGE (noladin ether)</a></li>\n<li><a href=\"/wiki/3,3%27-Diindolylmethane\" title=\"3,3&#39;-Diindolylmethane\">3,3'-Diindolylmethane</a></li>\n<li><a href=\"/wiki/4-O-Methylhonokiol\" title=\"4-O-Methylhonokiol\">4-O-Methylhonokiol</a></li>\n<li><a href=\"/wiki/%CE%91-Amyrin\" class=\"mw-redirect\" title=\"\u0391-Amyrin\">\u03b1-Amyrin</a></li>\n<li><a href=\"/wiki/%CE%92-Amyrin\" class=\"mw-redirect\" title=\"\u0392-Amyrin\">\u03b2-Amyrin</a></li>\n<li><a href=\"/wiki/A-796,260\" title=\"A-796,260\">A-796,260</a></li>\n<li><a href=\"/wiki/A-834,735\" title=\"A-834,735\">A-834,735</a></li>\n<li><a href=\"/wiki/A-836,339\" title=\"A-836,339\">A-836,339</a></li>\n<li><a href=\"/w/index.php?title=AM-1172&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-1172 (page does not exist)\">AM-1172</a></li>\n<li><a href=\"/wiki/AM-1221\" title=\"AM-1221\">AM-1221</a></li>\n<li><a href=\"/wiki/AM-1235\" title=\"AM-1235\">AM-1235</a></li>\n<li><a href=\"/wiki/AM-1241\" title=\"AM-1241\">AM-1241</a></li>\n<li><a href=\"/wiki/AM-2232\" title=\"AM-2232\">AM-2232</a></li>\n<li><a href=\"/wiki/Anandamide\" title=\"Anandamide\">Anandamide</a></li>\n<li><a href=\"/wiki/AZ-11713908\" title=\"AZ-11713908\">AZ-11713908</a></li>\n<li><a href=\"/wiki/Cannabinol\" title=\"Cannabinol\">Cannabinol</a></li>\n<li><a href=\"/wiki/Caryophyllene\" title=\"Caryophyllene\">Caryophyllene</a></li>\n<li><a href=\"/wiki/CB-13\" title=\"CB-13\">CB-13</a></li>\n<li><a href=\"/wiki/CBS-0550\" title=\"CBS-0550\">CBS-0550</a></li>\n<li><a href=\"/wiki/CP-55,940\" class=\"mw-redirect\" title=\"CP-55,940\">CP-55,940</a></li>\n<li><a href=\"/wiki/GW-405,833\" title=\"GW-405,833\">GW-405,833 (L-768,242)</a></li>\n<li><a href=\"/wiki/GW-842,166X\" title=\"GW-842,166X\">GW-842,166X</a></li>\n<li><a href=\"/wiki/HU-308\" title=\"HU-308\">HU-308</a></li>\n<li><a href=\"/wiki/JTE_7-31\" title=\"JTE 7-31\">JTE 7-31</a></li>\n<li><a href=\"/wiki/JWH-007\" title=\"JWH-007\">JWH-007</a></li>\n<li><a href=\"/wiki/JWH-015\" title=\"JWH-015\">JWH-015</a></li>\n<li><a href=\"/wiki/JWH-018\" title=\"JWH-018\">JWH-018</a></li>\n<li><a href=\"/w/index.php?title=JWH-73&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JWH-73 (page does not exist)\">JWH-73</a></li>\n<li><a href=\"/wiki/JWH-133\" title=\"JWH-133\">JWH-133</a></li>\n<li><a href=\"/wiki/L-759,633\" title=\"L-759,633\">L-759,633</a></li>\n<li><a href=\"/wiki/L-759,656\" title=\"L-759,656\">L-759,656</a></li>\n<li><a href=\"/w/index.php?title=Lenabasum&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Lenabasum (page does not exist)\">Lenabasum (anabasum)</a></li>\n<li><a href=\"/wiki/Magnolol\" title=\"Magnolol\">Magnolol</a></li>\n<li><a href=\"/wiki/MDA-19\" title=\"MDA-19\">MDA-19</a></li>\n<li><a href=\"/wiki/Nabitan\" title=\"Nabitan\">Nabitan</a></li>\n<li><a href=\"/wiki/N-Arachidonoyl_dopamine\" title=\"N-Arachidonoyl dopamine\">NADA</a></li>\n<li><a href=\"/wiki/Olorinab\" title=\"Olorinab\">Olorinab (APD-371)</a></li>\n<li><a href=\"/wiki/PF-03550096\" title=\"PF-03550096\">PF-03550096</a></li>\n<li><a href=\"/wiki/S-444,823\" title=\"S-444,823\">S-444,823</a></li>\n<li><a href=\"/wiki/SER-601\" title=\"SER-601\">SER-601</a></li>\n<li><a href=\"/wiki/Serinolamide_A\" title=\"Serinolamide A\">Serinolamide A</a></li>\n<li><a href=\"/wiki/UR-144\" title=\"UR-144\">UR-144</a></li>\n<li><a href=\"/wiki/Tedalinab\" title=\"Tedalinab\">Tedalinab</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol\" title=\"Tetrahydrocannabinol\">THC (dronabinol)</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabivarin\" title=\"Tetrahydrocannabivarin\">THCV</a></li>\n<li><a href=\"/w/index.php?title=Tetrahydromagnolol&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tetrahydromagnolol (page does not exist)\">Tetrahydromagnolol</a></li>\n<li><a href=\"/wiki/Virodhamine\" title=\"Virodhamine\">Virodhamine</a></li></ul>\n<ul><li><b>Antagonists:</b> <a href=\"/wiki/4-O-Methylhonokiol\" title=\"4-O-Methylhonokiol\">4-O-Methylhonokiol</a></li>\n<li><a href=\"/wiki/AM-630\" title=\"AM-630\">AM-630</a></li>\n<li><a href=\"/wiki/BML-190\" title=\"BML-190\">BML-190</a></li>\n<li><a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">Cannabidiol</a></li>\n<li><a href=\"/wiki/Honokiol\" title=\"Honokiol\">Honokiol</a></li>\n<li><a href=\"/wiki/JTE-907\" title=\"JTE-907\">JTE-907</a></li>\n<li><a href=\"/wiki/SR-144,528\" title=\"SR-144,528\">SR-144,528</a></li>\n<li><a href=\"/wiki/WIN_54,461\" title=\"WIN 54,461\">WIN 54,461</a></li>\n<li><a href=\"/wiki/WIN_56,098\" title=\"WIN 56,098\">WIN 56,098</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/NAGly_receptor\" title=\"NAGly receptor\"><abbr title=\"N-Arachidonyl glycine receptor\">NAGly</abbr><br />(<abbr title=\"G protein-coupled receptor 18\">GPR18</abbr>)</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists:</b> <a href=\"/wiki/Abnormal_cannabidiol\" title=\"Abnormal cannabidiol\">Abnormal cannabidiol</a></li>\n<li><a href=\"/wiki/Arachidonylcyclopropylamide\" title=\"Arachidonylcyclopropylamide\">ACPA</a></li>\n<li><a href=\"/wiki/AM251\" class=\"mw-redirect\" title=\"AM251\">AM251</a></li>\n<li><a href=\"/wiki/Anandamide\" title=\"Anandamide\">Anandamide</a></li>\n<li><a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">Cannabidiol</a></li>\n<li><a href=\"/wiki/N-Arachidonylglycine\" title=\"N-Arachidonylglycine\">NADGly</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol\" title=\"Tetrahydrocannabinol\">THC (dronabinol)</a></li>\n<li><a href=\"/wiki/O-1602\" title=\"O-1602\">O-1602</a></li></ul>\n<ul><li><b>Antagonists:</b> <a href=\"/wiki/CID-85469571\" title=\"CID-85469571\">CID-85469571</a></li>\n<li><a href=\"/wiki/O-1918\" title=\"O-1918\">O-1918</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/G_protein-coupled_receptor_55\" class=\"mw-redirect\" title=\"G protein-coupled receptor 55\"><abbr title=\"G protein-coupled receptor 55\">GPR55</abbr></a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists:</b> <a href=\"/wiki/2-Arachidonyl_glyceryl_ether\" title=\"2-Arachidonyl glyceryl ether\">2-AGE (noladin ether)</a></li>\n<li><a href=\"/w/index.php?title=2-Arachidonoyl_lysophosphatidylinositol&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"2-Arachidonoyl lysophosphatidylinositol (page does not exist)\">2-ALPI</a></li>\n<li><a href=\"/wiki/Abnormal_cannabidiol\" title=\"Abnormal cannabidiol\">Abnormal cannabidiol</a></li>\n<li><a href=\"/wiki/AM251\" class=\"mw-redirect\" title=\"AM251\">AM-251</a></li>\n<li><a href=\"/w/index.php?title=CID1011163&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CID1011163 (page does not exist)\">CID1011163</a></li>\n<li><a href=\"/w/index.php?title=CID1252842&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CID1252842 (page does not exist)\">CID1252842</a></li>\n<li><a href=\"/w/index.php?title=CID1792579&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CID1792579 (page does not exist)\">CID1792579</a></li>\n<li><a href=\"/wiki/CP_55,940\" title=\"CP 55,940\">CP 55,940</a></li>\n<li><a href=\"/w/index.php?title=GSK-494581A&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"GSK-494581A (page does not exist)\">GSK-494581A</a></li>\n<li><a href=\"/wiki/Lysophosphatidylinositol\" title=\"Lysophosphatidylinositol\">Lysophosphatidylinositol</a></li>\n<li><a href=\"/w/index.php?title=ML-184&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-184 (page does not exist)\">ML-184</a></li>\n<li><a href=\"/w/index.php?title=ML-185&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-185 (page does not exist)\">ML-185</a></li>\n<li><a href=\"/w/index.php?title=ML-186&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-186 (page does not exist)\">ML-186</a></li>\n<li><a href=\"/wiki/O-1602\" title=\"O-1602\">O-1602</a></li>\n<li><a href=\"/wiki/Oleoylethanolamide\" title=\"Oleoylethanolamide\">Oleoylethanolamide</a></li>\n<li><a href=\"/wiki/Palmitoylethanolamide\" title=\"Palmitoylethanolamide\">Palmitoylethanolamide</a></li>\n<li><a href=\"/wiki/Tetrahydrocannabinol\" title=\"Tetrahydrocannabinol\">THC (dronabinol)</a></li></ul>\n<ul><li><b>Antagonists:</b> <a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">Cannabidiol</a></li>\n<li><a href=\"/wiki/CID-16020046\" title=\"CID-16020046\">CID-16020046</a></li>\n<li><a href=\"/w/index.php?title=ML-191&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-191 (page does not exist)\">ML-191</a></li>\n<li><a href=\"/w/index.php?title=ML-192&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-192 (page does not exist)\">ML-192</a></li>\n<li><a href=\"/w/index.php?title=ML-193&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML-193 (page does not exist)\">ML-193</a></li>\n<li><a href=\"/wiki/O-1918\" title=\"O-1918\">O-1918</a></li>\n<li><a href=\"/wiki/PSB-SB-487\" title=\"PSB-SB-487\">PSB-SB-487</a></li>\n<li><a href=\"/wiki/PSB-SB-1202\" title=\"PSB-SB-1202\">PSB-SB-1202</a></li>\n<li><a href=\"/w/index.php?title=PSB-SB-1203&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PSB-SB-1203 (page does not exist)\">PSB-SB-1203</a></li>\n<li><a href=\"/w/index.php?title=Tetrahydromagnolol&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tetrahydromagnolol (page does not exist)\">Tetrahydromagnolol</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/G_protein-coupled_receptor_119\" class=\"mw-redirect\" title=\"G protein-coupled receptor 119\"><abbr title=\"G protein-coupled receptor 119\">GPR119</abbr></a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists:</b> <a href=\"/wiki/2-Oleoylglycerol\" title=\"2-Oleoylglycerol\">2-Oleoylglycerol</a></li>\n<li><a href=\"/wiki/Anandamide\" title=\"Anandamide\">Anandamide</a></li>\n<li><a href=\"/w/index.php?title=APD668&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"APD668 (page does not exist)\">APD668</a></li>\n<li><a href=\"/wiki/AR-231,453\" title=\"AR-231,453\">AR-231,453</a></li>\n<li><a href=\"/w/index.php?title=AS-1269574&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AS-1269574 (page does not exist)\">AS-1269574</a></li>\n<li><a href=\"/w/index.php?title=MBX-2982&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MBX-2982 (page does not exist)\">MBX-2982</a></li>\n<li><a href=\"/w/index.php?title=N-Oleoyldopamine&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"N-Oleoyldopamine (page does not exist)\">N-Oleoyldopamine</a></li>\n<li><a href=\"/wiki/Oleoylethanolamide\" title=\"Oleoylethanolamide\">Oleoylethanolamide</a></li>\n<li><a href=\"/w/index.php?title=Olvanil&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Olvanil (page does not exist)\">Olvanil</a></li>\n<li><a href=\"/wiki/PSN-375,963\" title=\"PSN-375,963\">PSN-375,963</a></li>\n<li><a href=\"/wiki/PSN-632,408\" title=\"PSN-632,408\">PSN-632,408</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\">Unsorted</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Agonists:</b> <a href=\"/w/index.php?title=Revosimeline&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Revosimeline (page does not exist)\">Revosimeline</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Endocannabinoid_transporters\" class=\"mw-redirect\" title=\"Endocannabinoid transporters\">Transporter</a><br /><small>(<a href=\"/wiki/Reuptake_modulator\" title=\"Reuptake modulator\">modulators</a>)</small></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th id=\"eCBTs\" scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Endocannabinoid_transporters\" class=\"mw-redirect\" title=\"Endocannabinoid transporters\"><abbr title=\"Endocannabinoid transporters\">eCBTs</abbr></a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Inhibitors:</b> <a href=\"/w/index.php?title=5%27-DMH-CBD&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"5&#39;-DMH-CBD (page does not exist)\">5'-DMH-CBD</a></li>\n<li><a href=\"/wiki/AM-404\" class=\"mw-redirect\" title=\"AM-404\">AM-404</a></li>\n<li><a href=\"/w/index.php?title=AM-1172&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"AM-1172 (page does not exist)\">AM-1172</a></li>\n<li><a href=\"/wiki/Arachidonoyl_serotonin\" title=\"Arachidonoyl serotonin\">Arachidonoyl serotonin</a></li>\n<li><a href=\"/w/index.php?title=Arvanil&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Arvanil (page does not exist)\">Arvanil</a></li>\n<li><a href=\"/wiki/Cannabidiol\" title=\"Cannabidiol\">Cannabidiol</a></li>\n<li><a href=\"/wiki/Guineensine\" class=\"mw-redirect\" title=\"Guineensine\">Guineensine</a></li>\n<li><a href=\"/wiki/LY-2183240\" title=\"LY-2183240\">LY-2183240</a></li>\n<li><a href=\"/w/index.php?title=O-2093&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"O-2093 (page does not exist)\">O-2093</a></li>\n<li><a href=\"/w/index.php?title=OMDM-2&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"OMDM-2 (page does not exist)\">OMDM-2</a></li>\n<li><a href=\"/wiki/Paracetamol\" title=\"Paracetamol\">Paracetamol (acetaminophen)</a></li>\n<li><a href=\"/w/index.php?title=SB-FI-26&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"SB-FI-26 (page does not exist)\">SB-FI-26</a></li>\n<li><a href=\"/w/index.php?title=UCM-707&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"UCM-707 (page does not exist)\">UCM-707</a></li>\n<li><a href=\"/wiki/URB-597\" class=\"mw-redirect\" title=\"URB-597\">URB-597</a></li>\n<li><a href=\"/wiki/VDM-11\" title=\"VDM-11\">VDM-11</a></li>\n<li><a href=\"/w/index.php?title=WOBE490&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"WOBE490 (page does not exist)\">WOBE490</a></li>\n<li><a href=\"/w/index.php?title=WOBE491&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"WOBE491 (page does not exist)\">WOBE491</a></li>\n<li><a href=\"/w/index.php?title=WOBE492&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"WOBE492 (page does not exist)\">WOBE492</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\"><a href=\"/wiki/Enzyme\" title=\"Enzyme\">Enzyme</a><br /><small>(<a href=\"/wiki/Enzyme_modulator\" title=\"Enzyme modulator\">modulators</a>)</small></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Fatty_acid_amide_hydrolase\" title=\"Fatty acid amide hydrolase\"><abbr title=\"Fatty acid amide hydrolase\">FAAH</abbr></a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Inhibitors:</b> <a href=\"/wiki/4-Nonylphenylboronic_acid\" title=\"4-Nonylphenylboronic acid\">4-Nonylphenylboronic acid</a></li>\n<li><a href=\"/wiki/AACOCF3\" class=\"mw-redirect\" title=\"AACOCF3\">AACOCF<sub>3</sub></a></li>\n<li><a href=\"/wiki/AM404\" title=\"AM404\">AM-404</a></li>\n<li><a href=\"/wiki/Arachidonoyl_serotonin\" title=\"Arachidonoyl serotonin\">Arachidonoyl serotonin</a></li>\n<li><a class=\"mw-selflink selflink\">BIA 10-2474</a></li>\n<li><a href=\"/wiki/Biochanin_A\" title=\"Biochanin A\">Biochanin A</a></li>\n<li><a href=\"/wiki/Genistein\" title=\"Genistein\">Genistein</a></li>\n<li><a href=\"/wiki/IDFP\" title=\"IDFP\">IDFP</a></li>\n<li><a href=\"/w/index.php?title=JNJ-1661010&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JNJ-1661010 (page does not exist)\">JNJ-1661010</a></li>\n<li><a href=\"/wiki/JNJ-42165279\" title=\"JNJ-42165279\">JNJ-42165279</a></li>\n<li><a href=\"/wiki/JZL-195\" class=\"mw-redirect\" title=\"JZL-195\">JZL-195</a></li>\n<li><a href=\"/wiki/Kaempferol\" title=\"Kaempferol\">Kaempferol</a></li>\n<li><a href=\"/wiki/LY-2183240\" title=\"LY-2183240\">LY-2183240</a></li>\n<li><a href=\"/wiki/Methoxy_arachidonyl_fluorophosphonate\" title=\"Methoxy arachidonyl fluorophosphonate\">MAFP</a></li>\n<li><a href=\"/w/index.php?title=Palmitoylisopropylamide&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Palmitoylisopropylamide (page does not exist)\">Palmitoylisopropylamide</a></li>\n<li><a href=\"/wiki/Paracetamol\" title=\"Paracetamol\">Paracetamol (acetaminophen)</a></li>\n<li><a href=\"/wiki/PF-3845\" title=\"PF-3845\">PF-3845</a></li>\n<li><a href=\"/wiki/PF-04457845\" title=\"PF-04457845\">PF-04457845</a></li>\n<li><a href=\"/w/index.php?title=PF-750&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PF-750 (page does not exist)\">PF-750</a></li>\n<li><a href=\"/w/index.php?title=SA-47&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"SA-47 (page does not exist)\">SA-47</a></li>\n<li><a href=\"/w/index.php?title=SA-57&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"SA-57 (page does not exist)\">SA-57</a></li>\n<li><a href=\"/w/index.php?title=TAK_21d&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"TAK 21d (page does not exist)\">TAK 21d</a></li>\n<li><a href=\"/w/index.php?title=TC-F_2&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"TC-F 2 (page does not exist)\">TC-F 2</a></li>\n<li><a href=\"/w/index.php?title=UCM710&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"UCM710 (page does not exist)\">UCM710</a></li>\n<li><a href=\"/wiki/URB-597\" class=\"mw-redirect\" title=\"URB-597\">URB-597</a></li></ul>\n<ul><li><b>Activators:</b> <a href=\"/w/index.php?title=PDP-EA&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PDP-EA (page does not exist)\">PDP-EA</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Monoacylglycerol_lipase\" title=\"Monoacylglycerol lipase\">MAGL</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Inhibitors:</b> <a href=\"/w/index.php?title=ABX-1431&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ABX-1431 (page does not exist)\">ABX-1431</a></li>\n<li><a href=\"/wiki/IDFP\" title=\"IDFP\">IDFP</a></li>\n<li><a href=\"/w/index.php?title=JJKK_048&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JJKK 048 (page does not exist)\">JJKK 048</a></li>\n<li><a href=\"/w/index.php?title=JW_642&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JW 642 (page does not exist)\">JW 642</a></li>\n<li><a href=\"/wiki/JZL-184\" class=\"mw-redirect\" title=\"JZL-184\">JZL-184</a></li>\n<li><a href=\"/wiki/JZL-195\" class=\"mw-redirect\" title=\"JZL-195\">JZL-195</a></li>\n<li><a href=\"/w/index.php?title=JZP-361&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JZP-361 (page does not exist)\">JZP-361</a></li>\n<li><a href=\"/w/index.php?title=KML_29&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"KML 29 (page does not exist)\">KML 29</a></li>\n<li><a href=\"/wiki/Methyl_arachidonyl_fluorophosphonate\" class=\"mw-redirect\" title=\"Methyl arachidonyl fluorophosphonate\">MAFP</a></li>\n<li><a href=\"/w/index.php?title=MJN110&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MJN110 (page does not exist)\">MJN110</a></li>\n<li><a href=\"/w/index.php?title=N-Arachidonoylmaleimide&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"N-Arachidonoylmaleimide (page does not exist)\">NAM</a></li>\n<li><a href=\"/w/index.php?title=Pristimerin&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Pristimerin (page does not exist)\">Pristimerin</a></li>\n<li><a href=\"/wiki/URB-602\" class=\"mw-redirect\" title=\"URB-602\">URB-602</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Alpha/beta-Hydrolase_domain_containing_6\" class=\"mw-redirect\" title=\"Alpha/beta-Hydrolase domain containing 6\"><abbr title=\"alpha/beta-Hydrolase domain containing 6\">ABHD6</abbr></a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Inhibitors:</b> <a href=\"/w/index.php?title=JZP-169&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JZP-169 (page does not exist)\">JZP-169</a></li>\n<li><a href=\"/w/index.php?title=JZP-430&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"JZP-430 (page does not exist)\">JZP-430</a></li>\n<li><a href=\"/w/index.php?title=KT182&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"KT182 (page does not exist)\">KT182</a></li>\n<li><a href=\"/w/index.php?title=KT185&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"KT185 (page does not exist)\">KT185</a></li>\n<li><a href=\"/w/index.php?title=KT195&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"KT195 (page does not exist)\">KT195</a></li>\n<li><a href=\"/w/index.php?title=KT203&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"KT203 (page does not exist)\">KT203</a></li>\n<li><a href=\"/w/index.php?title=LEI-106&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"LEI-106 (page does not exist)\">LEI-106</a></li>\n<li><a href=\"/w/index.php?title=ML294&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML294 (page does not exist)\">ML294</a></li>\n<li><a href=\"/w/index.php?title=ML295&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML295 (page does not exist)\">ML295</a></li>\n<li><a href=\"/w/index.php?title=ML296&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ML296 (page does not exist)\">ML296</a></li>\n<li><a href=\"/w/index.php?title=UCM710&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"UCM710 (page does not exist)\">UCM710</a></li>\n<li><a href=\"/w/index.php?title=WWL-70&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"WWL-70 (page does not exist)\">WWL-70</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:4em;;text-align:center;\"><a href=\"/wiki/Alpha/beta-Hydrolase_domain_containing_12\" class=\"mw-redirect\" title=\"Alpha/beta-Hydrolase domain containing 12\"><abbr title=\"alpha/beta-Hydrolase domain containing 12\">ABHD12</abbr></a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Inhibitors:</b> <a href=\"/wiki/Betulinic_acid\" title=\"Betulinic acid\">Betulinic acid</a></li>\n<li><a href=\"/wiki/Maslinic_acid\" title=\"Maslinic acid\">Maslinic acid</a></li>\n<li><a href=\"/wiki/Methyl_arachidonyl_fluorophosphonate\" class=\"mw-redirect\" title=\"Methyl arachidonyl fluorophosphonate\">MAFP</a></li>\n<li><a href=\"/wiki/Oleanolic_acid\" title=\"Oleanolic acid\">Oleanolic acid</a></li>\n<li><a href=\"/wiki/Orlistat\" title=\"Orlistat\">Orlistat (tetrahydrolipstatin)</a></li>\n<li><a href=\"/wiki/Ursolic_acid\" title=\"Ursolic acid\">Ursolic acid</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;text-align:center;\">Others</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><b>Precursors:</b> <a href=\"/wiki/Phosphatidylethanolamine\" title=\"Phosphatidylethanolamine\">Phosphatidylethanolamine</a></li>\n<li><a href=\"/wiki/N-Acylphosphatidylethanolamine\" title=\"N-Acylphosphatidylethanolamine\">NAPE</a></li>\n<li><a href=\"/wiki/Diacylglycerol\" class=\"mw-redirect\" title=\"Diacylglycerol\">Diacylglycerol</a></li></ul>\n<ul><li><b>Others:</b> <a href=\"/w/index.php?title=2-Palmitoylglycerol&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"2-Palmitoylglycerol (page does not exist)\">2-PG</a> <i>(directly potentiates activity of 2-AG at CB<sub>1</sub> receptor)</i></li>\n<li><a href=\"/w/index.php?title=ARN-272&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ARN-272 (page does not exist)\">ARN-272</a> <i>(FAAH-like anandamide transporter inhibitor)</i></li></ul>\n</div></td></tr><tr><td class=\"navbox-abovebelow\" colspan=\"2\"><div>\n<dl><dt>See also</dt>\n<dd><i> <a href=\"/wiki/Template:Receptor_modulators\" title=\"Template:Receptor modulators\">Receptor/signaling modulators</a></i></dd>\n<dd><i> <a href=\"/wiki/Template:Cannabinoids\" title=\"Template:Cannabinoids\">Cannabinoids</a> (cannabinoids by structure)</i></dd></dl>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw2260\nCached time: 20180914114730\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 1.228 seconds\nReal time usage: 1.356 seconds\nPreprocessor visited node count: 9308/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 344682/2097152 bytes\nTemplate argument size: 13147/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 4/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 123803/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.497/10.000 seconds\nLua memory usage: 6.19 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00% 1086.904      1 -total\n 41.66%  452.797      1 Template:Reflist\n 30.76%  334.300      1 Template:Drugbox\n 24.78%  269.353     68 Template:Cite_web\n 19.74%  214.501      1 Template:Infobox\n  7.71%   83.792      9 Template:Cite_journal\n  5.94%   64.542      6 Template:Navbox\n  5.11%   55.538     16 Template:Unbulleted_list\n  3.67%   39.927      1 Template:Infobox_drug/chemical_formula\n  2.71%   29.507      1 Template:Refimprove_science\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:49110893-0!canonical and timestamp 20180914114729 and revision id 846897491\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/BIA_10-2474","langname":"German","autonym":"Deutsch","*":"BIA 10-2474"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/BIA_10-2474","langname":"French","autonym":"fran\u00e7ais","*":"BIA 10-2474"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/BIA_10-2474","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"BIA 10-2474"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_French-language_sources_(fr)"},{"sortkey":"","hidden":"","*":"CS1_maint:_Uses_authors_parameter"},{"sortkey":"","hidden":"","*":"CS1_German-language_sources_(de)"},{"sortkey":"","hidden":"","*":"CS1_maint:_Explicit_use_of_et_al."},{"sortkey":"*","hidden":"","*":"Articles_without_EBI_source"},{"sortkey":"*","hidden":"","*":"Chemical_pages_without_DrugBank_identifier"},{"sortkey":"*","hidden":"","*":"Articles_without_KEGG_source"},{"sortkey":"*","hidden":"","*":"Articles_without_UNII_source"},{"sortkey":"","hidden":"","*":"Drugs_missing_an_ATC_code"},{"sortkey":"*","hidden":"","*":"Articles_containing_unverified_chemical_infoboxes"},{"sortkey":"","hidden":"","*":"Articles_lacking_reliable_references_from_January_2016"},{"sortkey":"","hidden":"","*":"All_articles_lacking_reliable_references"},{"sortkey":"","hidden":"","*":"All_pages_needing_factual_verification"},{"sortkey":"","hidden":"","*":"Wikipedia_articles_needing_factual_verification_from_January_2016"},{"sortkey":"","hidden":"","*":"Wikipedia_articles_in_need_of_updating_from_April_2016"},{"sortkey":"","hidden":"","*":"All_Wikipedia_articles_in_need_of_updating"},{"sortkey":"","*":"Clinical_trial_disasters"},{"sortkey":"","*":"Serine_protease_inhibitors"},{"sortkey":"","*":"Imidazoles"},{"sortkey":"","*":"Amine_oxides"},{"sortkey":"","*":"Ureas"}],"links":[{"ns":0,"*":"BIA 10-2474 (data page)"},{"ns":0,"exists":"","*":"(C6)-CP 47,497"},{"ns":0,"exists":"","*":"(C9)-CP 47,497"},{"ns":0,"exists":"","*":"11-Hydroxy-THC"},{"ns":0,"exists":"","*":"11-nor-9-Carboxy-THC"},{"ns":0,"exists":"","*":"2-Arachidonoylglycerol"},{"ns":0,"exists":"","*":"2-Arachidonyl glyceryl ether"},{"ns":0,"exists":"","*":"2-Oleoylglycerol"},{"ns":0,"exists":"","*":"3,3'-Diindolylmethane"},{"ns":0,"exists":"","*":"4-HTMPIPO"},{"ns":0,"exists":"","*":"4-Nonylphenylboronic acid"},{"ns":0,"exists":"","*":"4-O-Methylhonokiol"},{"ns":0,"exists":"","*":"5F-AB-FUPPYCA"},{"ns":0,"exists":"","*":"5F-ADB"},{"ns":0,"exists":"","*":"5F-ADB-PINACA"},{"ns":0,"exists":"","*":"5F-ADBICA"},{"ns":0,"exists":"","*":"5F-AMB"},{"ns":0,"exists":"","*":"5F-APINACA"},{"ns":0,"exists":"","*":"5F-CUMYL-PINACA"},{"ns":0,"exists":"","*":"5F-EMB-PINACA"},{"ns":0,"exists":"","*":"5F-NNE1"},{"ns":0,"exists":"","*":"5F-PB-22"},{"ns":0,"exists":"","*":"5F-PCN"},{"ns":0,"exists":"","*":"5F-SDB-006"},{"ns":0,"exists":"","*":"9-nor-9\u03b2-Hydroxyhexahydrocannabinol"},{"ns":0,"exists":"","*":"A-40174"},{"ns":0,"exists":"","*":"A-41988"},{"ns":0,"exists":"","*":"A-796,260"},{"ns":0,"exists":"","*":"A-834,735"},{"ns":0,"exists":"","*":"A-836,339"},{"ns":0,"exists":"","*":"AACOCF3"},{"ns":0,"exists":"","*":"AB-001"},{"ns":0,"exists":"","*":"AB-CHFUPYCA"},{"ns":0,"exists":"","*":"AB-CHMFUPPYCA"},{"ns":0,"exists":"","*":"AB-CHMINACA"},{"ns":0,"exists":"","*":"AB-FUBICA"},{"ns":0,"exists":"","*":"AB-FUBINACA"},{"ns":0,"exists":"","*":"AB-PICA"},{"ns":0,"exists":"","*":"AB-PINACA"},{"ns":0,"exists":"","*":"ADAMANTYL-THPINACA"},{"ns":0,"exists":"","*":"ADB-CHMINACA"},{"ns":0,"exists":"","*":"ADB-FUBICA"},{"ns":0,"exists":"","*":"ADB-FUBINACA"},{"ns":0,"exists":"","*":"ADB-PINACA"},{"ns":0,"exists":"","*":"ADBICA"},{"ns":0,"exists":"","*":"ADSB-FUB-187"},{"ns":0,"exists":"","*":"AM-087"},{"ns":0,"exists":"","*":"AM-1220"},{"ns":0,"exists":"","*":"AM-1221"},{"ns":0,"exists":"","*":"AM-1235"},{"ns":0,"exists":"","*":"AM-1241"},{"ns":0,"exists":"","*":"AM-1248"},{"ns":0,"exists":"","*":"AM-1714"},{"ns":0,"exists":"","*":"AM-2201"},{"ns":0,"exists":"","*":"AM-2232"},{"ns":0,"exists":"","*":"AM-2233"},{"ns":0,"exists":"","*":"AM-2389"},{"ns":0,"exists":"","*":"AM-4030"},{"ns":0,"exists":"","*":"AM-404"},{"ns":0,"exists":"","*":"AM-411"},{"ns":0,"exists":"","*":"AM-630"},{"ns":0,"exists":"","*":"AM-6545"},{"ns":0,"exists":"","*":"AM-679 (cannabinoid)"},{"ns":0,"exists":"","*":"AM-694"},{"ns":0,"exists":"","*":"AM-855"},{"ns":0,"exists":"","*":"AM-905"},{"ns":0,"exists":"","*":"AM-906"},{"ns":0,"exists":"","*":"AM-919"},{"ns":0,"exists":"","*":"AM-938"},{"ns":0,"exists":"","*":"AM251"},{"ns":0,"exists":"","*":"AM404"},{"ns":0,"exists":"","*":"AMB-CHMINACA"},{"ns":0,"exists":"","*":"AMB-FUBINACA"},{"ns":0,"exists":"","*":"AMG-1"},{"ns":0,"exists":"","*":"AMG-3"},{"ns":0,"exists":"","*":"AMG-36"},{"ns":0,"exists":"","*":"AMG-41"},{"ns":0,"exists":"","*":"APICA (synthetic cannabinoid drug)"},{"ns":0,"exists":"","*":"APINACA"},{"ns":0,"exists":"","*":"APP-FUBINACA"},{"ns":0,"exists":"","*":"AR-231,453"},{"ns":0,"exists":"","*":"AZ-11713908"},{"ns":0,"exists":"","*":"Abnormal cannabidiol"},{"ns":0,"exists":"","*":"Adaptive clinical trial"},{"ns":0,"exists":"","*":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9"},{"ns":0,"exists":"","*":"Ajulemic acid"},{"ns":0,"exists":"","*":"Alcoholism"},{"ns":0,"exists":"","*":"Allosteric regulation"},{"ns":0,"exists":"","*":"Alpha/beta-Hydrolase domain containing 12"},{"ns":0,"exists":"","*":"Alpha/beta-Hydrolase domain containing 6"},{"ns":0,"exists":"","*":"Analgesic"},{"ns":0,"exists":"","*":"Anandamide"},{"ns":0,"exists":"","*":"Anti-inflammatory"},{"ns":0,"exists":"","*":"Anxiety disorder"},{"ns":0,"exists":"","*":"Arachidonoyl serotonin"},{"ns":0,"exists":"","*":"Arachidonyl-2'-chloroethylamide"},{"ns":0,"exists":"","*":"Arachidonylcyclopropylamide"},{"ns":0,"exists":"","*":"BAY 38-7271"},{"ns":0,"exists":"","*":"BAY 59-3074"},{"ns":0,"exists":"","*":"BIM-018"},{"ns":0,"exists":"","*":"BML-190"},{"ns":0,"exists":"","*":"Betulinic acid"},{"ns":0,"exists":"","*":"Bial"},{"ns":0,"exists":"","*":"Bioavailability"},{"ns":0,"exists":"","*":"Biochanin A"},{"ns":0,"exists":"","*":"Biological half-life"},{"ns":0,"exists":"","*":"Blind experiment"},{"ns":0,"exists":"","*":"Blood"},{"ns":0,"exists":"","*":"Brain"},{"ns":0,"exists":"","*":"Brain MRI"},{"ns":0,"exists":"","*":"Brain dead"},{"ns":0,"exists":"","*":"Brittany (administrative region)"},{"ns":0,"exists":"","*":"BzODZ-EPyr"},{"ns":0,"exists":"","*":"CAS Registry Number"},{"ns":0,"exists":"","*":"CB-13"},{"ns":0,"exists":"","*":"CBD-DMH"},{"ns":0,"exists":"","*":"CBS-0550"},{"ns":0,"exists":"","*":"CID-16020046"},{"ns":0,"exists":"","*":"CID-85469571"},{"ns":0,"exists":"","*":"CP-55,940"},{"ns":0,"exists":"","*":"CP 47,497"},{"ns":0,"exists":"","*":"CP 55,244"},{"ns":0,"exists":"","*":"CP 55,940"},{"ns":0,"exists":"","*":"CUMYL-4CN-BINACA"},{"ns":0,"exists":"","*":"CUMYL-5F-P7AICA"},{"ns":0,"exists":"","*":"CUMYL-PEGACLONE"},{"ns":0,"exists":"","*":"CUMYL-PICA"},{"ns":0,"exists":"","*":"CUMYL-PINACA"},{"ns":0,"exists":"","*":"CUMYL-THPINACA"},{"ns":0,"exists":"","*":"Canbisol"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"Cannabichromene"},{"ns":0,"exists":"","*":"Cannabicyclohexanol"},{"ns":0,"exists":"","*":"Cannabicyclol"},{"ns":0,"exists":"","*":"Cannabidiol"},{"ns":0,"exists":"","*":"Cannabidivarin"},{"ns":0,"exists":"","*":"Cannabigerol"},{"ns":0,"exists":"","*":"Cannabinodiol"},{"ns":0,"exists":"","*":"Cannabinoid"},{"ns":0,"exists":"","*":"Cannabinoid receptor"},{"ns":0,"exists":"","*":"Cannabinoid receptor antagonist"},{"ns":0,"exists":"","*":"Cannabinoid receptor type 1"},{"ns":0,"exists":"","*":"Cannabinoid receptor type 2"},{"ns":0,"exists":"","*":"Cannabinol"},{"ns":0,"exists":"","*":"Cannabipiperidiethanone"},{"ns":0,"exists":"","*":"Cannabivarin"},{"ns":0,"exists":"","*":"Carboxylesterase"},{"ns":0,"exists":"","*":"Caryophyllene"},{"ns":0,"exists":"","*":"Central nervous system"},{"ns":0,"exists":"","*":"ChemSpider"},{"ns":0,"exists":"","*":"Chemical formula"},{"ns":0,"exists":"","*":"Chronic pain"},{"ns":0,"exists":"","*":"Clearance (medicine)"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Contract research organization"},{"ns":0,"exists":"","*":"Corticosteroid"},{"ns":0,"exists":"","*":"Crossover study"},{"ns":0,"exists":"","*":"Departments of France"},{"ns":0,"exists":"","*":"Der Spiegel"},{"ns":0,"exists":"","*":"Designer drug"},{"ns":0,"exists":"","*":"Dexanabinol"},{"ns":0,"exists":"","*":"Diacylglycerol"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dimethylheptylpyran"},{"ns":0,"exists":"","*":"Disorder (medicine)"},{"ns":0,"exists":"","*":"Docosatetraenoylethanolamide"},{"ns":0,"exists":"","*":"Drinabant"},{"ns":0,"exists":"","*":"Dronabinol"},{"ns":0,"exists":"","*":"Drug class"},{"ns":0,"exists":"","*":"Drug discovery"},{"ns":0,"exists":"","*":"EAM-2201"},{"ns":0,"exists":"","*":"Eating"},{"ns":0,"exists":"","*":"Echinacea"},{"ns":0,"exists":"","*":"Eicosanoid"},{"ns":0,"exists":"","*":"Endocannabinoid"},{"ns":0,"exists":"","*":"Endocannabinoid enhancer"},{"ns":0,"exists":"","*":"Endocannabinoid system"},{"ns":0,"exists":"","*":"Endocannabinoid transporters"},{"ns":0,"exists":"","*":"Enzyme"},{"ns":0,"exists":"","*":"Enzyme inhibitor"},{"ns":0,"exists":"","*":"Enzyme modulator"},{"ns":0,"exists":"","*":"Epicatechin"},{"ns":0,"exists":"","*":"Epicatechin gallate"},{"ns":0,"exists":"","*":"Epigallocatechin gallate"},{"ns":0,"exists":"","*":"European Investment Bank"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"FAB-144"},{"ns":0,"exists":"","*":"FDU-NNE1"},{"ns":0,"exists":"","*":"FDU-PB-22"},{"ns":0,"exists":"","*":"FUB-144"},{"ns":0,"exists":"","*":"FUB-APINACA"},{"ns":0,"exists":"","*":"FUB-JWH-018"},{"ns":0,"exists":"","*":"FUB-PB-22"},{"ns":0,"exists":"","*":"FUBIMINA"},{"ns":0,"exists":"","*":"Faeces"},{"ns":0,"exists":"","*":"Falcarinol"},{"ns":0,"exists":"","*":"Fatty acid amide hydrolase"},{"ns":0,"exists":"","*":"Federal Institute for Drugs and Medical Devices"},{"ns":0,"exists":"","*":"Fialuridine"},{"ns":0,"exists":"","*":"First-in-man study"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"GW-405,833"},{"ns":0,"exists":"","*":"GW-842,166X"},{"ns":0,"exists":"","*":"G protein-coupled receptor 119"},{"ns":0,"exists":"","*":"G protein-coupled receptor 55"},{"ns":0,"exists":"","*":"Gallocatechol"},{"ns":0,"exists":"","*":"Gendarmerie"},{"ns":0,"exists":"","*":"Genistein"},{"ns":0,"exists":"","*":"Guide to Pharmacology"},{"ns":0,"exists":"","*":"Guineensine"},{"ns":0,"exists":"","*":"Guineesine"},{"ns":0,"exists":"","*":"HU-210"},{"ns":0,"exists":"","*":"HU-243"},{"ns":0,"exists":"","*":"HU-308"},{"ns":0,"exists":"","*":"HU-320"},{"ns":0,"exists":"","*":"HU-331"},{"ns":0,"exists":"","*":"HU-336"},{"ns":0,"exists":"","*":"HU-345"},{"ns":0,"exists":"","*":"HUF-101"},{"ns":0,"exists":"","*":"Haemorrhagic"},{"ns":0,"exists":"","*":"Hemopressin"},{"ns":0,"exists":"","*":"High-throughput screening"},{"ns":0,"exists":"","*":"Hippocampus"},{"ns":0,"exists":"","*":"Histone deacetylase"},{"ns":0,"exists":"","*":"Honokiol"},{"ns":0,"exists":"","*":"Hormone-sensitive lipase"},{"ns":0,"exists":"","*":"Human equivalent"},{"ns":0,"exists":"","*":"Hypertension"},{"ns":0,"exists":"","*":"IC50"},{"ns":0,"exists":"","*":"IDFP"},{"ns":0,"exists":"","*":"IUPAC nomenclature of chemistry"},{"ns":0,"exists":"","*":"Ibipinabant"},{"ns":0,"exists":"","*":"Inflammation"},{"ns":0,"exists":"","*":"Inhibition constant"},{"ns":0,"exists":"","*":"International Chemical Identifier"},{"ns":0,"exists":"","*":"Investigational New Drug"},{"ns":0,"exists":"","*":"Investigator's brochure"},{"ns":0,"exists":"","*":"JNJ-42165279"},{"ns":0,"exists":"","*":"JSmol"},{"ns":0,"exists":"","*":"JTE-907"},{"ns":0,"exists":"","*":"JTE 7-31"},{"ns":0,"exists":"","*":"JWH-007"},{"ns":0,"exists":"","*":"JWH-015"},{"ns":0,"exists":"","*":"JWH-018"},{"ns":0,"exists":"","*":"JWH-019"},{"ns":0,"exists":"","*":"JWH-030"},{"ns":0,"exists":"","*":"JWH-051"},{"ns":0,"exists":"","*":"JWH-073"},{"ns":0,"exists":"","*":"JWH-081"},{"ns":0,"exists":"","*":"JWH-098"},{"ns":0,"exists":"","*":"JWH-116"},{"ns":0,"exists":"","*":"JWH-122"},{"ns":0,"exists":"","*":"JWH-133"},{"ns":0,"exists":"","*":"JWH-147"},{"ns":0,"exists":"","*":"JWH-149"},{"ns":0,"exists":"","*":"JWH-161"},{"ns":0,"exists":"","*":"JWH-164"},{"ns":0,"exists":"","*":"JWH-167"},{"ns":0,"exists":"","*":"JWH-175"},{"ns":0,"exists":"","*":"JWH-176"},{"ns":0,"exists":"","*":"JWH-182"},{"ns":0,"exists":"","*":"JWH-184"},{"ns":0,"exists":"","*":"JWH-185"},{"ns":0,"exists":"","*":"JWH-193"},{"ns":0,"exists":"","*":"JWH-196"},{"ns":0,"exists":"","*":"JWH-198"},{"ns":0,"exists":"","*":"JWH-200"},{"ns":0,"exists":"","*":"JWH-203"},{"ns":0,"exists":"","*":"JWH-210"},{"ns":0,"exists":"","*":"JWH-249"},{"ns":0,"exists":"","*":"JWH-250"},{"ns":0,"exists":"","*":"JWH-251"},{"ns":0,"exists":"","*":"JWH-302"},{"ns":0,"exists":"","*":"JWH-307"},{"ns":0,"exists":"","*":"JWH-359"},{"ns":0,"exists":"","*":"JWH-398"},{"ns":0,"exists":"","*":"JWH-424"},{"ns":0,"exists":"","*":"JZL-184"},{"ns":0,"exists":"","*":"JZL-195"},{"ns":0,"exists":"","*":"JZL184"},{"ns":0,"exists":"","*":"JZL195"},{"ns":0,"exists":"","*":"Janssen-Cilag"},{"ns":0,"exists":"","*":"Johnson & Johnson"},{"ns":0,"exists":"","*":"Judiciary"},{"ns":0,"exists":"","*":"KM-233"},{"ns":0,"exists":"","*":"Kaempferol"},{"ns":0,"exists":"","*":"Kavain"},{"ns":0,"exists":"","*":"L-759,633"},{"ns":0,"exists":"","*":"L-759,656"},{"ns":0,"exists":"","*":"LASSBio-881"},{"ns":0,"exists":"","*":"LBP-1 (drug)"},{"ns":0,"exists":"","*":"LY-2183240"},{"ns":0,"exists":"","*":"LY-320,135"},{"ns":0,"exists":"","*":"La Fl\u00e8che"},{"ns":0,"exists":"","*":"Le Figaro"},{"ns":0,"exists":"","*":"Leelamine"},{"ns":0,"exists":"","*":"Lesions"},{"ns":0,"exists":"","*":"Levonantradol"},{"ns":0,"exists":"","*":"Ligand (biochemistry)"},{"ns":0,"exists":"","*":"List of AM cannabinoids"},{"ns":0,"exists":"","*":"List of JWH cannabinoids"},{"ns":0,"exists":"","*":"List of designer drugs"},{"ns":0,"exists":"","*":"Liver"},{"ns":0,"exists":"","*":"Loi Huriet S\u00e9rusclat"},{"ns":0,"exists":"","*":"Lysophosphatidylinositol"},{"ns":0,"exists":"","*":"MAM-2201"},{"ns":0,"exists":"","*":"MDA-19"},{"ns":0,"exists":"","*":"MDMB-CHMICA"},{"ns":0,"exists":"","*":"MDMB-CHMINACA"},{"ns":0,"exists":"","*":"MDMB-FUBINACA"},{"ns":0,"exists":"","*":"MEPIRAPIM"},{"ns":0,"exists":"","*":"MK-4409"},{"ns":0,"exists":"","*":"MK-9470"},{"ns":0,"exists":"","*":"MMB-2201"},{"ns":0,"exists":"","*":"MN-18"},{"ns":0,"exists":"","*":"MN-25"},{"ns":0,"exists":"","*":"MST1R"},{"ns":0,"exists":"","*":"Magnolol"},{"ns":0,"exists":"","*":"Marisol Touraine"},{"ns":0,"exists":"","*":"Maslinic acid"},{"ns":0,"exists":"","*":"Maximum tolerated dose"},{"ns":0,"exists":"","*":"Mechanism of action"},{"ns":0,"exists":"","*":"Medical conditions"},{"ns":0,"exists":"","*":"Menabitan"},{"ns":0,"exists":"","*":"Merck & Co."},{"ns":0,"exists":"","*":"Metabolism"},{"ns":0,"exists":"","*":"Metabolites"},{"ns":0,"exists":"","*":"Methanandamide"},{"ns":0,"exists":"","*":"Methoxy arachidonyl fluorophosphonate"},{"ns":0,"exists":"","*":"Methyl arachidonyl fluorophosphonate"},{"ns":0,"exists":"","*":"Ministry of Justice (France)"},{"ns":0,"exists":"","*":"Molar mass"},{"ns":0,"exists":"","*":"Monoacylglycerol lipase"},{"ns":0,"exists":"","*":"Monoclonal antibody"},{"ns":0,"exists":"","*":"Morbihan"},{"ns":0,"exists":"","*":"Multiple sclerosis"},{"ns":0,"exists":"","*":"N-Acylphosphatidylethanolamine"},{"ns":0,"exists":"","*":"N-Arachidonoyl dopamine"},{"ns":0,"exists":"","*":"N-Arachidonylglycine"},{"ns":0,"exists":"","*":"NAGly receptor"},{"ns":0,"exists":"","*":"NE-CHMIMO"},{"ns":0,"exists":"","*":"NESS-0327"},{"ns":0,"exists":"","*":"NESS-040C5"},{"ns":0,"exists":"","*":"NM-2201"},{"ns":0,"exists":"","*":"NMP-7"},{"ns":0,"exists":"","*":"NNE1"},{"ns":0,"exists":"","*":"Nabazenil"},{"ns":0,"exists":"","*":"Nabilone"},{"ns":0,"exists":"","*":"Nabitan"},{"ns":0,"exists":"","*":"Naboctate"},{"ns":0,"exists":"","*":"Nature (journal)"},{"ns":0,"exists":"","*":"Nausea"},{"ns":0,"exists":"","*":"Necrosis"},{"ns":0,"exists":"","*":"Nervous system"},{"ns":0,"exists":"","*":"Neurology"},{"ns":0,"exists":"","*":"Neurotransmitter"},{"ns":0,"exists":"","*":"No-observed-adverse-effect level"},{"ns":0,"exists":"","*":"Nonabine"},{"ns":0,"exists":"","*":"O-1057"},{"ns":0,"exists":"","*":"O-1125"},{"ns":0,"exists":"","*":"O-1238"},{"ns":0,"exists":"","*":"O-1269"},{"ns":0,"exists":"","*":"O-1602"},{"ns":0,"exists":"","*":"O-1812"},{"ns":0,"exists":"","*":"O-1871"},{"ns":0,"exists":"","*":"O-1918"},{"ns":0,"exists":"","*":"O-2050"},{"ns":0,"exists":"","*":"O-2113"},{"ns":0,"exists":"","*":"O-2372"},{"ns":0,"exists":"","*":"O-2545"},{"ns":0,"exists":"","*":"O-2694"},{"ns":0,"exists":"","*":"O-774"},{"ns":0,"exists":"","*":"O-806"},{"ns":0,"exists":"","*":"O-823"},{"ns":0,"exists":"","*":"Obesity"},{"ns":0,"exists":"","*":"Oleamide"},{"ns":0,"exists":"","*":"Oleanolic acid"},{"ns":0,"exists":"","*":"Oleoylethanolamide"},{"ns":0,"exists":"","*":"Olorinab"},{"ns":0,"exists":"","*":"Open-label trial"},{"ns":0,"exists":"","*":"Org 27569"},{"ns":0,"exists":"","*":"Org 28312"},{"ns":0,"exists":"","*":"Org 28611"},{"ns":0,"exists":"","*":"Orlistat"},{"ns":0,"exists":"","*":"Otenabant"},{"ns":0,"exists":"","*":"PF-03550096"},{"ns":0,"exists":"","*":"PF-04457845"},{"ns":0,"exists":"","*":"PF-3845"},{"ns":0,"exists":"","*":"PF-514273"},{"ns":0,"exists":"","*":"PSB-SB-1202"},{"ns":0,"exists":"","*":"PSB-SB-487"},{"ns":0,"exists":"","*":"PSN-375,963"},{"ns":0,"exists":"","*":"PSN-632,408"},{"ns":0,"exists":"","*":"PTI-1"},{"ns":0,"exists":"","*":"PTI-2"},{"ns":0,"exists":"","*":"PX-1"},{"ns":0,"exists":"","*":"PX-2"},{"ns":0,"exists":"","*":"PX-3"},{"ns":0,"exists":"","*":"Pain"},{"ns":0,"exists":"","*":"Palmitoylethanolamide"},{"ns":0,"exists":"","*":"Paracetamol"},{"ns":0,"exists":"","*":"Parahexyl"},{"ns":0,"exists":"","*":"Parkinson's disease"},{"ns":0,"exists":"","*":"Patent"},{"ns":0,"exists":"","*":"Patent family"},{"ns":0,"exists":"","*":"Perrottetinene"},{"ns":0,"exists":"","*":"Pfizer"},{"ns":0,"exists":"","*":"Pharmacodynamics"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Phosphatidylethanolamine"},{"ns":0,"exists":"","*":"PipISB"},{"ns":0,"exists":"","*":"Pirnabine"},{"ns":0,"exists":"","*":"Pons"},{"ns":0,"exists":"","*":"Pravadoline"},{"ns":0,"exists":"","*":"Pregnenolone"},{"ns":0,"exists":"","*":"Priority right"},{"ns":0,"exists":"","*":"Protocol (science)"},{"ns":0,"exists":"","*":"PubChem"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"P\u00fablico (Portugal)"},{"ns":0,"exists":"","*":"QMPSB"},{"ns":0,"exists":"","*":"QUCHIC"},{"ns":0,"exists":"","*":"QUPIC"},{"ns":0,"exists":"","*":"RCS-4"},{"ns":0,"exists":"","*":"RCS-8"},{"ns":0,"exists":"","*":"RTI-371"},{"ns":0,"exists":"","*":"RVD-Hp\u03b1"},{"ns":0,"exists":"","*":"Radio labelling"},{"ns":0,"exists":"","*":"Radioactivity"},{"ns":0,"exists":"","*":"Random assignment"},{"ns":0,"exists":"","*":"Receptor (biochemistry)"},{"ns":0,"exists":"","*":"Receptor modulator"},{"ns":0,"exists":"","*":"Regulation of therapeutic goods"},{"ns":0,"exists":"","*":"Rennes"},{"ns":0,"exists":"","*":"Rennes University Hospital"},{"ns":0,"exists":"","*":"Reuptake modulator"},{"ns":0,"exists":"","*":"Rimonabant"},{"ns":0,"exists":"","*":"Risk assessment"},{"ns":0,"exists":"","*":"Rosonabant"},{"ns":0,"exists":"","*":"Route of administration"},{"ns":0,"exists":"","*":"Royal Statistical Society"},{"ns":0,"exists":"","*":"S-444,823"},{"ns":0,"exists":"","*":"SDB-006"},{"ns":0,"exists":"","*":"SER-601"},{"ns":0,"exists":"","*":"SR-144,528"},{"ns":0,"exists":"","*":"STS-135 (drug)"},{"ns":0,"exists":"","*":"Safety pharmacology"},{"ns":0,"exists":"","*":"Sanofi"},{"ns":0,"exists":"","*":"Sarthe"},{"ns":0,"exists":"","*":"Science (magazine)"},{"ns":0,"exists":"","*":"Science Magazine"},{"ns":0,"exists":"","*":"Serinolamide A"},{"ns":0,"exists":"","*":"Serious adverse event"},{"ns":0,"exists":"","*":"Simplified molecular-input line-entry system"},{"ns":0,"exists":"","*":"Sleep"},{"ns":0,"exists":"","*":"Spinal cord"},{"ns":0,"exists":"","*":"Stearoylethanolamide"},{"ns":0,"exists":"","*":"Stroke"},{"ns":0,"exists":"","*":"Surinabant"},{"ns":0,"exists":"","*":"Symptom"},{"ns":0,"exists":"","*":"Synthetic cannabis"},{"ns":0,"exists":"","*":"TGN1412"},{"ns":0,"exists":"","*":"THC-O-acetate"},{"ns":0,"exists":"","*":"THC-O-phosphate"},{"ns":0,"exists":"","*":"THJ-018"},{"ns":0,"exists":"","*":"THJ-2201"},{"ns":0,"exists":"","*":"TM-38837"},{"ns":0,"exists":"","*":"Taranabant"},{"ns":0,"exists":"","*":"Target affinity"},{"ns":0,"exists":"","*":"Tedalinab"},{"ns":0,"exists":"","*":"Tetrahydrocannabinol"},{"ns":0,"exists":"","*":"Tetrahydrocannabinol-C4"},{"ns":0,"exists":"","*":"Tetrahydrocannabinolic acid"},{"ns":0,"exists":"","*":"Tetrahydrocannabivarin"},{"ns":0,"exists":"","*":"The British Medical Journal"},{"ns":0,"exists":"","*":"The New England Journal of Medicine"},{"ns":0,"exists":"","*":"Tinabinol"},{"ns":0,"exists":"","*":"Toxicology"},{"ns":0,"exists":"","*":"Toxicology testing"},{"ns":0,"exists":"","*":"UR-144"},{"ns":0,"exists":"","*":"URB-597"},{"ns":0,"exists":"","*":"URB-602"},{"ns":0,"exists":"","*":"URB597"},{"ns":0,"exists":"","*":"URB602"},{"ns":0,"exists":"","*":"URB754"},{"ns":0,"exists":"","*":"Urine"},{"ns":0,"exists":"","*":"Ursolic acid"},{"ns":0,"exists":"","*":"VCHSR"},{"ns":0,"exists":"","*":"VDM-11"},{"ns":0,"exists":"","*":"Vernalis plc"},{"ns":0,"exists":"","*":"Virodhamine"},{"ns":0,"exists":"","*":"WIN 54,461"},{"ns":0,"exists":"","*":"WIN 55,212-2"},{"ns":0,"exists":"","*":"WIN 56,098"},{"ns":0,"exists":"","*":"XLR-11"},{"ns":0,"exists":"","*":"XLR-12"},{"ns":0,"exists":"","*":"Yangonin"},{"ns":0,"exists":"","*":"\u0391-Amyrin"},{"ns":0,"exists":"","*":"\u0392-Amyrin"},{"ns":0,"*":"Cannabichromevarin"},{"ns":0,"*":"Cannabigerol monoethyl ether"},{"ns":0,"*":"Cannabigerovarin"},{"ns":0,"*":"8,11-Dihydroxy-THC"},{"ns":0,"*":"2-Arachidonoyl lysophosphatidylinositol"},{"ns":0,"*":"A-42574"},{"ns":0,"*":"AM-926"},{"ns":0,"*":"JWH-139"},{"ns":0,"*":"JWH-229"},{"ns":0,"*":"O-224"},{"ns":0,"*":"O-581"},{"ns":0,"*":"O-1191"},{"ns":0,"*":"O-2048"},{"ns":0,"*":"O-2365"},{"ns":0,"*":"O-2373"},{"ns":0,"*":"O-2383"},{"ns":0,"*":"O-2426"},{"ns":0,"*":"O-2484"},{"ns":0,"*":"O-2715"},{"ns":0,"*":"O-2716"},{"ns":0,"*":"O-3223"},{"ns":0,"*":"O-3226"},{"ns":0,"*":"HU-446"},{"ns":0,"*":"HU-465"},{"ns":0,"*":"HU-910"},{"ns":0,"*":"O-1376"},{"ns":0,"*":"O-1422"},{"ns":0,"*":"O-1601"},{"ns":0,"*":"O-1656"},{"ns":0,"*":"O-1657"},{"ns":0,"*":"O-1660"},{"ns":0,"*":"O-1663"},{"ns":0,"*":"SPA-229"},{"ns":0,"*":"1-Butyl-3-(2-methoxybenzoyl)indole"},{"ns":0,"*":"1-Butyl-3-(4-methoxybenzoyl)indole"},{"ns":0,"*":"1-Pentyl-3-(2-methoxybenzoyl)indole"},{"ns":0,"*":"CHM-081"},{"ns":0,"*":"MAM-1220"},{"ns":0,"*":"JWH-192"},{"ns":0,"*":"JWH-194"},{"ns":0,"*":"JWH-195"},{"ns":0,"*":"JWH-197"},{"ns":0,"*":"JWH-199"},{"ns":0,"*":"CUMYL-BICA"},{"ns":0,"*":"CUMYL-5F-PICA"},{"ns":0,"*":"5Br-UR-144"},{"ns":0,"*":"5Cl-UR-144"},{"ns":0,"*":"5Cl-APINACA"},{"ns":0,"*":"AB-FUBINACA 2-fluorobenzyl isomer"},{"ns":0,"*":"EMB-FUBINACA"},{"ns":0,"*":"JWH-369"},{"ns":0,"*":"JWH-370"},{"ns":0,"*":"AM-883"},{"ns":0,"*":"AM-1346"},{"ns":0,"*":"O-585"},{"ns":0,"*":"O-689"},{"ns":0,"*":"O-1860"},{"ns":0,"*":"O-1861"},{"ns":0,"*":"5F-PY-PICA"},{"ns":0,"*":"5F-PY-PINACA"},{"ns":0,"*":"5F-3-pyridinoylindole"},{"ns":0,"*":"A-955,840"},{"ns":0,"*":"CB-86"},{"ns":0,"*":"CUMYL-4CN-B7AICA"},{"ns":0,"*":"GSK-554,418A"},{"ns":0,"*":"MDA-7"},{"ns":0,"*":"O-889"},{"ns":0,"*":"O-1270"},{"ns":0,"*":"O-1399"},{"ns":0,"*":"O-2220"},{"ns":0,"*":"URB-447"},{"ns":0,"*":"VSN-16"},{"ns":0,"*":"Org 27759"},{"ns":0,"*":"Org 29647"},{"ns":0,"*":"Arvanil"},{"ns":0,"*":"CAY-10401"},{"ns":0,"*":"CAY-10429"},{"ns":0,"*":"JNJ 1661010"},{"ns":0,"*":"O-1624"},{"ns":0,"*":"O-2093"},{"ns":0,"*":"Olvanil"},{"ns":0,"*":"PF-622"},{"ns":0,"*":"PF-750"},{"ns":0,"*":"PHOP"},{"ns":0,"*":"URB447"},{"ns":0,"*":"AM281"},{"ns":0,"*":"AM-1387"},{"ns":0,"*":"AM-4113"},{"ns":0,"*":"AM-6527"},{"ns":0,"*":"Brizantin"},{"ns":0,"*":"CAY-10508"},{"ns":0,"*":"CB-25"},{"ns":0,"*":"CB-52"},{"ns":0,"*":"Dietressa"},{"ns":0,"*":"LH-21"},{"ns":0,"*":"MDA-77"},{"ns":0,"*":"MJ-15"},{"ns":0,"*":"NIDA-41020"},{"ns":0,"*":"O-606"},{"ns":0,"*":"O-1184"},{"ns":0,"*":"O-1248"},{"ns":0,"*":"O-2654"},{"ns":0,"*":"AM-1172"},{"ns":0,"*":"JWH-73"},{"ns":0,"*":"Lenabasum"},{"ns":0,"*":"Tetrahydromagnolol"},{"ns":0,"*":"CID1011163"},{"ns":0,"*":"CID1252842"},{"ns":0,"*":"CID1792579"},{"ns":0,"*":"GSK-494581A"},{"ns":0,"*":"ML-184"},{"ns":0,"*":"ML-185"},{"ns":0,"*":"ML-186"},{"ns":0,"*":"ML-191"},{"ns":0,"*":"ML-192"},{"ns":0,"*":"ML-193"},{"ns":0,"*":"PSB-SB-1203"},{"ns":0,"*":"APD668"},{"ns":0,"*":"AS-1269574"},{"ns":0,"*":"MBX-2982"},{"ns":0,"*":"N-Oleoyldopamine"},{"ns":0,"*":"Revosimeline"},{"ns":0,"*":"5'-DMH-CBD"},{"ns":0,"*":"OMDM-2"},{"ns":0,"*":"SB-FI-26"},{"ns":0,"*":"UCM-707"},{"ns":0,"*":"WOBE490"},{"ns":0,"*":"WOBE491"},{"ns":0,"*":"WOBE492"},{"ns":0,"*":"JNJ-1661010"},{"ns":0,"*":"Palmitoylisopropylamide"},{"ns":0,"*":"SA-47"},{"ns":0,"*":"SA-57"},{"ns":0,"*":"TAK 21d"},{"ns":0,"*":"TC-F 2"},{"ns":0,"*":"UCM710"},{"ns":0,"*":"PDP-EA"},{"ns":0,"*":"ABX-1431"},{"ns":0,"*":"JJKK 048"},{"ns":0,"*":"JW 642"},{"ns":0,"*":"JZP-361"},{"ns":0,"*":"KML 29"},{"ns":0,"*":"MJN110"},{"ns":0,"*":"N-Arachidonoylmaleimide"},{"ns":0,"*":"Pristimerin"},{"ns":0,"*":"JZP-169"},{"ns":0,"*":"JZP-430"},{"ns":0,"*":"KT182"},{"ns":0,"*":"KT185"},{"ns":0,"*":"KT195"},{"ns":0,"*":"KT203"},{"ns":0,"*":"LEI-106"},{"ns":0,"*":"ML294"},{"ns":0,"*":"ML295"},{"ns":0,"*":"ML296"},{"ns":0,"*":"WWL-70"},{"ns":0,"*":"2-Palmitoylglycerol"},{"ns":0,"*":"ARN-272"},{"ns":14,"exists":"","*":"Category:Articles lacking reliable references from January 2016"},{"ns":14,"exists":"","*":"Category:Wikipedia articles needing factual verification from January 2016"},{"ns":14,"exists":"","*":"Category:Wikipedia articles in need of updating from April 2016"},{"ns":14,"exists":"","*":"Category:CS1 maint: Explicit use of et al."},{"ns":14,"exists":"","*":"Category:CS1 maint: Uses authors parameter"},{"ns":10,"exists":"","*":"Template:Cannabinoids"},{"ns":10,"exists":"","*":"Template:Cannabinoid receptor modulators"},{"ns":10,"exists":"","*":"Template:Receptor modulators"},{"ns":4,"exists":"","*":"Wikipedia:Manual of Style/Dates and numbers"},{"ns":4,"exists":"","*":"Wikipedia:NOTRS"},{"ns":4,"exists":"","*":"Wikipedia:No original research"},{"ns":4,"exists":"","*":"Wikipedia:Reliable sources"},{"ns":4,"exists":"","*":"Wikipedia:Scientific citation guidelines"},{"ns":11,"exists":"","*":"Template talk:Cannabinoid receptor modulators"},{"ns":11,"exists":"","*":"Template talk:Cannabinoids"}],"templates":[{"ns":10,"exists":"","*":"Template:Drugbox"},{"ns":10,"exists":"","*":"Template:Infobox drug"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Infobox drug/title"},{"ns":10,"exists":"","*":"Template:Infobox drug/licence"},{"ns":10,"exists":"","*":"Template:Infobox drug/pregnancy category"},{"ns":10,"exists":"","*":"Template:Unbulleted list"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatATC"},{"ns":10,"exists":"","*":"Template:Infobox drug/legal status"},{"ns":10,"exists":"","*":"Template:Abbr"},{"ns":10,"exists":"","*":"Template:Collapsible list"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatCASnumber"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemCID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemSID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatIUPHARBPS"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatDrugBank"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemSpider"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatUNII"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatKEGG"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEBI"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEMBL"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemDBNIAID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPDBligand"},{"ns":10,"exists":"","*":"Template:Infobox drug/chemical formula"},{"ns":10,"exists":"","*":"Template:Chembox Elements/molecular formula"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Chem molar mass"},{"ns":10,"exists":"","*":"Template:Chem molar mass/format"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatJmol"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Button"},{"ns":10,"exists":"","*":"Template:Border-radius"},{"ns":10,"exists":"","*":"Template:Linear-gradient"},{"ns":10,"exists":"","*":"Template:Infobox drug/maintenance categories"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Refimprove science"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Primary source inline"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Better source"},{"ns":10,"exists":"","*":"Template:Update inline"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Columns-list"},{"ns":10,"exists":"","*":"Template:Div col"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Clear"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite patent"},{"ns":10,"exists":"","*":"Template:Citation/patent"},{"ns":10,"exists":"","*":"Template:Citation/make link"},{"ns":10,"exists":"","*":"Template:Citation/authors"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:DOI"},{"ns":10,"exists":"","*":"Template:Doi"},{"ns":10,"exists":"","*":"Template:Hide in print"},{"ns":10,"exists":"","*":"Template:Str left"},{"ns":10,"exists":"","*":"Template:Only in print"},{"ns":10,"exists":"","*":"Template:PMID"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Cannabinoids"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":10,"exists":"","*":"Template:Abbrlink"},{"ns":10,"exists":"","*":"Template:Cannabinoidergics"},{"ns":10,"exists":"","*":"Template:Cannabinoid receptor modulators"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:List"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:Collapsible list"},{"ns":828,"exists":"","*":"Module:TemplatePar"},{"ns":828,"exists":"","*":"Module:ParameterCount"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Navbox"}],"images":["Lock-green.svg","Bia102474_corrected.svg","Question_book-new.svg"],"externallinks":["https://www.bial.com/en/pressroom.138/news.140/phase_i_clinical_trial_rennes.a558.html","http://www.breizh-info.com/2016/01/15/rennes-biotrial-bialessai-therapeutique/","http://www.ansm.sante.fr/S-informer/Actualite/La-survenue-d-effets-graves-ayant-entraine-l-hospitalisation-de-6-patients-dont-un-en-etat-de-mort-cerebrale-a-conduit-a-l-arret-premature-d-un-essai-clinique-du-laboratoire-BIAL-Point-d-information","http://social-sante.gouv.fr/actualites/presse/discours/article/accident-grave-dans-le-cadre-d-un-essai-clinique-intervention-de-marisol","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_13/17_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n2.pdf","http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-de-Rennes-Rapport-final-du-CSST-inhibiteurs-de-la-FAAH","http://www.sciencemag.org/news/2017/06/new-clues-why-french-drug-trial-went-horribly-wrong","http://ansm.sante.fr/content/download/84681/1069223/version/1/file/protocole_BIAL_102474+101-22012016131259.pdf","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581","//doi.org/10.1016/j.bmcl.2011.06.096","//www.ncbi.nlm.nih.gov/pubmed/21764305","http://www.tandfonline.com/doi/abs/10.1517/17460441.2013.780021?journalCode=iedc20","//doi.org/10.1517/17460441.2013.780021","//www.ncbi.nlm.nih.gov/pubmed/23488865","https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO2015012708A1","https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO2015016729","https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO2010074588","http://cdsouthan.blogspot.se/2016/01/molecular-details-related-to-bia-10-2474.html","http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-de-Rennes-Compte-rendu-de-la-premiere-reunion-du-CSST-inhibiteurs-de-la-FAAH","http://www.collabchem.com/2016/01/21/lets-do-it-all-again-updating-predictions-for-the-real-bia-10-2474/","http://www.alzforum.org/news/community-news/will-death-french-drug-trial-lead-tighter-phase-1-rules","http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-BIA-102474-101-du-laboratoire-BIAL-Publication-du-protocole-clinique-Point-d-Information","http://sante.lefigaro.fr/actualite/2016/01/21/24518-drame-rennes-protocole-lessai-clinique-accusation","http://en.youscribe.com/catalogue/tous/current-affairs-and-social-debate/current-affairs-events/document-le-protocole-de-l-essai-clinique-de-rennes-2691486","http://social-sante.gouv.fr/IMG/pdf/fevrier_2016_-_note_etape_-_accident_essai_clinique.pdf","http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)00154-9.pdf","//doi.org/10.1016/S0140-6736(16)00154-9","//www.ncbi.nlm.nih.gov/pubmed/26842439","http://www.sciencemediacentre.org/expert-reaction-to-french-drug-trial-reports-of-one-patient-dying-and-five-others-in-hospital-and-of-the-paris-prosecutors-office-having-opened-an-investigation-into-what-happened","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf","http://www.in-pharmatechnologist.com/Regulatory-Safety/Bial-cannot-rule-out-link-between-BIA-10-2474-and-lung-lesions-in-study-dogs","http://www.irishtimes.com/news/world/europe/survivor-of-lethal-french-drug-trial-speaks-out-1.2554593","http://social-sante.gouv.fr/actualites/presse/discours/article/intervention-de-marisol-touraine-conference-de-presse-accident-d-essai-clinique","http://www.sciencemag.org/news/2016/01/more-details-emerge-fateful-french-drug-trial","http://www.nature.com/news/researchers-question-design-of-fatal-french-clinical-trial-1.19221","//doi.org/10.1038/nature.2016.19221","http://www.statslife.org.uk/news/2660-rss-issues-statement-regarding-tragic-first-in-man-clinical-trial","http://ansm.sante.fr/S-informer/Actualite/Essai-clinique-BIA-102474-101-Bial-Biotrial","http://www.biotrial.com/news/press-release-february-4th-2016.html","http://www.ladepeche.fr/article/2016/01/15/2256528-accident-grave-lors-d-un-essai-therapeutique-pres-de-rennes.htmlwith","https://www.bbc.com/news/world-europe-35320895","https://www.reuters.com/article/us-france-health-test-idUSKCN0UT131","https://www.bbc.com/news/world-europe-35327053","http://www.ouest-france.fr/bretagne/rennes-35000/essai-clinique-le-patient-decede-etait-un-artiste-morbihannais-3979793","http://blogs.channel4.com/victoria-macdonald-on-health-and-social-care/french-drug-trial-death-interview-victims-brother/3276","http://www.lemonde.fr/sante/article/2016/03/11/essai-clinique-de-rennes-des-choses-ont-ete-cachees-accusent-les-proches-de-la-victime_4881348_1651302.html","http://www.ledauphine.com/france-monde/2016/03/11/le-frere-de-la-victime-je-lui-ai-dit-de-ne-pas-le-faire","http://www.lemonde.fr/societe/article/2016/01/15/essai-therapeutique-a-rennes-un-volontaire-en-etat-de-mort-cerebrale_4848001_3224.html","http://www.ouest-france.fr/bretagne/rennes-35000/essai-therapeutique-rennes-un-patient-en-etat-de-mort-clinique-3972041","http://www.ledauphine.com/france-monde/2016/01/15/rennes-un-patient-en-etat-de-mort-clinique-apres-un-essai-therapeutique","https://www.theguardian.com/world/2016/jan/15/french-drug-trial-one-person-in-coma-and-five-critically-ill","http://abcnews.go.com/Technology/wireStory/fall-ill-france-participating-clinical-trial-36309158","https://www.bloomberg.com/news/articles/2016-01-15/testing-on-bial-s-drug-led-to-brain-dead-patient-france-says","https://www.newscientist.com/article/dn28782-six-in-hospital-after-french-pain-relief-drug-trial-goes-wrong/","http://www.bioworld.com/content/six-hospitalized-bial-clinical-trial-france-0","http://news.bbc.co.uk/2/hi/uk_news/england/london/4807042.stm","https://www.publico.pt/2016/07/05/sociedade/noticia/bial-vai-lancar-medicamento-para-parkinson-no-final-do-verao-1737330","http://www.nature.com/news/scientists-in-the-dark-after-french-clinical-trial-proves-fatal-1.19189","//doi.org/10.1038/nature.2016.19189","//www.ncbi.nlm.nih.gov/pubmed/26791697","http://www.biotrial.com/news/message-from-biotrial.html","http://www.biotrial.com/news/communication-from-biotrial.html","https://www.theguardian.com/science/2016/jan/17/man-dies-rennes-hospital-drug-trial-left-him-brain-dead","https://www.theguardian.com/science/2016/mar/07/french-drug-trial-man-dead-expert-report-unprecidented-reaction","http://www.sciencemag.org/news/2016/05/france-tightens-rules-wake-fatal-clinical-trial","http://www.spiegel.de/gesundheit/diagnose/todesfall-bei-biotrial-studie-welche-fehler-wurden-gemacht-a-1075734.html","https://doi.org/10.1016%2FS0140-6736(16)00318-4","http://www.raps.org/Regulatory-Focus/News/2016/01/19/23925/EMA-Will-Assess-ANSM-Review-of-Botched-Clinical-Trial-in-France/","http://www.sciencemag.org/news/2016/07/europe-overhauls-rules-first-human-trials-wake-french-disaster","//doi.org/10.1126/science.aag0686","http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002572.jsp&mid=WC0b01ac058004d5c1","http://www.ft.com/cms/s/0/acceb104-c0fe-11e5-9fdb-87b8d15baec2.html","http://www.fda.gov/Drugs/DrugSafety/ucm482740.htm","http://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2016/pm1-2016.html","https://www.nejm.org/doi/full/10.1056/NEJMoa1604221","//doi.org/10.1056/NEJMoa1604221","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_15/19_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n4.pdf","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_16/20_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n5.pdf","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_18/26_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n7.pdf","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_17/21_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n6.pdf","http://ansm.sante.fr/L-ANSM/Comites-scientifiques-specialises-temporaires/Comites-scientifiques-specialises-temporaires/Comites-scientifiques-specialises-temporaires/CSST-Examens-des-donnees-cliniques-et-d-imagerie-cerebrale-des-volontaires-sains-inclus-dans-l-essai-mene-avec-le-BIA-10-2474-et-conduit-a-Rennes","http://www.chu-rennes.fr/sections/autres_professionnel/relations_presse/dossiers_et_communiq/du_16_au_20_mars_les/downloadFile/FichierJoint_14/18_janvier_2016_-_CP_CHU_de_Rennes_-_Point_de_situation_n3.pdf","https://www.nature.com/news/fatal-french-clinical-trial-failed-to-check-data-before-raising-drug-dose-1.21190","http://www.ouest-france.fr/sante/essais-therapeutiques/essai-therapeutique-que-dit-la-loi-3972224","http://pubs.acs.org/doi/abs/10.1021/ml5001239","https://www.merck.com/research/pipeline/MerckPipeline_Oct09_Final_10-15-09_10-Q.pdf","https://clinicaltrials.gov/ct2/results?term=jnj-42165279","https://clinicaltrials.gov/ct2/results?term=V158866&Search=Search","https://doi.org/10.1517%2F17460440903018857","//doi.org/10.1093/jat/bkt062","//www.ncbi.nlm.nih.gov/pubmed/23946450","https://doi.org/10.1016%2Fj.forsciint.2014.03.013","//www.ncbi.nlm.nih.gov/pubmed/24769262","http://www.janssen.com/janssen-research-development-llc-voluntarily-suspends-dosing-phase-2-clinical-trials-experimental","http://www.in-pharmatechnologist.com/Regulatory-Safety/FAAH-inhibitor-safety-under-microscope-after-Bial-drug-trial-death","http://www.commonchemistry.org/ChemicalDetail.aspx?ref=1233855-46-3","https://pubchem.ncbi.nlm.nih.gov/compound/46831476","http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9001","http://www.chemspider.com/Chemical-Structure.41628677.html","https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC(N1C%3DC(C2%3DC%5BN%2B%5D(%5BO-%5D)%3DCC%3DC2)N%3DC1)N(C3CCCCC3)C","http://onlinelibrary.wiley.com/doi/10.1111/bcp.12920/epdf","//doi.org/10.1111/bcp.12920","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4799914","http://www.bmj.com/content/352/bmj.i466","//doi.org/10.1136/bmj.i466","http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_073165.pdf","http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117","http://onlinelibrary.wiley.com/doi/10.1111/j.1467-985X.2007.00481.x/epdf","//doi.org/10.1111/j.1467-985x.2007.00481.x","http://cdsouthan.blogspot.com.au/2016/01/molecular-details-related-to-bia-10-2474.html","http://www.cyclicarx.com/bia-10-2474/","https://www.bial.com/en/r_d.2/pipeline.29/pipeline.a27.html","http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000489.jsp","http://www.biotrial.com/","http://www.chu-rennes.fr/sections"],"sections":[{"toclevel":1,"level":"2","line":"Structure and action","number":"1","index":"1","fromtitle":"BIA_10-2474","byteoffset":2472,"anchor":"Structure_and_action"},{"toclevel":1,"level":"2","line":"Preclinical studies","number":"2","index":"2","fromtitle":"BIA_10-2474","byteoffset":9812,"anchor":"Preclinical_studies"},{"toclevel":2,"level":"3","line":"Pharmacodynamics and pharmacokinetics","number":"2.1","index":"3","fromtitle":"BIA_10-2474","byteoffset":11281,"anchor":"Pharmacodynamics_and_pharmacokinetics"},{"toclevel":2,"level":"3","line":"Safety pharmacology and toxicology","number":"2.2","index":"4","fromtitle":"BIA_10-2474","byteoffset":15253,"anchor":"Safety_pharmacology_and_toxicology"},{"toclevel":1,"level":"2","line":"Phase I clinical trial","number":"3","index":"5","fromtitle":"BIA_10-2474","byteoffset":21393,"anchor":"Phase_I_clinical_trial"},{"toclevel":2,"level":"3","line":"Overview","number":"3.1","index":"6","fromtitle":"BIA_10-2474","byteoffset":21421,"anchor":"Overview"},{"toclevel":2,"level":"3","line":"Trial details","number":"3.2","index":"7","fromtitle":"BIA_10-2474","byteoffset":23576,"anchor":"Trial_details"},{"toclevel":2,"level":"3","line":"Starting dose and subsequent doses","number":"3.3","index":"8","fromtitle":"BIA_10-2474","byteoffset":26340,"anchor":"Starting_dose_and_subsequent_doses"},{"toclevel":2,"level":"3","line":"Trial status at the time of serious adverse events","number":"3.4","index":"9","fromtitle":"BIA_10-2474","byteoffset":30584,"anchor":"Trial_status_at_the_time_of_serious_adverse_events"},{"toclevel":1,"level":"2","line":"Death and serious adverse events","number":"4","index":"10","fromtitle":"BIA_10-2474","byteoffset":32241,"anchor":"Death_and_serious_adverse_events"},{"toclevel":1,"level":"2","line":"Reaction and investigations","number":"5","index":"11","fromtitle":"BIA_10-2474","byteoffset":37948,"anchor":"Reaction_and_investigations"},{"toclevel":2,"level":"3","line":"French authorities","number":"5.1","index":"12","fromtitle":"BIA_10-2474","byteoffset":44398,"anchor":"French_authorities"},{"toclevel":3,"level":"4","line":"Inspection g\u00e9n\u00e9rale des affaires sociales reports","number":"5.1.1","index":"13","fromtitle":"BIA_10-2474","byteoffset":47503,"anchor":"Inspection_g\u00e9n\u00e9rale_des_affaires_sociales_reports"},{"toclevel":3,"level":"4","line":"ANSM Comit\u00e9 Scientifique Sp\u00e9cialis\u00e9 Temporaire","number":"5.1.2","index":"14","fromtitle":"BIA_10-2474","byteoffset":51036,"anchor":"ANSM_Comit\u00e9_Scientifique_Sp\u00e9cialis\u00e9_Temporaire"},{"toclevel":2,"level":"3","line":"Agencies outside France","number":"5.2","index":"15","fromtitle":"BIA_10-2474","byteoffset":53748,"anchor":"Agencies_outside_France"},{"toclevel":1,"level":"2","line":"Outcome for trial participants","number":"6","index":"16","fromtitle":"BIA_10-2474","byteoffset":57900,"anchor":"Outcome_for_trial_participants"},{"toclevel":1,"level":"2","line":"Implications for other FAAH inhibitors","number":"7","index":"17","fromtitle":"BIA_10-2474","byteoffset":67182,"anchor":"Implications_for_other_FAAH_inhibitors"},{"toclevel":1,"level":"2","line":"See also","number":"8","index":"18","fromtitle":"BIA_10-2474","byteoffset":72462,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"Further reading","number":"9","index":"19","fromtitle":"BIA_10-2474","byteoffset":72940,"anchor":"Further_reading"},{"toclevel":1,"level":"2","line":"References","number":"10","index":"20","fromtitle":"BIA_10-2474","byteoffset":74778,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"11","index":"21","fromtitle":"BIA_10-2474","byteoffset":74820,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"BIA 10-2474","iwlinks":[{"prefix":"fr","url":"https://fr.wikipedia.org/wiki/Inspection_g%C3%A9n%C3%A9rale_des_affaires_sociales","*":"fr:Inspection g\u00e9n\u00e9rale des affaires sociales"},{"prefix":"fr","url":"https://fr.wikipedia.org/wiki/Procureur_g%C3%A9n%C3%A9ral_(France)","*":"fr:Procureur g\u00e9n\u00e9ral (France)"}],"properties":[{"name":"wikibase_item","*":"Q22082929"}]}}